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Abstract 
In this Thesis we have aimed the study of the molecular recognition processes of 
receptors involved in the innate immunity. More concretely, we have focused in 
two different types of lectins, Galectins and DC-SIGN, and in Toll-like receptor 4. 
We have made use of computational techniques, including docking and virtual 
screening, molecular dynamics simulations, conformational analysis and quantum 
mechanics calculations. The work has been organized into several chapters that are 
summarized as follows: 
Chapter 1 corresponds to the current knowledge and perspectives about receptors 
related to immunity, in particular: galectins, DC-SIGN, and Toll-like receptor 4, 
corresponding to the molecular recognition events and modulation by small 
molecules. 
Chapter 2 describes the state-of-the-art methods in molecular modeling and 
computational chemistry applied to the study of molecular recognition processes 
and drug design.  
Chapter 3 reports the fragment-based design of modulators of Galectins 1, 3 and 7, 
by studying the pocket adjacent to the carbohydrate recognition domain (CRD). 
While there are no differences in the CRDs among the different galectins, major 
structural differences can be observed in the adjacent pocket. A fragment-based 
virtual screening (VS) approach was applied in order to identify fragments able to 
bind to these pockets in a selective way among the different galectins. With the 
best fragments, more than 500 lactose-based ligands were designed and docked 
into all galectins. In collaboration with other groups, selected compounds have 
been synthesized and preliminary NMR and ITC results are very promising, 
showing lactose derivatives with high selectivity and affinity towards galectins 1, 3 
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and 7. These selective ligands may contribute to the understanding of the highly 
relevant biological functions of galectins and their role in several pathological 
processes, such as cancer and immune diseases. 
Following on chapter 4, a computational study of the DC-SIGN has been carried 
out aiming the design of glycomimetics with high affinity and selectivity. We have 
demonstrated by means of MD simulation that the mannose binding site of DC-
SIGN and the surrounding regions have a structural plasticity that is crucial to 
understand the molecular recognition process. We have elucidated that Val351 can 
adopt two orientations, being one of them clearly favored. We have performed 
fragment-based VS and identified a pocket where positively charged fragments are 
hosted with high predicted affinity. This “ammonium binding” pocket, which is 
adjacent to the mannose binding site, has served as an anchorage site to design 
new ligands based on a pseudo-dimannoside core. The peculiarity, in this case, is 
that the modifications have been carried out at the carbon 2, not at the carbon 6, 
already described in the literature. Newly designed pseudo-dimannosides have 
been predicted to bind with improved affinity to DC-SIGN. 
In chapter 5, we report the studies performed in several TLR4 modulators. First of 
all, we have demonstrated that RS01 and RS09 peptides, TLR4 agonists, have 
different binding modes to the TLR4/MD-2 system. RS09 is buried inside MD-2 
pocket, while RS01 is located at the rim of the pocket. After MD simulations, we 
observed that only in the case of RS01, the agonist conformation of Phe126 loop is 
maintained. This is agreement with the experimental results indicating that RS01 is 
a better agonist than RS09. The TLR4 antagonist peptide MDMP has also been 
studied. This peptide is a mimetic of the TLR4 binding region of MD-2, with a 
disulfide bond in its structure. After a structure optimization, we performed 
docking and MD simulations of this peptide bound to TLR4. We clearly observed 
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that MDMP can bind TLR4 in a similar region that MD-2 in a very similar way to 
MD-2. Thus, we have proposed a binding mode for several peptides to TLR4 
accounting for their observed biological activity towards TLR4.  
We also have studied the binding mode of cardiolipin (CL), a lipid present in the 
mitochondria membrane with observed synergistic effect together with LPS, to 
TLR4. Our computational studies indicate that CL can bind to MD-2, having the 
FA chains inserted in the hydrophobic pocket. Cardiolipin counters its lower 
number of FA chains (4) compared to E. coli LPS with the length of them (18 
against 14), so is able to mimic the interactions that occur at the hydrophobic 
pocket of MD-2. Then, we assessed the mechanism for the observed synergistic 
effect by constructing a mixed TLR4/MD-2 dimer, with one monomer occupied by 
CL and the other by E. coli LPS. We observed that this complex is stable and that 
the agonist conformation of MD-2 in maintained, so we proposed that CL and E. 
coli LPS can form a stable complex that main explain the observed synergistic 
effect.  
Finally, a mixture of LPS from Bacteroides vulgatus was studied. This mixture 
contains a tetracylated LPS and a pentacylated LPS, and our collaborators 
observed experimentally that the mixture has a weak agonist activity towards 
TLR4. After docking and MD simulations of both species in TLR4/MD-2 system we 
observed that only the pentacylated fully accomplish the features of a TLR4 
agonist. The tetracylated, on the contrary, was not able to maintain the agonist 
conformation of MD-2. So, given that the pentacylated has an agonist behavior and 
the tetracylated has an antagonist behavior, the mixture may act as a weak TLR4 
agonist.  
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On chapter 6, a VS protocol has been applied to several public, commercial and in-
house libraries in the TLR4/MD-2 system. The VS was performed following both 
structure-based and ligand-based strategies. Several new chemical scaffolds that 
could bind to MD-2 pocket have been identified. After the virtual screening 
protocol and having identified the possible TLR4 binders, we tested the activity of 
around 50 compounds on HEK-BLUE TLR4 cells and we observed antagonist 
activity on 7 of them. Assays on 744 macrophage cell line confirmed the antagonist 
activity of 2 of these compounds, while no cytotoxic effect was observed. Thus, we 
have identified novel drug-like compounds with TLR4/MD-2 antagonist activity.  
Finally, on chapter 7, computational studies of the different independent domains 
composing the TLR4 were undertaken aiming to uncover details of the precise 
mechanism of activation of the receptor. Understanding, at the atomic scale, the 
dimerization of both the transmembrane domain and the intracellular domain of 
TLR4 permitted to favor certain binding modes and specific secondary structures 
increasing the available knowledge regarding the activation. We have performed a 
series of coarse grain simulations of the transmembrane domain in different 
membrane models. We observed that the dimerization of the transmembrane 
domain depends on the composition of the membrane. We also have proposed two 
possible models for the dimerization of the intracellular domain that are in 
agreement with mutagenesis studies. Finally, we also have provided a model for 
the binding of MAL adaptor protein to each intracellular dimer.  
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Resumen 
En esta tesis hemos estudiado los procesos reconocimiento molecular de receptores 
involucrados en la inmunidad innata. Más concretamente, nos hemos centrado en 
dos tipos diferentes de lectinas, Galectinas y DC-SIGN, y en el receptor Toll-like 4 
(TLR4). Hemos utilizado técnicas computacionales, incluyendo docking y cribado 
virtual, simulaciones de dinámica molecular, análisis conformacional y cálculos de 
mecánica cuántica. El trabajo se ha organizado en diferentes capítulos que se 
resumen como sigue: 
El capítulo 1 corresponde al estado del arte y las perspectivas relacionadas con los 
estudios de reconocimiento molecular proteína-carbohidrato y diseño de nuevos 
moduladores con actividad biológica en receptores de la inmunidad, en particular 
galectinas, DC-SIGN y el receptor Toll-like 4. 
El capítulo 2 describe el estado actual de los métodos en modelado molecular y 
química computacional aplicados al estudio de los procesos de reconocimiento 
molecular y diseño de fármacos. 
El capítulo 3 describe el diseño basado en fragmentos de moduladores de las 
galectinas 1, 3 y 7, estudiando el bolsillo adyacente al dominio de reconocimiento 
de carbohidratos. Aunque no hay diferencias en este dominio entre las diferentes 
galectinas, sí se pueden observar diferencias estructurales en este bolsillo vecino. 
Aplicamos un protocolo de cribado virtual basado en fragmentos con la finalidad 
de identificar fragmentos capaces de unirse a este bolsillo de una forma selectiva a 
las diferentes galectinas. Se seleccionaron los mejores fragmentos para cada bolsillo 
y se diseñaron más de 500 ligandos basados en lactosa. En colaboración con otros 
grupos de investigación, se sintetizaron algunos de los ligandos diseñados y 
 XI 
 
fueron, a continuación, estudiados por técnicas biofísicas (RMN y calorimetría). 
Los resultados indican que los compuestos presentan una afinidad superior a la de 
la lactosa (compuesto de referencia) y selectividad por las galectinas. Estos 
ligandos pueden contribuir al conocimiento de las funciones biológicas de las 
galectinas y de su papel en distintos procesos patológicos, como el cáncer y las 
enfermedades inmunológicas. 
En el capítulo 4, se ha realizado un estudio computacional de la proteína DC-SIGN 
para diseñar glicomiméticos con afinidad y selectividad mejoradas. Utilizando 
métodos de simulación de dinámica molecular, se demostró que el sitio de unión a 
manosa y los sitios adyacentes a este sitio de unión presentan una plasticidad que 
es crucial para entender el proceso de reconocimiento molecular. Se ha observado 
que la Valina 351 puede adoptar dos conformaciones y que una de ellas está 
claramente favorecida. Se realizó un cribado virtual basado en fragmentos, a través 
del cual hemos identificado un bolsillo donde los fragmentos cargados 
positivamente se unen con gran afinidad. Este “bolsillo de unión de amonio”, 
vecino al bolsillo de unión a manosa, ha servido de base para el diseño de nuevos 
ligandos derivados de un pseudo-dimanósido. En este caso, la peculiaridad reside 
en que las modificaciones se han realizado en el carbono 2 del manósido, y no en el 
carbono 6, el cual ya estaba descrito. Estos nuevos ligandos se unen con una gran 
afinidad a la proteína DC-SIGN. 
En el capítulo 5, describimos los estudios realizados con distintos moduladores del 
TLR4. Primero, hemos demostrado que los péptidos agonistas de TLR4, RS01 y 
RS09, tienes distintos modos de unión al complejo TLR4/MD-2. RS09 está insertado 
dentro del bolsillo de MD-2, mientras que RS01 se aloja el borde de este mismo 
bolsillo. Tras simulaciones de dinámica molecular, observamos que solo en el caso 
del péptido RS01, la conformación agonista de MD-2 se mantiene. Esta observación 
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es concordante con resultados experimentales que indican que el péptido RS01 es 
más potente como agonista del TLR4 que el péptido RS09. También se ha 
estudiado el péptido antagonista MDMP. Este péptido es un mimético de la región 
de unión a TLR4 de MD-2. Después de optimizar su estructura, realizamos 
estudios de docking y de dinámica molecular de este péptido unido a TLR4. Hemos 
observado claramente que MDMP se une a TLR4 de una manera muy similar a 
MD-2. Así pues, en este capítulo se ha propuesto el modo de unión de diversos 
péptidos a TLR4 que pueden justificar su actividad experimental. 
También se ha estudiado el modo de unión a TLR4 de la cardiolipina (CL), un 
lípido endógeno presente en la membrana mitocondrial, para determinar el 
mecanismo del efecto sinérgico observado con LPS. Nuestros estudios 
computacionales indican que la CL puede unirse a MD-2, con todas sus cadenas 
alifáticas dentro del bolsillo hidrofóbico de esta proteína. El menor número de 
cadenas alifáticas (4), comparado con el LPS de E. coli (6), se contrarresta con la 
mayor longitud de éstas (18 frente a 14), y es capaz de mimetizar su modo de 
unión con los residuos del bolsillo hidrofóbico de MD-2. Además, hemos 
construido un dímero mixto de TLR4/MD-2, con un monómero ocupado por la CL 
y el otro por el LPS de E. coli. Hemos observado que este complejo es estable y que 
la conformación agonista de MD-2 se mantiene. Así pues, hemos propuesto que la 
CL y el LPS de E. coli pueden formar un complejo estable que podría explicar el 
efecto sinérgico observado. 
Por último, también hemos estudiado el LPS de Bacteroides vulgatus. Este LPS es 
una mezcla de moléculas de LPS tetra-acilado y penta-acilado, y presenta una 
actividad como agonista débil del receptor TLR4. Después de estudios de docking y 
simulación de dinámica molecular de estas dos especies de LPS en complejo con 
TLR4/MD-2, observamos que únicamente el LPS penta-acilado cumple totalmente 
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las características de un agonista de TLR4. Por el contrario, el tetra-acilado no es 
capaz de mantener la conformación agonista del MD-2. Así pues, dado que el LPS 
penta-acilado se comporta como un agonista y el tetra-acilado como un 
antagonista, la mezcla puede presentar actividad como un agonista débil. 
En el capítulo 6, se ha aplicado un protocolo de cribado virtual utilizando 
quimiotecas (comerciales, públicas y de colaboradores) de compuestos tipo-
fármaco y fármacos genéricos en el receptor TLR4. El cribado virtual se realizó 
siguiendo estrategias basadas en la estructura del ligando y la estructura del 
receptor. A través de este método, se han identificado nuevos compuestos que 
podrían unirse al bolsillo de MD-2. Después de este cribado virtual, la actividad de 
los 50 compuestos seleccionados fue ensayada en la línea celular Hek Blue TLR4 y 
se observó actividad antagonista en 7 de ellos. Posteriores ensayos en la línea de 
macrófagos J774 confirmaron la actividad de dos de ellos, mientras que no se 
observaba citotoxicidad. Así pues, se han identificado nuevos compuestos tipo-
fármaco (evitando la estructura de glicolípido) con actividad antagonista sobre el 
complejo TLR4/MD-2. 
Finalmente, en el capítulo 7, se han realizado estudios computacionales de los 
diferentes dominios del receptor TLR4, con el objetivo de comprender más 
profundamente los detalles precisos de la activación de este receptor y de su 
proceso de dimerización a nivel atómico. Hemos realizado simulaciones “coarse 
grain” del dominio transmembrana en diferentes modelos de membrana. Hemos 
observado que la dimerización de este dominio depende de la composición de la 
membrana. También se habn propuesto dos posibles modelos de dimerización del 
dominio intracelular concordantes con estudios experimentales descritos de 
mutagénesis. Finalmente, hemos propuesto un modelo de unión de la proteína 
MAL para cada modelo de dímero intracelular. 
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INTRODUCTION 
The immune system of all living organisms emerged as a protection against 
environmental microorganisms that can be hazardous for them. In the case of 
vertebrate immune system, it comprises innate and acquired immunity. Both types 
of immunity are essential for the survival of the organism, but innate immunity is 
the first barrier of defense and, thus, less specific. The lower specificity of this 
system indicates that the same component of the innate immune system can 
recognize and neutralize different pathogens.1 One of these components of the 
innate immune system comprises the so called Pathogen Recognition Receptors 
(PRRs). These receptors recognize distinct structural motifs that are present in a set 
of microorganisms, giving to opportunity to the organism to give a quick and 
effective response. The structural motifs that are associated with hazardous 
microorganisms are called Pathogen Associated Molecular Patterns (PAMPs). 
Therefore, PAMPs recognition by PRRs is one of the main events of the innate 
immunity.   
1.1 TLRs 
Toll-like receptors (TLRs) are PRRs that have a fundamental role in innate 
immunity. They are responsible of the initiation and propagation of the 
inflammation and they have a role in inflammatory and immune diseases, cancer 
and other pathogenic processes.2 In 2011, Beutler and Hoffmann were awarded 
with the Nobel Prize in Medicine3 for their studies on TLR and the activation of the 
innate immune system, highlighting the increasing importance of these receptors 
in drug design. TLRs antagonist may be beneficial to control an inappropriate TLR 
stimulation and, thus, helpful to treat inflammation and autoimmune diseases. On 
the other hand, TLRs agonists can help in the treatment of cancer, viral infections 
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and as adjuvants for vaccines.4 The first identified TLR was TLR4, the mammalian 
endotoxin sensor.5 This TLR recognizes lipopolysaccharide (LPS) from Gram-
negative bacteria. The structure of TLR4 comprises a Toll-like extracellular domain, 
and helical transmembrane domain and a TIR (Toll/Interleukin 1 receptor) 
intracellular domain.  
In 1989, Janeway proposed that cells use pattern recognition to identify pathogens.6 
Receptors recognize and subsequently bind to structural shapes or patterns called 
pathogen-associated molecular patterns (PAMPs) which are present in entire 
groups of pathogens, but not in the host. According to Janeway's theory, receptors 
cannot precisely recognize a particular microbe, but they can identify it as a foreign 
entity. Ten years after Janeway´s proposal, the first human pattern-recognition 
receptors (PRRs) were identified. Using the amino acid sequence of the Toll gene 
from the fruit fly,7 related sequences were searched in the Human Genome Project 
database, finally leading to the identification of TLRs.  
Since some TLR binders are originated from the host, these new ligands are 
hypothesized to act as damage signals (damage-associated molecular patterns, or 
DAMPs) to alert the body about cell or tissue injury. For example, this is evident in 
cases of necrosis, ischemic injury, etc.8 Blocking various TLRs (such as TLR2 and 
TLR4) with antagonists may be useful in these circumstances to prevent an 
overactive immune response. There is also evidence that TLRs contribute to the 
development of atherosclerosis and Alzheimer's disease through sensing damage 
signals in the form of oxidized lipoproteins.9 
Given their therapeutic potential, there is considerable interest in pharmaceuticals 
able to modulate TLR activation. TLR antagonists hold great clinical promise for 
the treatment of numerous inflammatory diseases and they are under investigation 
for the treatment of viral infections, through redirecting allergic T cell responses 
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and as anticancer therapeutics. Some TLR agonists have also proven to be safe and 
efficacious as vaccine adjuvants in humans and they are currently used in 
Europe.10  
The human TLR family comprises 10 to 12 type I transmembrane glycoproteins 
with a single transmembrane domain, a conserved cytoplasmic Toll-
like/interleukin-1 receptor signaling domain, and an extracellular antigen 
recognition domain comprising of 19–25 tandem leucine-rich repeat (LRR) 
modules.11 The LRR modules have approximately 20-30 amino acid residues with 
conserved ‘‘LxxLxLxxN’’ motifs.12  
TLRs function mainly as heterodimers (Figure 1). There are a wide variety of 
ligands with distinct PAMPs and that is the reason why ten human TLRs are able 
to recognize more than ten different PAMPs. In fact, the list of known TLR binders 
keeps growing. Heterodimer formation also increases binder diversity: for 
example, TLR1/TLR2 heterodimer recognizes triacylated lipopeptides, while 
TLR2/TLR6 recognizes diacylated lipopeptides.13 The association with proteins 
outside of the TLR family also increases the complexity of the molecular 
recognition process; for example, TLR4 recognizes LPS in association with the 
accessory proteins MD-2 (myeloid differentiation factor 2) and CD14 (cluster of 
differentiation 14). Upon binding of the ligands to the extracellular domains of 
TLRs, rearrangement of the receptor complex is promoted, thus triggering the 
recruitment of specific adaptor proteins in the intracellular TIR domains.14 In 
particular, MyD88 is a universal adapter protein used by almost all TLRs (except 
TLR3) to activate the transcription factor NF-κβ. Mal (also known as TIRAP) is 
another adaptor protein necessary to recruit MyD88 into TLR2 and TLR4. TLR 
expression is particularly significant in different types of white blood cells: mast 
cells, macrophages, and dendritic cells. The innate immune response is initiated by 
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mast cells and macrophages, whereas the adaptive immune response is primarily 
initiated by dendritic cells.1 
 
Figure 1: The Toll-like receptor family. Adapted from15.  
 TLRs 1, 2, 4, 5, and 6 are located primarily in the plasma membrane, where they 
recognize components of microbial cell walls and membranes that are present 
exclusively in pathogens. The best characterized ligands are bacterial. Examples 
include lipopolysaccharide (LPS) and lipoteichoic acid from the cell wall, 
lipoproteins from the cell membrane, and flagellin, a structural component of 
bacterial flagella. TLRs 3, 7, 8, and 9 are situated in the membranes of endosomes 
and lysosomes. These TLRs bind to microbial nucleic acids, such as DNA from 
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most organisms, and double and single stranded RNA from RNA viruses. Since 
these TLRs cannot distinguish self-nucleic acids (those of the host cell), recognition 
of foreign nucleic acids (those from the pathogen) largely depends on the 
localization in the cell.16 
1.2 TLR4 
TLR4 is an interesting case of study not only because is the only TLR that requires 
an accessory protein, called MD-2 (Myeloid differentiation factor 2), to perform its 
function but because it can activate the immune response through two different 
signaling pathways and, more importantly, subtle changes in the structure of 
PAMP lipopolysaccharides can lead to an agonist or an antagonist response of 
TLR4.17  
The activation mechanism of TLR4 by LPS goes as follows: after an infection by 
Gram-negative bacteria, the LPS present in the cell wall binds to 
lipopolysaccharide binding protein (LBP). LBP brings the LPS to CD14, the 
following component of the LPS-sensing machinery. CD14 is present 
extracellularly in the plasma membrane and transfers LPS to MD-2, the accessory 
protein of TLR4. TLR4 and MD-2 form a highly stable heterodimer and, after the 
binding of LPS to MD-2, the formation of TLR4/MD-2/TLR4*/MD-2* dimer is 
induced. Although both LBP and CD14 are necessary to the TLR4 activation by 
LPS, huge amounts of LPS can also activate it. Finally, the TLR4/MD-2/TLR4*/MD-
2* dimer formation brings the intracellular domains close to each other, inducing 
its dimerization (Figure 2). Once the intracellular domains are in the form of a 
dimer, the recruitment of the signaling adaptors takes place and induces the 
activation of the immune response. The activation of the TLR4 complex triggers the 
release of pro-inflammatory cytokines. After that, the maturation of dendritic cell 
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is induced, as well as the expression of type-1 interferon and IFN-regulated genes. 
TLR4 can activate the immune response through two different pathways: the 
MyD88 dependent pathways and the TRIF-dependent pathways. This different 
activation leads to the recruitment of different downstream adaptors. In the 
MyD88 dependent pathway, the MyD88-adapter-like (MAL) protein and Myeloid 
differentiation factor 88 (MyD88) are recruited. This pathway regulates the 
activation of NF-ƙB nuclear factor. On the other hand, TIR-domain-containing 
adapter-inducing interferon-β (TRIF) and TRIF-related adapter molecule (TRAM) 
are recruited in the TRIF-dependent pathway and TNF-α is activated. 
Furthermore, this pathway requires the endocytosis of the activated TLR4 complex 
completely.18  
 
Figure 2: Left) Representation of the full TLR4/MD2 heterodimer. Right) Detail of 
the TLR4 ectodomain. 
To describe the structure of the TLR4 complex, which comprises TLR4 protein and 
its accessory protein MD-2, we have to describe the structure of its component 
separately.  
TLR4 belongs to the superfamily of the LRR proteins, which they have a typical 
horse-shoe-like conformation. This conformation is characterized form presenting 
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parallel β-strands in its concave surface and unstructured loop in its convex 
surface (Figure 2). The whole sequence can be divided in three regions: N-terminal 
domain, containing modules 1 to 6; central domain, with modules from 7 to 12; 
and C-terminal domain, containing modules 13 to 22. The central and N-terminal 
domains provide charge complementarity to bind MD-2.19  
The structure of the MD-2 is characterized by two antiparallel β-sheets, containing 
three and six β-strands, respectively (Figure 3). These two β-sheets adopt a β-cup-
like fold, forming a large internal hydrophobic pocket of approximately 1000 Å2. 
This pocket will be able to host the large lipophilic fatty acid (FA) chains from the 
LPS. This pocket is completely built by hydrophobic residues on the interior, and 
positively charged residues surrounding the entrance, at the rim of the pocket, 
allowing the binding of the phosphate groups and the sugars present in the LPS 
structure. The formation of the disulfide bond between Cys25 and Cys51, and the 
hydrogen bond between Tyr34 and Tyr36, are crucial for the stability of the MD-2 
structure. Here, we should mention the loop between residues Ile124 and Phe126. 
This loop is the only part of the protein that changes its conformation, depending 
of the nature of the ligand that is bound to MD-2 (i.e. if it is agonist or antagonist). 
When an agonist ligand is bound, Phe126 is buried in the MD-2 pocket, while 
Ile124 is more exposed to the solvent. On the contrary, when an antagonist ligand 
is inside MD-2, Phe126 changes its conformation and exposes its side chain to the 
solvent, while Ile124 occupies the initial position of Phe126. It is said that this twist 
in the loop acts as a switch ON/OFF (Figure 3).20 
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Figure 3: MD-2 agonist structure (red, PDB ID 3FXI) and MD-2 antagonist 
structure (grey, PDB ID 2E59). Ile124 and Phe126 are highlighted in sticks.  
The TLR4/MD-2 complex interacts through a narrow interface, the so-called 
primary contact interface. The formation of the TLR4/MD-2 complex occurs before 
the binding of LPS, so the LPS binds to the preformed TLR4/MD-2 dimer (Figure4).  
The narrow TLR4/MD-2 binding interface is divided into A and B patches, which 
contain residues of the N-terminal and central domains of TLR4, respectively.19  
The binding of LPS to TLR4/MD-2 is determined mainly by two parts of the LPS 
structure: the lipid A and the sugar core (Figure 5). Lipid A is formed by 6 
saturated fatty acid chains linked to two N-acetylglucosamines with 1 phosphate 
group in its carbon 4.21 The fatty acid chains of lipid A are buried inside the 
hydrophobic pocket of MD-2, interacting with the hydrophobic residues of this 
region while the sugars interact with the residues located at the rim of MD-2 
through hydrogen bonds mainly. The phosphate groups stablish polar contacts 
with both MD-2 and TLR4. On the contrary, the sugar core of LPS stablishes a 
network of hydrogen bonds with the residues of TLR4 located and the central 
domain of the protein.22  
Chapter 1 
11 
 
 
Figure 4: Representation of the dimerization interface of TLR4. 
Once the LPS is bound to TLR4/MD-2, the formation of the multimeric complex 
composed by two copies of TLR4/MD-2/LPS occurs. TLR4 interacts with its partner 
through the C-terminal domains. This is the primary dimerization interface of the 
complex. Polar interactions can be observed mainly in this interface, for example 
between His458 of both TLRs as well as the interaction between Asn433 and 
Asn433 of the partner TLR4. There is also another dimerization interface that helps 
to the maintenance of the dimer formed by the MD-2 and the partner TLR4*. In this 
interface, which includes residues of the C-terminal domain of the TLR4 and 
residues located at the Phe126 loop, there can be seen, apart from polar contacts, an 
hydrophobic interaction between Leu87 of MD-2 and Phe463 of TLR4*. An 
important detail to point out in this interface is the fact that the 6th FA chain of LPS 
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protrudes from the hydrophobic pocket of MD-2 and interacts with Phe440 and 
Phe463 of the partner TLR4. Finally the sugars at the sugar core of LPS can reach 
the partner TLR4, stablishing hydrogen bonds with it and, thus, contributing to the 
stability of the complex.19  
 
Figure 5: Structure of E. coli LPS and its binding mode on TLR4/MD-2. FA chain 
that interacts with the partner TLR4 in the activated form of this receptor is marked in 
blue. 
The agonistic activity of LPS has been attributed to the number, length and 
chemical structure of its FA chains, as well as to its phosphorylation degree. 
However, recent findings have questioned this paradigm because LPSs bearing 
penta-acylated lipid A and positively-charged residues decorating their lipid A 
molecules with agonistic activity have been reported.23 These data suggest that 
subtle changes in lipid A structure may have a deep effect on its activity. For 
example, tetracylated lipid IVa, a lipid A precursor, has an antagonist behavior in 
human and an agonist behavior in mouse (Figure 6). X-ray crystallographic 
structures of hMD-2/lipid IVa (PDB ID 2E59) and mMD-2/lipid IVa (PDB ID 3VQ1) 
complexes, reveal that four FA chains of lipid IVa are inserted into the MD-2 
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pocket, occupying a similar volume in both human and mouse TLR4/MD-2, 
although with different consequences: exerting an agonist activity in human and 
an antagonist activity in mouse. From the crystal structures, one can see that the 
orientation of the lipid IVa is rotated by 180° in the di-saccharide plan.20, 24 Thus, 
lipid IVa presents two different molecular patterns of interaction for human and 
mouse. These different binding modes of lipid IVa, which determine how the 
phosphate groups interact with the TLR4/MD-2 complex, may be crucial to 
explaining its distinct behavior in different species. This illustrates the importance 
of scrutinizing the key ligand/receptor interaction to rationalize the mechanism for 
TLR4 modulation. 
MD-2 can only be found in the antagonist conformation, either bound to 
antagonists (MD-2/lipid IVa, PDB ID 2E59, and TLR4/MD-2/Eritoran, PDB ID 
2Z65), or without any ligand (TLR4/MD-2, PDB ID 2Z64). This observation may 
suggest that the conformational change of the Phe126 loop which leads to the 
dimerization, and to the activation of the immune response, is promoted upon 
agonist binding. The MD-2 conformational change could be explained by the 
induced fit paradigm rather than by the conformational selection from the MD-2 
conformational landscape. This has also been suggested by reported NMR studies 
on hexaacylated endotoxin bound to wild-type and F126A mutant MD-2, which 
indicate that re-orientation of the aromatic side chain of Phe126 is induced by 
binding of hexaacylated endotoxin, preceding interaction with TLR4.25 Multimeric 
complexes are available with natural agonist binder LPS (PDB ID 3FXI, human 
TLR4/MD-2), and with lipid IVa (PDB ID 3VQ1, mouse TLR4/MD-2).  
In this way, lipid IVa acts as a dual binder of TLR4 depending on the species, able 
to activate the TLR4 immune response in mice, but to block the TLR4 system in 
humans. As an agonist, it is able to bridge between the two phosphate binding 
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sites of the two TLR4/MD-2 units. As an antagonist (the glucosamine backbone is 
in opposite orientation to that for LPS) it is buried more deeply into the cavity of 
MD-2 (4-5 Å) and thus can only connect to one phosphate binding site. Eritoran is 
not able to bridge between the two TLR4/MD-2 subunits of any of the analyzed 
species. 
 
Figure 6: Lipid A and synthetic lipid A analogues with activity as TLR4 
modulators. Activity is referred to hTMR4/MD-2. Extracted from 2. 
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1.2.1 TLR4 agonists and antagonists 
TLR agonists have shown to improve anticancer vaccination protocols, and they 
are also the focal point for new vaccine development as non-infectious vaccines.26 
For example, the natural product monophosphoryl lipid A (MPLA,, a detoxified 
component of LPS from Salmonella Minnesota which contains the lipid A  moiety 
that binds to TLR4/MD-2, is incorporated into several vaccines, including vaccines 
for Hepatitis B (Fendrix™), and cervical cancer (Cervarix™). It is also been applied 
in the immunotherapy against melanoma.27 
Also synthetic TLR4 agonists have been designed and assayed. Compound E602028 
have shown good adjuvant activity with antitumoral trastuzumab,29 or enhancing 
vaccine efficacy.30 Lipid A mimetics, such as the aminoalkyl glucosaminide 
phosphates, have been developed as TLR4 stimulants31 with good adjuvant 
activity,32 including the potent vaccine adjuvant RC-529,33 and the bioisoster CRX-
547, which has reduced toxicity in comparison to RC-529.34 Small molecules 
pyrimido[5,4-b]indoles have shown to stimulate TLR4 and could potentially be 
used as adjuvants or immune modulators,35 synthetic analogues of natural product 
euodenine A have exhibited potent and selective agonism towards TLR4,36 and 
synthetic peptides to mimic the TLR4/LPS interaction have also been reported.37 
The design of LPS mimetics with TLR4 antagonist activity is an emerging strategy 
for the treatment of sepsis,38 combined with the challenge of obtaining good drug-
like properties. Lipid IVa is an underacylated lipid A analogue with intriguing 
properties, being antagonist in human TLR4 but agonist in mouse. The 
tetraacylated synthetic compound Eritoran reached phase III in clinical trials, but 
failed to demonstrate sufficient efficacy in late stage human trials, although it has 
recently shown promising activity in preventing influenza induced acute lung 
injury, through a TLR4 antagonism mechanism.39  
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Simplified derivatives without the phosphate group have also been reported,40 
exploring the presence of a cation. Of merit, new glycolipids and 
benzylammonium lipids (for example, IAXO-102 and IAXO-103) are the first 
family derived from a monosaccharide core with effective TLR4 antagonist 
activity.40b Other synthetic lipid A analogues include, for example, compound D1,41 
and one lipid X mimetic42 exhibiting a TLR4 antagonist mechanism by blocking the 
interaction of LPSs with both CD14 and MD-2 proteins. 
Several small non LPS-like molecules with TLR4 antagonist activity have also been 
developed, such as ethyl 4-oxo-4-(oxazolidin-3-yl)-butenoate derivatives (OSL07), 
benzothiazole-based inhibitors, ethyl phenyl-sulfamoyl-cyclohexene-carboxylate 
derivatives (TAK-242 or resatorvid), and β-amino alcohol derivatives.43 However, 
no successful progress was shown when reaching clinical phases (for example, in 
the case of compound OSL07). Examples of non-lipid TLR4 antagonists based on 
dendrimer architecture can also be found in the recent literature, showing that the 
presence of lipidic chains is not an absolute requirement for an MD-2 antagonist, 
and thus opening interesting opportunities for immunity modulation.44 
1.2.2 Computational studies of TLR4 modulators 
Several computational studies have been performed in order to clarify the binding 
mode of TLR4/MD-2 agonist and antagonist ligands. As introduced above, the 
unveiling of the molecular recognition process at atomic detail is one of the major 
challenges in TLR4/MD-2 modulation. Molecular modeling, docking studies and 
MD simulations have already provided relevant contributions about the 
ligand/receptor interactions with promising impact for rational drug design. 
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Synthetic LPS Mimetics 
Inspired by the LPS structure, different ligands have been designed and 
synthesized. 
 
Figure 7: Synthetic LPS mimetics studied by computational approaches. Extracted 
from 26. 
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One of the first compounds to enter into clinical trials was Eritoran, a synthetic 
lipid A mimetic, potent TLR4 antagonist, which reached phase III clinical trials as 
an antisepsis agent, but failed since the study did not meet its primary endpoint of 
reduction in 28-day all-cause mortality in patients with severe sepsis45. Eritoran is a 
tetraacylated lipid A, the structural analogue of lipid A from RsLA, antagonist of 
human TLR4 and agonist of TLR4 from mouse and horse. In order to analyze the 
species-dependent activity of Eritoran, Scior et al. 46 built homology models by 
means of the SCWRL4 program.47 Afterwards, docking of Eritoran was performed 
with AutoDock in order to determine the characteristics of the agonist/antagonist 
binding in the TLR4 structures from different species: human, mouse and horse. 
Some key amino acids were identified as relevant in species-specific binding: 
Lys58 (that corresponds to Asn in mouse and to Glu in horse), Lys388 (which is a 
Ser in mouse and a Lys in horse) and Gln436 (which is an Arg in mouse and a Gln 
in horse). The different pattern of interactions that are presented by these different 
residues impairs the TLR4-TLR4* bridging role of the ligand, thus preventing the 
effective dimerization and the agonist activity. 
Modifications of the chemical structure of the lipid A scaffold have served as a 
starting point for the design of novel TLR4 modulators. One modification reported 
by Cighetti et al.42 was the diphosphorylation of the scaffold of lipid X (Figure 7), a 
biosynthetic precursor of lipid A, leading to compound 1 , which has been found to 
be an antagonist in both human and mouse TLR4/MD-2. This compound was also 
shown to stimulate CD14 internalization in one-marrow-derived murine 
macrophages, thus demonstrating targeting of also CD14 in a TLR4-independent 
manner. In order to propose 3D models for the ligand recognition processes, 
computational studies were undertaken on both CD14 and MD-2 proteins. 
Docking calculations in MD-2 with AutoDock and AutoDock VINA,48 followed by 
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MD simulations of the resulting complexes, led to the identification of two possible 
binding poses: the most stable one (in terms of predicted binding energy) allocated 
both FA chains inside the MD-2 binding pocket, mimicking the lipid IVa binding 
to MD-2 in the crystal structure (PDB ID 2E59). The MD-2/1 complex is stabilized 
by hydrophobic interactions between its two FA chains and aliphatic and aromatic 
residues from the MD-2 pocket together with polar interactions at the rim of MD-2, 
involving mainly the phosphate groups and side chains from Ser118 and Arg96 
residues and, in some cases, interactions between the amide CO or ester CO 
groups from compound 3 and the Ser120 OH group. This result was in agreement 
with NMR experiments performed by the authors that clearly showed FA chain-
protein interactions. In a few cases, calculations predicted a second docked binding 
pose for compound 1 presenting only one FA chain inside the MD-2 hydrophobic 
pocket, while the second FA chain was lying over Ile124. Interestingly, in the 
agonist conformation, this residue has moved towards the inside of MD-2 and 
Phe126 occupies its place. This synchronism allows the agonist/antagonist switch. 
In the bound/unbound equilibrium, this alternative binding pose could co-exist 
with the first and most stable one. Cighetti et al.42 also combined docking and MD 
simulations to propose a binding mode for compound 1 with CD14. CD14 is also 
characterized by having a wide lipophilic pocket, but with fewer polar residues at 
the rim. Compound 1 was predicted to bind with the saccharide moiety and the 
phosphate groups at the entrance of the CD14 hydrophobic cavity and with the FA 
chains inside the pocket, in agreement with the CD14 binding properties observed 
experimentally. In addition to its properties to prevent TLR4 signaling, Compound 
1 has also been proposed as a promising hit as TLR4 modulator because of its 
favorable solubility properties and for its lack of toxicity according to the MTT 
tests. 
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Another strategy to mimic lipid A was the design of tetraacylated lipid A mimetics 
based on the βGlcN (1↔1) αGlcN scaffold analogue by substituting the β(1→6) 
with βα(1↔1) glycosidic linkage in order to confer rigidity to the molecule.49 In 
particular, compound DA193 (Figure 7) resulted in being a dose-dependent 
antagonist in human and mouse, according to assays performed in HEK293 cells 
transiently transfected with membrane CD14 (mCD14)/hMD-2TLR4, HEK293 cells 
transfected with hMD-2TLR4 only and assays on human macrophage-like cell line 
(THP-1). In order to propose an atomistic understanding of the interactions 
between the ligand and the receptor, MD simulations were performed starting 
from two possible binding orientations of the ligand into the MD-2 protein: one 
with the α-GlcN ring facing the Phe126 loop and the second one with the β-GlcN 
facing the Phe126 loop with an energy difference similar to that found for 
orientations of lipid A in the binding site of hMD-2. Dissociation constants, 
calculated from MD simulations of the MD-2/DA193 complex, estimated a binding 
to MD-2 20-fold stronger than lipid A and three-fold more than lipid IVa. It was 
concluded that the conformational rigidity of the βα(1↔1) diglucosamine 
backbone of these tetraacylated lipid A mimetics ensures strong binding to MD-2, 
in two possible binding poses, unlike the native lipid A structures. 
The commercial TLR4 antagonist IAXO-10250 has also served as inspiration  
for the rational design of TLR4 modulators and probes. Recently, the design and 
synthesis of IAXO-102-based TLR4 modulators were reported by Ciaramelli et al.51 
The design was based on a previous docked binding mode of IAXO-102 into MD-2 
that showed the possibility to host two ligands simultaneously. A dimeric scaffold 
with two glycolipid units was designed by connecting both units through C4 
diamino and di-ammonium linkers. Both compounds were confirmed to inhibit 
TLR4 activation and signaling in HEK-BlueTM cells expressing hTLR4 in a 
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concentration-dependent manner. Unfortunately, these compounds had a very 
poor solubility in aqueous solution. 
The same IAXO-102 scaffold was used to design fluorescent probes51. The 
fluorescein moiety was chosen as the chromophore, and two thiourea-based 
linkers with different lengths attached to the C6 position of the glucose moiety 
were considered. Normal mode analysis of CD14 was used to obtain motions and 
conformational changes, and docking calculations of both designed probes 4 and 5 
were performed in three different conformations (Figure 7). Calculations predicted 
binding poses in which the fatty acid chains are buried inside the CD14 binding 
site (human and mouse) with the sugar located in the external portion. The 
thiourea linker and the fluorescein moiety established polar interactions with the 
hydrophilic rim without adopting a preferred pose. The best complexes were 
selected, according to their preferred docked poses, and were submitted to MD 
simulations and MM-GBSA analysis. In order to perform docking studies in the 
hTLR/MD-2, a hybrid hTLR4/MD-2 model in the antagonist conformation was 
modeled. As expected, predicted binding poses were similar to those found for 
CD-14, with the FA chains inside the pocket and the fluorescein moiety reaching 
TLR4 in the case of the longer probe. In fact, calculations of the SASA with 
CASTP52 in both CD14 and MD-2 showed that both pockets have similar topologies 
and volumes. However, the presence of a lower number of polar residues in the 
rim of CD-14 allows it to recognize a wide range of microbial and cellular 
molecular determinants, such as lipopeptides to be transferred to TLR2. In 
contrast, MD-2 rim’s polarity confers selectivity to the protein towards LPS. 
Natural LPSs 
Rhodobacter sphaeroides lipid A (RsLA,)53 has five acyl chains, with one unsaturated 
and two shorter chains than Escherichia coli lipid A (Figure 6). It is an antagonist in 
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human and mouse, but an agonist in horse, although, intriguingly, the horse 
TLR4/MD-2 sequence is more closely related to the human sequence than to the 
mouse one. To clarify the species-specific response, a computational-aided study of 
the three 3D structures was undertaken. A homology model was built for horse 
and hamster TLR4/MD-2, with human and murine X-ray crystallographic 
structures as templates (PDB ID 3FXI and 2Z64).54 The role of Arg385 had been 
proven in horse TLR4 complex activation by lipid IVa55 through polar interactions 
between the guanidinium moiety and the phosphate group of lipid IVa. In fact, in 
other species, this residue is substituted by glycine in human and hamster and by 
an alanine in murine. The docked structure with AutoDock VINA of the horse 
TLR4/MD-2/RsLa complex closely resembled the pose of lipid IVa in murine 
crystal structure of TLR4/MD-2. On the contrary, the docked binding pose found in 
the hamster MD-2 was similar to the lipid IVa pose in the crystal structure from 
chicken (PDB ID 3MU3) and human. The difference between the species was 
mainly attributed to the different characteristic of each protein. By docking studies 
on hMD-2 with AutoDock, it has been observed that the longest chain of RsLPS 
could be accommodated in MD-2 by folding the chains itself as has been observed 
with the Eritoran fatty acid chains. The polar head (diglucosamine) is always 
exposed to the solvent. 
Molecular modeling by Irvine et al. has also showed that the different human/horse 
TLR4 responses towards RsLA is related to two different amino acids, Gly384 and 
Ser441, in human TLR4 (Arg385 and Pro442 in horse). 56 Residue Arg385 in horse 
TLR4, although located around a 9 Å distance from the docked RsLA, could 
establish a long-range electrostatic interaction with a phosphate group of RsLA, 
while the Pro442 is situated near the dimerization interface with TLR4* and 
interacts with an FA chain of RsLA by van der Waals interactions. This hypothesis 
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was confirmed by experimental assays with transfected HEK293 cells with 
G384R/S441P hTLR4 with eqMD-2 and R385G/P442S eqTLR4 with hMD-2. It was 
observed that the R385G/P442S mutations in horse caused a complete loss of 
activity, and in human, the double mutant G384R/P441S TLR4 was unable to 
activate the signaling event. Since the double mutation did not recover the activity, 
other residues must be required. The docking of RsLA in human TLR4/MD-2 
shares some similarity with the Eritoran crystal structure, such as the folding of the 
longest acyl chain and the polar interaction with charged residues of MD-2. RsLPS 
can adopt two orientations depending on the position of 1-PO4 (oriented towards 
primary TLR4 in the case of horse and towards partner TLR4* in the case of 
human). This fact leads to different contacts between acyl chains of RsLPS and the 
hydrophobic pocket of MD-2. Moreover, superimposition of docked RsLA with X-
ray crystallography poses of lipid A and lipid IVa showed that RsLA and lipid A 
acyl chains occupy more volume than lipid Iva, an, more importantly, the R2 chain 
of RsLA and lipid A protrudes from MD-2 and establishes interactions with the 
partner TLR4 in contrast to the R2 chain of lipid IVa, which is folded into the MD-2 
pocket. 
The severe pathogen B. cenocepacia LPS has been reported by Di Lorenzo et al. to 
strongly activate human TLR4/MD-2, despite the fact that its lipid A has only five 
acyl chains (Figure 6).57 The Ara4N residues in lipid A have been shown to 
contribute to TLR4-lipid A interactions, and experiments in a mouse model of LPS-
induced endotoxic shock confirmed the proinflammatory potential of B. cenocepacia 
penta-acylated lipid A. A combination of docking calculations and MD 
simulations, together with experimental mutagenesis of the TLR4/MD-2 interacting 
surfaces, suggested that the longer acyl chains allow reaching deeper regions 
inside the MD-2 pocket, thus compensating the absence of one FA chain and, at the 
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same time, allowing the exposure of the fifth FA chain on the surface of MD-2. This 
enables interactions with partner TLR4* and promotes its dimerization. The 
replacement of Val82 by Phe enhanced the inflammatory response, and it was 
related to the changes of van der Waals interactions into stronger CH–π 
interactions with the FA chain, longer than the corresponding one on E. coli LPS. 
The molecular model also showed that Ara4N residues provide additional polar 
interactions affecting the B. cenocepacia LPS binding to the TLR4/MD-2, and 
contribute to the anchoring of the lipid A into the receptor complex by interactions 
with both, TLR4 and TLR4*. Interestingly, the presence of the positively-charged 
ammonium groups in the Ara4N seems to favor the electrostatic interactions and, 
consequently, the binding, whereas uncharged amino acids are critical for 
responses to Bordetella pertussis lipid A, for example.58 As described in Section 2.2, 
this model for the TLR4/MD-2/LPSBC complex was used to generate a 
computational mutant TLR4/MD-2/LPSBC complex (D294A, R322A, S415A* and 
S416A*), which was submitted to MD simulations and energy analysis for 
quantification of the per residue contributions to the final binding energy.23a 
Altogether, these results provided a molecular model for the activation of the 
human TLR4/MD-2 complex by penta-acylated lipid A, which sheds some light 
onto the comprehension of the molecular recognition of LPS by TLR4/MD-2. 
Non LPS-like modulators 
The species-specific discrimination of TLR4 ligands by MD-2 is exemplified by 
taxanes, in particular paclitaxel, a proinflammatory murine TLR4/MD-2 ligand, 
which activates the subsequent inflammatory cytokine response (Figure 8).59 
Zimmer et al. demonstrated with different experiments that the activation of TLR4 
by PTX requires the mMD-2 protein, being independent from TLR4 species.60 This 
requirement is due to the electrostatic potential surfaces, hydrophobicity, binding 
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pocket size and the conformational gating of the 123–130 amino acids loop. hMD-2 
and mMD-2 have a very large cavity volume that in principle allows lipid IVa, PTX 
and Eritoran to fit inside. The study of the electrostatic surfaces of mMD-2 (PDB ID 
2Z64) and hMD-2 (PDB ID 2Z65) by means of SYBYL software61 shows that the 
cavities for both structures are close to electroneutral, being mMD-2 more 
electronegative than hMD-2, especially in the Cys95–Cys105 loop, which is critical 
for the MD-2/TLR4 interaction. Furthermore, the electrostatic surface of hMD-2 
displays three electropositive patches corresponding to Lys58, Lys122 and Lys125, 
which are absent on the mMD-2 surface.  
Docking studies were performed with the help of the Glide program62 by using the 
crystal structure of hMD-2 (PDB ID 2Z65) and mMD-2 (PDB ID 2Z64). In the best 
predicted MD-2/PTX binding poses, the benzamido group of PTX is very close to 
Phe126, suggesting that a π-stacking interaction may exist between both aromatic 
groups. In addition, the Lys125 side chain establishes hydrophobic contact with the 
phenyl ring. Another key interaction (cation-π) is established between the phenyl 
group of PTX and the Lys122, which is the only different amino acid in the MD-2 
species-conserved sequence Phe119–Gly123. In MD-2, the multiple interactions 
attract the Gly123–Lys130 loop so as to form a concave surface facing the docked 
PTX. The same loop in the mouse protein is oriented in the reverse direction. The 
presence of a Glu122 instead of the Lys122 in mMD-2 leads to a completely 
different binding pose, possibly due to the absence of the cation-π interaction.60 
Other work by Resman et al.59c proposed a similar binding mode for paclitaxel and 
the analogue docetaxel, on the basis of docking performed with AutoDock in hMD-
2 (PDB ID 2E59). Also in this case, the most favorable docked binding poses of both 
taxanes oriented the benzoyl group towards the nearby region formed by Ile61, 
Phe76, Leu78, Phe119 and Phe151 of hMD-2 
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Figure 8: Non-LPS like TLR4 modulators studied by means of computational 
approaches. Extracted from 2. 
A docked binding mode for a prenylated chalcone-type into the antagonist 
conformation of hMD-2 (PDB ID 2E59) has been proposed by Fu et al.63 For this 
purpose, the Glide docking program was used, and the results highlighted the 
importance of the H-bonds between the OH groups present in the xanthohumol 
and residues Tyr102 and Arg90. Moreover, another H-bond between the OH of the 
phenolic group and Glu92 was identified from the docking studies, but this 
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interaction was rapidly broken during the subsequent MD simulation (50 ns), 
leading to a final MD-2/xanthohumol complex stabilized by the above-mentioned 
interactions. An analogue behavior was found for curcumin (Figure 8) after 
docking with AutoDock also in the same crystal structure of hMD-2 (PDB ID 2E59). 
The hMD-2/curcumin complex resulting from the docking was subjected to MD 
simulations leading to a stable complex with equivalent interactions with Tyr102 
and Arg90. Accordingly, experimental studies with MD-2 mutants (MD-
2R90A/Y102A) have pointed to a direct binding of curcumin to MD-2 in the same 
binding site as LPS. This ligand would occupy a large part of the hydrophobic 
pocket and form H-bonds with residues Arg90 and Tyr102, which were stable 
along the simulation trajectory. Analogously, the H-bond with Gly92 was broken 
during the simulation. In addition, MD simulations have revealed that the 
presence of the ligand stabilizes the complex. In particular, MD simulations of the 
apo-state and bound state of MD-2 have shown that, in the case of the apo-state, 
MD-2 suffers an important conformational change, reducing the volume of the 
cavity entrance, in agreement with other similar MD simulations performed on the 
apo MD-2,64 whereas the bound MD-2 shows good stability.65 
Cell-based high throughput screening (HTS) allowed the identification of novel 
chemical entities as potent NFκB activators as selective TLR4 ligands: substituted 
pyramid[5-4-b]indole derivatives66 and 4-amino-quinazolines67 From the former 
family, one hit compound was selected). A series of pyrimido[5,4-b]indole rings 
with carboxamides substituted with various alkyl, cycloalkyl, aromatic and 
heteroaromatic groups was synthesized and biologically tested in order to 
establish the SAR. One of the most active compounds was docked in the mouse 
TLR4/MD-2 system. The ligand was predicted to bind within the LPS-binding 
pocket forming H-bonds with residues Glu439(TLR4) and Arg90(MD-2), and 
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multiple hydrophobic interactions. This computational study supported that active 
compounds appeared to bind primarily to MD-2 in the TLR4/MD-2 complex. 
From the second HTS, one 4-amino-quinazoline was identified with selective 
agonist activity for human TLR4/MD-2 rather than mouse.67 The docking 
calculations of this 4-amino-quinazoline into TLR4/MD-2 showed that the ligand 
establishes hydrophobic interactions with Phe119-121-126 and Leu87 and makes 
H-bonds with the residues Gln436 and Glu439 of TLR4 and Arg90 of MD-2. 
Noteworthy is the interaction of the two polar nitro oxygens of the compound with 
the backbone nitrogens of Ile124 and Lys122 of the MD-2 protein. Moreover, the 
results from the computational study underlined the importance of the Lys122, 
which happens to be a glutamic acid in mouse. This could produce an electrostatic 
repulsion effect with the nitro group, thus justifying the decreased activity in 
mTLR4/MD-2.67 Several analogues were synthesized to establish the basis for SAR, 
confirming the relevant role of the nitro group for the TLR binding and guiding 
further optimization of the lead compound. 
It was shown by liquid chromatography-mass spectrometry analysis that the 
compound termed sulforaphane (SFN) forms a covalent bond with the residue 
Cys133 of hMD-2. Covalent docking methods were applied in an attempt to 
explain the propensity of SFN to impair LPS engagement with the MD-2 
hydrophobic pocket. The authors proposed a model in which SFN, once covalently 
linked to Cys133, occupies the same position as the R3” lipid chain of LPS (PDB ID 
3FXI) and XA2 lipid chain of lipid IVa (cf. PDB ID 2E59). More precisely, in their 
model, SFN is found in close proximity with residues Ile46, Phe76, Phe147, Phe151, 
Val135 and Leu149 of MD-2. This model suggests that SFN sterically prevents 
other LPS/lipid A from approaching or settling inside the pocket.68 The same 
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mechanism was reported for the caffeic acid phenethyl ester compound, using only 
experimental methods (thus, not reviewed herein).69 
A series of compounds built by functionalizing pyrazole rings was reported by 
Bevan et al. 70 to inhibit TLR4 activation. Experimental studies indicated that two 
compounds were the lead inhibitors. Thus, these compounds were used for 
docking studies against TLR4 (using the 3D coordinates extracted from the PDB ID 
2Z65). The results indicate that both compounds independently bind at the surface 
of TLR4 where a protruding loop of MD-2 is normally found in the crystal 
structure. These predicted binding modes suggest that these compounds compete 
with MD-2 for binding TLR4, thus preventing or impairing the formation of the 
TLR4/MD-2 complex, resulting in a TLR4 able to carry out its innate immunity 
role. 
Polyphenol procyanidin B1 (Figure 8) has been shown to be able to regulate innate 
and adaptive immunity by, inter alia, impairing LPS-induced inflammatory 
responses in human monocytes.71 In order to explain its mode of action at atomic 
level, the authors undertook experimental and docking studies.72 They noted a 
high degree of similarity in terms of the interactions found in the predicted 
binding pose with the TLR4/MD-2 system when compared to the interactions 
established by LPS with TLR4/MD-2 in the crystal structure (PDB ID 3FXI). For 
instance, the phosphate group of LPS forms a hydrogen bond with Ser118 of MD-2 
where procyanidin B1 is predicted to form a hydrogen bond with Ser120, which is 
in close proximity to Ser118. In turn, the binding mode proposed by the authors 
would suggest that procyanidin B1 impairs TLR4 signaling by successfully 
competing with LPS to bind to MD-2 inside the hydrophobic pocket. 
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1.2.3 Computational studies of the TLR4/MD2 mechanism 
There are several studies in the literature focused on the extracellular domain of 
the TLR4/MD-2 complex, more specifically on its ability to recognize lipid A and 
lipid IVa. Garate et al.73 report MD simulations of at least 11 ns of apo-MD-2, 
TLR4/MD-2 dimer, MD-2/lipid A, MD-2/lipid IVa and TLR4/MD-2/lipid A 
complexes; they conclude by highlighting the hydrophobicity of the MD-2 pocket 
and its ability to close promptly in an aqueous environment. According to the 
authors, the flexibility of the helix connecting MD-2 with TLR4 (helix H1) is 
essential for the observation of this behavior, and they propose a putative 
equilibrium between the open and the closed states of MD-2. MD-2 has been 
observed to close at a similar rate in the simulations where it was in the presence 
or in the absence of TLR4. However, in the former case, MD-2 was observed to 
fluctuate less due to the presence of TLR4, reducing the number of degrees of 
freedom. Another interesting conclusion by the authors is the key role that charged 
phosphates play in the early recognition of lipids with the corresponding impact 
on the formation of heterotetramers. The MD simulations performed on the 
TLR4/MD-2/lipid A complex also showed that the presence of the ligand 
energetically stabilizes the complex, indicating cooperativity in the binding 
process.  
Evidence of the plasticity of MD-2 has also been observed by DeMarco et al. after 
several MD simulations performed in complex with variably-acylated lipid A 
molecules from Escherichia coli and Neisseria meningitidis. The results of these 
simulations (50 ns for each production run) led to the conclusion that the level of 
acylation of these ligands greatly influences the final architecture of the 
dimerization interface, leading to agonist or antagonist conformation of the 
TLR4/MD-2 system.  
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Paramo et al. performed long MD simulations of at least 100 ns on the TLR4/MD-2 
system in complex with different ligands observing the Phe126 transition from a 
closed (agonist/active conformation) to an open (antagonist/inactive conformation) 
state in the presence of lipid IVa, Eritoran and in the apo-form. The dimerization 
interface between the two partners’ heterodimers (TLR4/MD-2/TLR4*/MD-2*) was 
destabilized in agonist-free systems, especially due to the opening of the Phe126 
switch, which disrupts the arrangement of nearby side chains from Leu87, Val82 
and Met85 of MD-2. These simulations are in agreement with the NMR studies 
pointing at the re-orientation of the Phe126 aromatic side chain induced by the 
binding of hexa-acylated endotoxin. As can be observed, the lengths of the MD 
simulations range from relatively short to longer ones, depending on the origin 
(experimental vs. homology modeling) of the starting geometries, as well as the 
aim that is pursued: geometry optimization, study of the stability of the ligand-
protein/protein-protein interactions, flexibility studies, binding free energy 
calculations, etc. 
MD simulations of TLR4 alone, MD-2 alone, TLR4/MD-2 complex and TLR4/MD-
2/TLR4*/MD-2* complex were reported by de Aguiar et al.74 The simulations of the 
TLR4 ectodomain revealed pronounced conformation and structural alterations in 
the N- and C-terminal domains, showing higher RMSD values compared to the 
overall protein RMSD values. Furthermore, over 100 ns of MD simulation, the 
distance between the N-terminal and the C-terminal regions increased from 5.7 Å 
to 10.9 Å, suggesting a straightening of the TLR4 curvature. In the MD simulations 
of the TLR4/MD-2 complex, these fluctuations and deformations were lessened, 
indicating a stabilizing role of MD-2. MD simulations of MD-2 alone showed high 
mobility of the loops, especially the one containing Lys109 and the region 
comprising residues Lys55 and Lys58. Interestingly, the Lys55-Lys58 region does 
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not interact directly with TLR4, as one can observed in the crystal structure of the 
TLR4/MD-2 complex (PDB ID 3FXI). However, throughout the MD simulation of 
the TLR4/MD-2/TLR4*/MD-2* complex, MD-2 underwent structural 
rearrangements and interacted with TLR4 and TLR4*, reinforcing the idea of a 
stabilizing role of MD-2 for the TLR4 complexation. 
Anwar et al. performed computational studies of the TLR4 signaling mechanism by 
studying the species-specific behavior of TLR4/MD-2 in the recognition of RsLA.53 
In addition to the docking, the authors also reported 25-ns MD simulations of the 
docked complexes. Over the simulation, they monitored the local and global 
mobility, the surface accessible solvent area of the ligand and the surface charge 
distributions of TLR4 and MD-2. The GlcN1-GlcN2 backbone was shown to adopt 
an agonist-like conformation in horse and hamster TLR4/MD-2 and an antagonist-
like conformation in human and murine TLR4/MD-2. Additionally, the Phe126 
MD-2 loop, from residue 123 to residue 129, containing the on/off switch Phe126, 
proved to be less stable in the human and the murine complex, than in the horse 
and the hamster ones. The RMSD of the MD-2 loop from residue 81 to residue 89, 
which interact with TLR4* thus mediating the dimerization event, showed greater 
variations in humans and mice than in horses and hamsters. These data suggest a 
relationship between the flexibility of both loops (residues 81-89 and residues 123-
129) and the agonist/antagonist activity of the ligand and provide a plausible 
explanation for the species-specific behavior of RsLA regarding TLR4 activation. 
Computational strategies were also applied to study TLR4 and MD-2 mutants. In a 
2009 study, Slivka et al. used the Rosetta software75 to compare the binding energy 
of a truncated MD-2 with the original one.76 MD-2 was truncated (termed MD-2-I) 
to keep only the residues identified as playing a major role in maintaining the 
TLR4/MD-2 heterodimer stability. The docking experiment was performed 
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targeting both a partial human TLR4 retrieved from the Protein Data Bank (PDB ID 
2Z65) and a full-length TLR4 humanized model built by mutating the residues at 
the TLR4/MD-2 heterodimer interface in the mouse crystal structure (PDB ID 2Z64) 
into their human counterparts (TLR4: F160L, G234N, K263R, D264N, T290A; MD-2: 
H96R, H98R). In the first case, the affinity of MD-2-I was found higher than the one 
of the full-length MD-2. When docked against the human TLR4 model, MD-2-I 
exhibited a lower affinity than the full-length MD-2. Altogether, these results 
indicate that MD-2-I is theoretically able to bind TLR4 and might even compete 
with the full-length MD-2. This was confirmed by cell assay experiments showing 
that the addition of MD-2-I abolishes cell responsiveness to LPS stimulation. Flow 
cytometry analyses on HEK293 cells transfected with all proteins involved in the 
TLR4 activation pathway incubated with LPS covalently linked to fluorescein 
isothiocyanate indicate that MD-2-I impedes TLR4/MD-2 dimerization. The SEAP 
assay shows that MD-2-I also alters downstream signaling. 
Recently, the critical role of residue Val135 of MD-2, located deeply inside the 
hydrophobic pocket, was reported by Vasl et al.77 hMD-2 has the ability to bind LPS 
in the absence of TLR4, while mMD-2 is responsive to LPS only when engaged in a 
complex with TLR4. Site-directed mutagenesis was applied to hMD-2 to mutate 
Val135 to its murine alanine counterpart. This single point mutation led to a 
mutant V135A hMD-2 lacking the ability to bind LPS. A series of 50-ns MD 
simulations of the WT hMD-2 and the V135A mutant hMD-2 in solution and in 
complex with TLR4 was performed to study the conformational changes. In the 
case of the WT hMD-2, the authors reported an abrupt decrease of the SASA and 
volume in the first nanoseconds of the simulation, describing it as a hydrophobic 
collapse. This phenomenon was not observed in the V135A systems, suggesting 
that Val135 is primordial to confer plasticity to MD-2. This trend was confirmed by 
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another simulation of MD-2 in complex with three myristic acids (as reported in 
PDB ID 2E26). The V135A mutant hMD-2 needed a much longer simulation time to 
adapt its shape to the three 
1.2.4 Computational studies of the TLR4 intracellular domain 
The intracellular domain of the TLR4 transmembrane protein contains a 
Toll/interleukin-1 receptor (TIR) homology domain, which is a common feature of 
all adaptors involved in the initiation of TLR4 signaling, mediating protein-protein 
interactions between the TLR4 and the signal transduction components. TLR4 has 
two distinguished signaling pathways involving primarily four TIR-domain-
containing adaptors. In the first pathway, the MyD88 adapter-like (Mal) acts as a 
“sorting” adaptor by recruiting the myeloid differentiation primary response gene 
88 (MyD88), the “signaling” adaptor, to the plasma membrane. In the second 
pathway, the TRIF-related adaptor molecule (TRAM) plays the role of “sorting” 
adaptor, which recruits the TIR-domain-containing adapter-inducing interferon-β 
(TRIF), the “signaling” adaptor, to the membrane to initiate the signal (Figure 9) 
.As a major component of theses adaptors, the TIR domain is believed to play a 
central role in the recruitment processes.14, 78 
The crystal structures of human TLR1 (PDB ID 1FYV) and TLR2 (PDB ID 1FYW) 
revealed the structural basis of the TIR domain79 followed by the crystal structure 
of TLR10 TIR domain (PDB ID 2J67)80 and the solution structure of MyD88 TIR 
domain resolved by NMR (PDB ID 2JS7 and 2Z5V).81 Prior to that release, two 
homology models of the TIR domain of MyD88 were reported. Both were built 
based on the TLR2 TIR domain crystal structure (PDB ID 1FYW) resolved by X-ray 
crystallography.82 In 2012, the crystal structure of Mal was also resolved by X-ray 
crystallography (PDB ID 3UB2).83 
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The lack of structural information for the TIR domain of TLR4 has driven the 
creation of models to clarify the recruitment of adaptors from a structural 
perspective. Dunne et al.84 built monomer models of TLR4, Mal and MyD88 using 
comparative modeling and loop refining techniques. They noted differences in the 
electrostatic surface potentials suggesting that adaptor binding is driven by 
electrostatic complementarity (Figure 10).  
 
Figure 9: MyD88 and TRAM signalling pathways involved in TLR4 activation. 
Extracted from 85. 
This point was also emphasized in a study by Kubarenko et al.86 in which they 
compared the surface charges of TIR domains of the crystal structure of hTLR2 and 
of the models of hTLR3 and hTLR4 and noted that the surface charge distribution 
of the BB loop and the αC-helix present similarities in TLR2 and TLR4 and differ 
between TLR3 and TLR4. The authors considered that these findings could explain 
why TLR2 and TLR4 recruit MyD88, whereas TLR3 does not. In the computational 
study by Gong et al.,87 it was highlighted that, whereas the BB-loop is highly 
conserved among TIR-domains, the APBS electrostatic surfaces differ. The authors 
hypothesized that this finding might explain the specificity and selectivity of 
adaptors recruitment. An experimental study showed that a single point mutation 
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in the TIR domain of murine TLR4 (P712H) renders the system hyporesponsive to 
LPS stimulation. The authors noted that their data do not suggest a direct role for 
this residue. 
Dunne et al.84 used a docking procedure based on hydrophobicity and geometry. 
Their results suggest that Mal and MyD88 bind at two distinct binding sites (non-
overlapping): the DD- and DE-loops of Mal forming interactions with the BB-loop 
and αC helix of TLR4-TIR domain and the AA- and DD-loop of MyD88 with the 
CD-loop of TLR4. The biological relevance of this binding mode was later 
questioned, as it was discovered that TLR4 activation required homodimerization. 
In line with that, in 2007, Miguel et al.88 reported the first 3D model of the dimer of 
the TIR domain of TLR4; a dimer composed of two identical subunits, arranged in 
a two-fold axis of symmetry. Despite the observation that some loops are 
differently oriented, the overall monomeric fold and the secondary structure of 
each subunit are very similar to the monomer model reviewed above.84 This dimer 
model outlines significant interactions between the BB-loops of each monomer; for 
instance, residues Phe712 are engaged in homotypic aromatic interactions. A flat, 
but slightly curved surface was observed and attributed to the side facing the 
membrane. The authors also reported a docking study of TRAM and Mal with the 
TLR4 dimeric model in which the two adaptors bind at either sides of the dimer 
interface formed by the union of the two TLR4-TIR domains, which are identical 
due to the symmetry. They noted that both adaptors are forming strong 
interactions with TLR4 Trp757. Mal is also interacting with His728, Arg763 and 
Lys819, whereas TRAM interacts with Glu684, Arg780 and Glu824. The residues of 
the adaptors found at the TLR4 interface are mostly located on the BB-loop 
suggesting that the BB-loop of all three TIR-containing structures is of critical 
importance for binding specificity and selectivity. 
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Gong et al.87 performed a docking study based on the geometry, hydrophobicity 
and electrostatic complementarity of the molecular surface reporting a dimeric 
model different from the model described above. The interface is formed by 
residues Pro714 to Ala717 from the BB-loop of one monomer protruding into a 
groove formed by residues Cys747 to Ile748 from the αC of the other monomer, 
and vice versa. In another study, Basith et al.89 used in silico approaches (homology 
modeling, protein-protein docking and 5.5-ns MD simulations) to investigate the 
inhibitory effect of ST2L toward TLR4 activation. ST2L (IL-33r) is a member of the 
Toll-like/IL-1 receptor superfamily known to negatively regulate MyD88-
dependant signaling pathway. The authors reported a TLR4-TLR4 homodimer 
model,88 and their docking study also gave a similar binding mode for Mal (at each 
side of the dimer). Their results indicate that MyD88 is recruited by Mal, and that 
ST2L prevents the recruitment of MyD88 by binding at the Mal interface. Thus, 
according to these results, ST2L successfully competes with MyD88 to bind at the 
Mal interface. 
 
Figure 10: Representation of the different ways the dimer is proposed by published 
computational strategies to be assembled in the literature by computational strategies. (a) 
First reported by Miguel et al.88; (b) reported by Gong et al.87; (c-e) reported by Guven-
Maiorov et al.90 
In a later study, Bovijn et al.91 reported a homology model constructed based on the 
crystal structure of the dimeric TLR10 TIR domain. This model is also in agreement 
with the first model reported by Miguel et al.88 The authors proposed that Mal and 
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TRAM adaptors are competing for binding an extended site formed by the reunion 
of two TLR4 intracellular domains. An experimental mutation study showed that 
all mutations that impaired Mal binding also impaired TRAM binding, 
strengthening the idea that Mal and TRAM bind to the same molecular surface. 
They define the TLR4/TLR4* dimer interface as binding site II, composed of 
residues from the BB-loop, DD-loop and αC. Then, they describe that the binding 
site for TRAM and Mal is formed by the reunion of two sites (as defined in the 
study: residues from αA αB BB and BC), which is in disagreement with the 
binding site proposed by Miguel et al.88 The authors thus argue that their model is 
supported by experimental data and residue conservation analysis. The binding 
site III is defined as being located at the opposite direction of binding site I and 
might be implicated in the interferon regulatory factor 3 (IRF-3) activation. 
Singh et al.92 studied the importance of the highly conserved β-sheets among TLRs’ 
TIR domain and revealed their primordial implications in the communication 
network. MD simulations of 100 ns of models based on sequence similarity were 
performed. MD simulations were used to study the long-range interactions 
between residues separated by at least 20 residues in the sequence. They reported 
interactions between the backbone atoms of the first β-sheet with the BB-loop and 
the third β-sheet. The authors identified four interacting hubs mainly constituted 
of hydrophobic residues. Among them, three are in the β-sheets just before the BB-
loop, the αC helix and the DD-loops, stressing their role in TIR/TIR interaction. 
This hypothesis was further supported by analyzing the mutations known to 
completely abrogate signaling. They show that mutants IFI767-769AAA and L815A 
disturb the interacting network, thus explaining the impaired TIR domain 
homodimerization capacity. In a very recent paper by Guven-Maiorov et al.,93 the 
authors used computational techniques to describe the architecture of the 
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signalosome of TLR4. They built three models of the intracellular part of the TLR4 
protein. These three dimer models are all unprecedented despite that the 
secondary structure of the monomer is in great agreement with all of the published 
models. Furthermore, the authors used two of their models to propose different 
binding modes for Mal. 
1.3 Sugars and proteins 
The fundamental dogma of molecular biology establishes that the information 
flux in a biological system starts in the DNA and ends in proteins, via the RNA. 
Thus, study fields that emerge from this affirmation are three: genomics (study of 
the DNA), transcriptomics (study of the RNA) and proteomics (study of 
proteins). However, this view is not complete inasmuch as step by step we 
realize, the two forgotten in the dogma, lipids and carbohydrates, play a 
fundamental role in the correct interpretation of the cell signaling. Due to the 
increasing importance these two cellular components, the lipidomics (study of 
lipids) and glycomics (study of carbohydrates), are getting, they are making their 
way to consolidate themselves as a study field, together with the other three, of 
the general interest in the scientific community.94 
Carbohydrates are very abundant in nature and they key players in numerous 
biological roles. They are the fundamental source of metabolic energy. In fact they 
represent an important element in our diet; some insoluble carbohydrate polymers 
serve to lubricate skeletal joints and provide adhesion between cells and others 
serve as structural and protective elements in the cell walls of bacteria and plants 
and in the connective tissues and cell coats of animals. Sugars can exist in nature as 
single entities or as a forming part of glycoconjugates, essentially glycolipids and 
glycoproteins. Chemically, carbohydrates are polyhydroxy aldehydes or ketones, 
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and their chemical formula is usually Cn(H2O)n (carbon “hydrates”), but some 
“natural” carbohydrates can also contain nitrogen, phosphorus, sulphur. Their 
chemical variability is enormous, due to the possibilities of branching at either 
hydroxyl group as well as the possible presence of pendant substituents, either 
neutral or charged.95 In turn, this variability generates a huge possibility of 
constitutional isomers and a plethora of conformations. Moreover, their chemical 
properties in terms of the presence of polar and non-polar patches make them to 
exhibit peculiar stability and, acting as ligands for receptors, to be fairly adaptable 
to a variety of environments. They may adopt different shapes and display rather 
distinct conformational and dynamic properties. Glycan diversity depends on the 
monosaccharides (basic unit of saccharide) which are made by, on the linkages that 
connect monosaccharides (glycosidic linkage), and on other factors such as the 
anomeric effects, the orientation of all the torsional angles,96 and the intramolecular 
hydrogen bonding between adjacent OH groups.97 Therefore, it is of paramount 
importance to predict and characterize their conformational and structural 
properties in a systematic manner. Computational techniques have proven to be 
essential in this aspect.98 
1.3.1 Sugars 
Monosaccharides 
Carbohydrates are made by small constituents, named monosaccharides (or simply 
sugars). Monosaccharides are composed of a single polyhydroxy aldehyde or 
ketone unit and may have different number of carbons normally from five to nine. 
The most abundant monosaccharide in nature is D-glucose. Usually the carbons of 
a monosaccharide have hydroxyl groups attached and they are normally 
stereogenic centres.  
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Monosaccharides of six carbons (called pyranoses) usually adopt chair 
conformations and the substituents can be found either in the axial or equatorial 
position. In pyranose sugars, if there is a hydroxyl group at the anomeric carbon 
(the hemiacetal/acetal carbon) the monosaccharide can adopt an α or a β 
configuration. Both α and β isomers are optically active and usually present similar 
physical properties. If the substituent on the anomeric carbon is electronegative 
(like a methoxy group) there is a preference of the substituent to adopt an axial 
configuration rather than an equatorial one. This phenomenon is called anomeric 
effect, which is countered by steric factors, reason why D-sugars present more 
stability as α isomer.99 If the hydroxyl group is attached to another carbon which is 
not the anomeric one, leads to a different monosaccharide (epimer) with 
completely different properties. For example, glucose and mannose differ on the 
position of the OH group in position 2 (in equatorial position in glucose and in 
axial in mannose) and glucose and galactose in the OH of position 4 (in equatorial 
position in glucose and in axial in galactose) (Figure 11). 
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Figure 11: α and β configuration of glucose (top) and epimers of the β-glucose on 
C2 (mannose) and C4 (galactose)(bottom). 
Moreover, simple monosaccharides may adopt distinct three-dimensional shapes. 
The most common shape for a pyranose is the chair conformation that minimizes 
steric congestion and includes the anomeric effect. However, also other shapes are 
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allowed, depending on the orientation, nature and number of substituents. The 
most prevalent alternative shapes for a pyranose are the boat, the skew and the 
envelope. 
Regarding the conformation of the dihedral angle (ω) around C5-C6 in a pyranose 
ring (ω formed by O5-C5-C6-O6 according to the X-ray definition or by H5-C5-C6-
O6 according to the NMR definition), a combination of solvation, steric, and 
stereoelectronic (gauche effect) effects drive the observed geometries. It has been 
monitored that for glucose-type sugars, a combination of gauche-gauche (gg) and 
gauche-trans (gt) rotamers coexists, while for galactose-type, ω prefers gauche-trans 
(gt) and trans-gauche (tg) geometries. This experimental behavior has also been 
validated using computational protocols.100 
Disaccharides 
Monosaccharides are attached among them through the so-called glycosidic 
linkage. The anomeric oxygen of one particular monosaccharide is attached to a 
secondary (or primary) hydroxyl group from the second sugar moiety to build one 
disaccharide (Figure 12). The glycosidic linkage is an acetal linkage with particular 
chemical properties and conformational features. For example, it is sensitive to 
strong acid and basic conditions. 
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Figure 12: Formation of a Maltose unit from two glucose units. 
If the substituent at the anomeric carbon presents lone pair electrons, for example 
an alkoxy group, retrodonation can occur from the exocyclic oxygen to the sigma 
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anti-bonding orbital of the intracyclic bond C-O. This effect is known as the exo-
anomeric effect.101 In this case, the lone-pair orbital has to be anti-periplanar to the 
antibonding orbital of C-O and, consequently, the alkyl substituent at the 
glycosidic oxygen adopts a syn-type orientation. The molecular orbital theory is 
able to predict also the modification of the bond length. In fact, for equatorially 
substituted pyranosides, the intracyclic C-O bond is longer than the exocyclic C-O 
bond.  
Actually, these preferences lead to a syn-type conformation, although it has been 
observed that a minor proportion of anti- conformation may co-exist in β-
glycosides (e.g. in 1→2, 1→3 and 1→4 linkages) provided that the contiguous OH-
2 displays an equatorial orientation (i.e., glucose or galactose). The anti-type 
geometry is also favoured by the exo-anomeric effect. Combined modelling/Nuclear 
Magnetic Resonance (NMR) approaches are mandatory to characterize the 
glycosidic linkage of a particular disaccharide or oligo-saccharide (either α and β, 
either 1→2, 1→3, 1→4, or 1→6).100, 102 All the particular features mentioned above 
for saccharides, besides their intrinsic dynamic properties require the synergy 
combination of rigorous experimental and theoretical protocols.103 
Oligosaccharides and polysaccharides 
Oligosaccharides are composed of a small number of monosaccharides. Their 
conformational properties, adaptability and recognition features have been, and 
still are, deeply analyzed.104 Chemical methods have been employed to provide 
stable chemical analogues of oligosaccharides, with increased resistance to glycosyl 
hydrolases. Typically, either the glyosidic (inter-unit) or the endocyclic oxygen 
within the ring is substituted by other chemical element. Therefore, C-,105 S-,106 Se-
,107 and N-108 glycosyl analogues have been synthesized to provide chemical probes 
for interaction studies or to prepare enzyme inhibitors. Given the different 
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chemical properties of these analogues, their conformational properties have been 
carefully analyzed and compared to those of their parent O-glycosides.109 
Computational studies have been directed towards the analysis of the flexibility of 
these new linked glycosides, and the preferences of the binding proteins to select 
the proper “binding pose” from the conformational assemble, not always being the 
most stable conformer in terms of potential energy.110  
1.3.2 Proteins 
Proteins that bind carbohydrates are called GBPs (Glycan Binding Protein) and in 
this group lectins, receptors, toxins, microbial adhesins, antibodies and enzymes, 
among others111 are included. In the framework of cellular recognition, non-
enzymatic proteins are the most important proteins that bind carbohydrates 
without changing its chemical structure. Between them, lectins are widely 
distributed in nature since they can be found in almost all living organisms. The 
recognition process between a lectin and a carbohydrate usually occurs through: 
A) hydrophobic interactions, such as CH-π interaction (between the sugar moiety 
and residues such as tryptophan, tyrosine and phenylalanine); B) a net of 
hydrogen bonds between the OH groups of the sugar and the polar groups of the 
protein (frequently, also water molecules are involved in this net); and C) metal 
coordination (usually with calcium or manganese) present in the binding site of the 
lectins (Figure 13). 
These characteristic interactions occur in a specific region of the protein normally 
named Carbohydrate Recognition Domain (CRD). Unconventional sugars binding 
sites have been observed, as for the C-type lectin-like receptor 2 (CLEC-2).112 The 
specificity of a lectin to recognize selectively some epitopes is due to the diversity 
of the CRD. Actually lectins have been classified based on their CRD, the sugar 
specificity and their expression patterns. In particular, human lectins are divided 
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into two classes: C-type (or calcium-dependent) lectins and S-type (sulfhydryl-
dependent or calcium-independent) lectins. Their main functions are the cellular 
recognition, cellular adhesion regulation, as well as immunological functions such 
as recognition of sugars from pathogen organisms.113 Lectins also play an essential 
role in the infection process. One of the most studied players in this event is the 
Dendritic-Cell Specific ICAM-3 Grabbing Nonintegrin (DC-SIGN). DC-SIGN is a 
C-type lectin that has been demonstrated to spread and evade the immune system 
by the HIV virus. Fittingly, this lectin seems to be involved in several infections by 
pathogens, such as Ebola virus and Mycobacterium tuberculosis.114  
 
Figure 13: Examples of carbohydrate-protein interactions. Left) DC-SIGN in 
complex with a trimannoside, which coordinates through a calcium atom. Right) Galectin-3 
in complex with lactose. Glucose moiety interacts with a Histidine and an Arginine 
through hydrogen bonds and with a Tryptophan through a CH-π interaction. 
Plant lectins are accumulated in seeds or other tissues and mainly have a storage 
function but also they seem to play an important role in plant defence. Twelve 
families of lectins have been identified, although they commonly share some 
features. Plant lectins are usually found as dimers or tetramers, in which each 
monomer has a CRD with two metal binding sites for calcium and manganese. In 
the dimer there is a side-side protein-protein interaction forming 12-strandeed 
sheet. Plant lectins are very interesting because due to their easy availability are 
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extensively used as spy molecules due to their high glycans specificity. For 
example, it is very well known that Pea lectin and Concanavalin A selectively bind 
mannose or glucose, while Maackia amurensis lectin binds sialic acids. To date, 
more than 132 crystal structures of legume lectins from 18 different plants are 
available from the Protein Data Bank (PDB).115  
Galectins 
A special type of lectins evolutionary-conserved116 is galectins (abbreviation of 
galactose binding lectins). Galectins constitute a family of β-D-galactoside binding 
proteins. They are localized in cytoplasm, nucleus, cell surface, and extracellular 
matrix,117 and present a S-type sequence motif. To date 15 members of this family 
have been identified in mammals (gal-1 to -15), but only 10 of them are present in 
humans (gal-1, -2, -3, -4, -7, -8, -9, -10, -12, -13).118 They are soluble proteins with a 
molecular weight around 14-36 kDa119 and they lack of enzymatic activity.96b 
Among the physiological processes in which galectins have an important role, 
there are regulation of the immune response, cell cycle, cell growth and 
apoptosis.120 Due to these functions, an alteration in these proteins can trigger 
various pathological processes, depending on which galectin is affected. Thus, it 
has been demonstrated that galectins are involved in processes like cancer, 
metastasis, inflammation, hypersensitivity and atherosclerosis, among other 
pathologies.121 Therefore, in the last years the interest in these proteins as 
therapeutic targets has increased since the development of selective galectins 
modulators could improve the prognosis of many diseases.122  
Based on the structural features, mammalian galectins have been classified in 
proto, tandem-repeat, and chimera types. Proto-type galectins (gal-1, -2, -5, -7, -10, 
-11, -13, -14, and -15) are usually dimers containing only one type of CRD 
(homodimers) non-covalently joined (Figure 13). Tandem-repeat-type galectins 
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(gal-4, -6, -8, -9, and -12) have two different CRDs, almost homologous, that are 
covalently joined. Chimera-type galectin (only gal-3) has a carboxyl-terminal CRD 
associated to an amino-terminal peptide which is rich in tyrosine, proline and 
glycine (collagen-like sequence),123 forming a tail that intervenes in the 
oligomerization of this unique galectin.124 
 
Figure 14: Schematic representation of the three galectin groups (prototype, tandem 
repeat and chimera) and their role in the recognition of microbial glycans.  
Extracted from 125. 
The activity of galectins is ligand-concentration dependent and it can be both 
stimulatory and inhibitory.126 These proteins recognize carbohydrates through the 
CRD, which consists of 130 amino acids approximately,127 and it folds into a β-
sandwich structure comprising two anti-parallel β-sheets (the F-sheet and S-
sheet).128 The CRD that is different among the galectins family, establishes a net of 
interactions selectively with the β-galactoside moiety through the formation of 
hydrogen bonds and hydrophobic interactions with tryptophan, histidine), and 
arginine residues.129 Apart from the CRD, galectins differ in other aspects, such as 
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chain length or number of domains in their structure. To date, more than one 
hundred X-ray structures of human galectins are available at the PDB.115 For the 
studies performed in this Thesis, we selected one or two X-ray crystallographic 
structures for each human galectin (PDB ID codes are shown in Table 1.2). 
DC-SIGN 
Dendritic Cell-Specific Intercellular adhesion molecule-3 grabbing non-integrin 
(DC-SIGN) is a type II membrane receptor that was characterized initially as a 
receptor for the HIV glycoprotein gp120. It was some years later when DC-SIGN 
was postulated as a cell-adhesion receptor, which has an important role in the 
infection by HIV.130 DC-SIGN is expressed in dendritic cell, macrophages that 
infiltrate tumors and antigen presenting cells of tissues like the placenta.  
The main function of DC-SIGN is the recognition of glycans through its CRD. 
This CRD is a C-type lectin like domain that binds fucose and mannose and has 
two Ca2+ coordination sites. Thus, DC-SIGN recognizes fucosylated glycans, like 
blood-type Lewis antigens, and high mannose glycans. The relatively broad 
specificity confers DC-SIGN to recognize a huge variety of ligands, both 
pathogenic (e.g. from HIV, Micobacterium tuberculosis, Candida albicans and Ebola 
virus) and self-glycoproteins, such as intercellular adhesion molecule and the Fc 
portion of immunoglobulins.131 Furthermore, the supramolecular organization of 
DC-SIGN enhances its pathogen-recognition capacity. It is assembled as a 
tetramer through the interaction of its α-helical neck domain into a four-stranded 
bundle. This configuration achieves two goals: it projects the CRD about 35nm 
away from the membrane, and clusters the four CRDs together to facilitate the 
interactions with the ligand.132  
DC-SIGN mediates the receptor-mediated endocytosis upon ligand binding. This 
internalization promotes and efficient antigen processing and presentation to 
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MHC class II.133 Interestingly, DC-SIGN can also deliver its cargo to an 
uncharacterized cross-presentation route,134 which makes this protein an 
interesting candidate for the development of cancer vaccines as activator of the 
CD8+ T cell responses.135 Moreover, DC-SIGN-dependent cross-presentation is 
enhanced by the simultaneous triggering of TLRs. It has been demonstrated that 
the activation of TLR4 promotes the translocation of the cargo of activated DC-
SIGN to the cytosol, leading to an increased CD8+ T cell activation.136 
DC-SIGN also behaves as a signaling receptor. In vitro experiments have 
demonstrated that the triggering of DC-SIGN alone does not initiate changes in 
DC activation status or cytokine secretion, but can shape immune responses by 
modulating the signaling elicited by other pattern-recognition receptors. 
Interaction of DC-SIGN with mannose-containing ligands results in the 
recruitment of the upstream effector Rho guanine nucleotide exchange factor 12 
(LARG) and Ras homolog family member A (RhoA). This recruitment yields to 
the increase in the transcription rate of genes like IL12 and IL6. On the contrary, 
fucose-containing DC-SIGN ligands suppress the production of pro inflammatory 
cytokines.137 The capacity of DC-SIGN to discriminate among its multiple ligands 
to modulate the signaling of TLRs into a pro- or an anti-inflammatory response is 
unique among the C-type lectin family.138 Mannose glycans are present in higher 
mammals only in the endoplasmic reticulum so, the exposure of these molecules 
on glycoproteins or in the extracellular space might be a sign for DC-SIGN of cell 
damage or invasion thus leading to the expression of proinflammatory 
cytokines.139 
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1.4 Objectives 
The main objective of this thesis is to study by means of computational techniques 
the molecular recognition processes of receptors involved in the innate immunity. 
More concretely, on one hand, we will focus in two different types of lectins, 
Galectins and DC-SIGN, and on the other hand, we will focus in Toll-like receptor 
4. The studies regarding these proteins will be carried out by addressing the 
following specific objectives along the following chapters: 
Chapter 3. We propose the computational design of novel binders with improved 
affinity and selectivity towards galectins 1, 3 and 7, main players in tumoral 
events. By means of fragment-based virtual screening protocols, the vicinal pocket 
close to the carbohydrate recognition domain will be explored to identify 
appropriate moieties able to be selectively anchored to these pockets. We aim the 
design of modified lactose derivatives able to bind the galectins with improved 
affinity and with selectivity towards the different galectin subtypes 1, 3 and 7. 
Selected candidates will be synthesized by collaborators and their affinity and 
selectivity will be measured by biophysical techniques. 
Chapter 4. We aim the design of new glycomimetics as DC-SIGN antagonists with 
high affinity and selectivity. A fragment-based virtual screening strategy will be 
used to explore adjacent pockets near the mannose binding site as accessible 
pockets to be anchored. Designed compounds will be docked and their binding 
mode studied by MD simulations. A selection of compounds will be synthesized to 
be tested and studied by biophysical techniques. 
Chapter 5. This chapter will be devoted to the study of the molecular recognition 
process of several TLR4 modulators and their binding mode at atomic level. By 
means of docking and MD simulation, we will propose binding modes for three 
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reported peptides: peptides RS01 and RS09 with agonist activity, and MDMP 
peptide with antagonist activity. Moreover, we will study and propose the binding 
mode of cardiolipin to TLR4 to explain the synergistic effect of this compound in 
combination with LPS. Finally, the binding mode of a tetracylated and 
pentacylated Bacteroides vulgatus LPS accounting for the observed weak agonist 
activity will be proposed. 
Chapter 6. We aim the discovery of non LPS-like compounds with activity as TLR4 
modulators. We will develop a virtual screening strategy to be applied from 
public, commercial and in-house libraries, followed by re-docking and biological 
assays, in order to identify novel TLR4 modulators with a non LPS-related 
chemical structure. 
Chapter 7. We will deepen in the knowledge of the structure of the full TLR4/MD-2 
heterodimer system in order to gain insights into its functioning for drug design 
purposes. To do so, we will build a complete heterodimer including the 
extracellular, transmembrane and intracellular domains, including the membrane 
environment. We will model the dimerization of the transmembrane and 
intracellular domains. Also the binding mode of the MAL intracellular adaptor 
protein will be studied 
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OVERVIEW 
The rise of computational methods and their wider application in research has 
been very helpful to solve biological problems, since they allows to explain 
molecular recognition events, facilitate the design of novel molecules with higher 
affinity and guide the synthesis in the optimization of new molecules.1 Docking 
techniques predict the possible binding poses at a concrete binding site of a given 
target, and provides a first estimation of the binding energy. The estimation of the 
strength of the intermolecular interaction between the ligand and its biological 
target is predicted through molecular mechanics (MM) and molecular dynamics 
(MD). These methods are also used to predict the conformation of the small 
molecules and to model conformational changes in the target that may occur when 
the binding occurs. In the case that the 3D structure of the target is not available (it 
has not been elucidated structurally), homology modelling will allow us to predict 
it, using templates that share common features with it. Semi-empirical, ab initio 
quantum mechanics methods and density functional theory (DFT) are often used 
to provide optimized parameters for the molecular mechanics calculations and also 
to estimate the electronic properties (electrostatic potential, polarizability, etc.) of 
the drug candidate that will influence binding affinity.  
This chapter aims to describe the different computational techniques that have 
been used is this thesis.  
1.1 Docking 
The interactions between biologically relevant molecules such as proteins, nucleic 
acids, carbohydrates, or lipids, play a central role in signal transduction. 
Furthermore, the relative orientation of the two interacting partners may affect the 
type of produced signal (e.g., agonism or antagonism). Molecular docking is a 
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computational procedure that aims to predict the preferred orientation of a ligand 
with a macromolecular target (also called receptor) in which they are bound to 
each other to form a stable complex. Docking is a useful tool to predict bioactive 
conformations, identify binding sites inside a given receptor, unveil essential 
ligand-receptor interactions, and to screen vast databases of potential ligands.2  
Several docking programs are available in the context of molecular recognition and 
drug design. We can cite AutoDock3, AutoDock Vina4, DOCK5, FlexX6,  GLIDE7,  
ICM8, PhDOCK9, and Surflex10). They have been extensively tested and compared.11 
Although each docking program operates slightly differently, a docking 
calculation is basically characterized by two main steps: in the first step, a 
conformational search is performed, to predict possible conformations of the small 
molecule (ligand); in the subsequent second step, for the different binding poses, 
the ligand binding energy is calculated by applying a scoring function, so the 
predicted ligand-receptor complexes are scored and ranked. Therefore, the main 
differences among the existing docking programs rely on how they perform the 
computational search and which scoring function they use in order to rank the 
docked poses.12  
Regarding the conformational search, the accuracy and the computational cost of a 
docking calculation depend also on the number of rotatable bonds present in the 
ligand. Each program has a threshold of the maximum number of allowed 
rotatable bonds, due to the exponentially growth of the computational cost that 
causes a higher number of this feature. 
Three types of search algorithm can be applied: shape matching, systematic search 
and stochastic or non-deterministic algorithms. The more time-efficient algorithms, 
in terms of accuracy and computational time, are the stochastic algorithms. 
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In the stochastic algorithm, random changes in the ligand are executed. This 
change will be accepted or rejected according to probabilistic criteria. Four types of 
stochastic algorithms are known: Monte Carlo (MC) methods, Evolutionary 
Algorithms (EA), Tabu search methods and Swarm Optimization (SO) methods.  
In MC methods, Boltzmann probability function is applied: 
 𝑃𝑃 = 𝑒𝑒𝑒𝑒𝑒𝑒 �−(𝐸𝐸1 − 𝐸𝐸0)
𝑘𝑘𝐵𝐵𝑇𝑇
� [2-1] 
E0 and E1 represent the energy score before and after the change of the conformer, 
respectively, kB the Boltzmann constant and T the absolute temperature of the 
system. 
EA algorithms search for the correct ligand binding mode using ideas based on 
genetics and evolutionary processes in biological systems. A “natural protocol” is 
applied, which consists in the first generation of individuals and the evaluation of 
the fitness. According to the Darwin theory, the best-fit individuals for 
reproduction are selected, and after crossover and mutations new individuals are 
generated. Thus, the optimization is based on a selection process that mimics 
biological evolution. One of the most popular is the Genetic Algorithm (GA), in 
which an analogy with evolutionary selection is applied. Basically, the translation, 
orientation, and conformation of a small molecule describe the gene, each state 
(conformation) corresponds to the genotype, and the atomic coordinates 
correspond to the phenotype. The best solutions will survive and will reproduce 
(with crossover and mutation), whereas the worse ones will be discarded. Other 
genetic algorithms have been proposed in order to represent more complex 
situations.13 For example, an improvement of the genetic algorithm can be obtained 
by introducing a local search (LS) method.14 A LS method performs energy 
minimization, without requiring gradient information about the local energy 
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landscape. The hybrid method between GA and LS is named Lamarckian Genetic 
Algorithm (LGA). Another hybrid algorithm is the simulated annealing, in which a 
GA and LS methods are applied depending on the temperature. The advantage of 
this method is the possibility to overcome energy barriers separating energetic 
valleys by means of high temperature.  
Regarding the second step, the scoring and ranking of the different predicted 
binding poses are performed by means of a scoring function. The available scoring 
functions can be of three types:  
- Force Field (FF) based scoring functions,15 where a classic force field 
is employed to compute individual interaction terms such as van der Waals 
and electrostatic energies and stretching, bending, and torsional energies. 
Several disadvantages are related to this scoring function. One of the 
disadvantages is the solvent effect, which is finally defined by a distance-
dependent dielectric constant. Another problem related to the FF scoring 
function is how to treat the water. The Poisson-Boltzmann/Surface Area 
(PB/SA) model and the Generalized-Born/Surface Area (GB/SA) use implicit 
solvent models to overcome this problem. But the more severe challenge 
still remains the entropic effect.  
 𝐸𝐸 =  ���𝐴𝐴𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖12 − 𝐵𝐵𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖6 + 𝑞𝑞𝑖𝑖𝑞𝑞𝑖𝑖𝜀𝜀�𝑟𝑟𝑖𝑖𝑖𝑖�𝑟𝑟𝑖𝑖𝑖𝑖�𝑖𝑖𝑖𝑖  [2-2] 
In equation [2-2], rij represents the distance between an atom i of the protein 
and an atom j of the ligand. Aij and Bij are the van der Walls parameters, 
and qi and qj are the atomic charges of the atom i and j respectively. ε(rij) 
reflects the screening effect of water on electrostatic interactions and it is 
usually set to 4rij. 
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- Empirical scoring function16 calculates the overall binding free 
energy, by summing up a set of weighted empirical energy terms, including 
hydrogen bond (H-bond) and hydrophobic interactions. Compared to the 
FF scoring functions, it is more computationally efficient. Its applicability 
depends on the training set (i.e. known experimental data for a set of 
molecules) and the fitting to known binding affinities. Glide Score is one of 
the examples of empirical scoring function.  
 ∆𝐺𝐺 =  �𝑊𝑊𝑖𝑖∆𝐺𝐺𝑖𝑖
𝑖𝑖
 [2-3] 
ΔGi stands for the individual empirical energy terms and the corresponding 
coefficients Wi. 
- Knowledge-Based (KB) scoring functions17 are based on the sum of 
distance-dependent statistical potentials between the ligand and the target. 
The structural information of the complex formed by the protein and the 
ligand is needed.  
 𝜔𝜔(𝑟𝑟) = −𝑘𝑘𝐵𝐵𝑇𝑇𝑇𝑇𝑇𝑇 � 𝜌𝜌(𝑟𝑟)𝜌𝜌∗(𝑟𝑟)� [2-4] 
 
the scoring function is dependent on the density of the protein-ligand atom 
pair ρ at the distance r in the training set, and the pair density in a reference 
state ρ* where there are no interatomic interactions at the absolute 
temperature T. kB is the Boltzmann constant. 
In this thesis, three different docking programs were used: AutoDock, AutoDock 
Vina, and GLIDE. 
1.2.1 Autodock 
AutoDock18 is an automated procedure for predicting the interaction of ligands 
with bio-macromolecular targets developed by Olson and coworkers in 1996.19 It 
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works with autodocktools and autogrid, accessory programs that pre-calculate 
grid maps of interaction energies for various atom types with the receptor. These 
maps are used by AutoDock during the docking calculation to estimate the total 
energy of binding between the ligand and the macromolecule. This pre-calculation 
greatly reduce the time needed for the docking calculation. 
AutoDock 4.2 uses a semi-empirical free energy force field to evaluate 
conformations during docking simulations. The force field was parameterized 
using a large number of protein-inhibitor complexes for which both structure and 
inhibition constants, or Ki, were known.18 The force field evaluates the binding in 
two steps. The ligand and protein start in an unbound conformation. In the first 
step, intramolecular energetics are estimated for the transition from the unbound 
state of both ligand and protein to the conformation of the ligand and protein in 
the bound state. The second step evaluates then the intermolecular energetics of 
combining the ligand and protein in their bound conformation. The force field 
includes six pair-wise evaluations (V) and an estimation of the conformational 
entropy lost upon binding (ΔSconf): 
∆𝐺𝐺 = (𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿 − 𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿 ) + (𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑃𝑃−𝑃𝑃 − 𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑃𝑃−𝑃𝑃 )+ �𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑃𝑃−𝐿𝐿 − 𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑃𝑃−𝐿𝐿 + ∆𝑆𝑆𝑐𝑐𝑏𝑏𝑏𝑏𝑐𝑐� [2-5] 
where L refers to the ligand and P refers to the protein in a ligand-protein docking 
calculation.18 
Each of the pair-wise energetic terms include evaluations for dispersion/repulsion, 
hydrogen bonding, electrostatics, and desolvation: 
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𝑉𝑉 = 𝑊𝑊𝑣𝑣𝑏𝑏𝑣𝑣��𝐴𝐴𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖12 − 𝐵𝐵𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖6 �𝑖𝑖,𝑖𝑖 + 𝑊𝑊ℎ𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏�𝐸𝐸(𝑡𝑡)�𝐶𝐶𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖12 − 𝐷𝐷𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖10�𝑖𝑖,𝑖𝑖+ 𝑊𝑊𝑒𝑒𝑒𝑒𝑒𝑒𝑐𝑐� 𝑞𝑞𝑖𝑖𝑞𝑞𝑖𝑖𝑒𝑒(𝑟𝑟𝑖𝑖𝑖𝑖)𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖,𝑖𝑖 + 𝑊𝑊𝑠𝑠𝑏𝑏𝑒𝑒��𝑆𝑆𝑖𝑖𝑉𝑉𝑖𝑖 + 𝑆𝑆𝑖𝑖𝑉𝑉𝑖𝑖�𝑒𝑒(− 𝑟𝑟𝑖𝑖𝑖𝑖22𝜎𝜎2)𝑖𝑖,𝑖𝑖  [2-6] 
The weighting constants W have been optimized to calibrate the empirical free 
energy based on a set of experimentally determined binding constants. The first 
term is a typical 6/12 potential for dispersion/repulsion interactions. The 
parameters are based on the Amber force field. The second term is a directional H-
bond term based on a 10/12 potential. The parameters C and D are assigned to give 
a maximal well depth of 5 kcal/mol at 1.9 Å for hydrogen bonds with oxygen and 
nitrogen, and a well depth of 1 kcal/mol at 2.5 Å for hydrogen bonds with sulfur. 
The function E(t) provides directionality based on the angle t from ideal H-
bonding geometry. The third term is a screened Coulomb potential for 
electrostatics. The final term is a desolvation potential based on the volume of 
atoms (V) that surround a given atom and shelters it from the solvent, weighted by 
a solvation parameter (S) and an exponential term with distance-weighting factor 
σ=3.5 Å.18 
By default AutoDock 4.2 estimates the contribution of the unbound state by 
assuming that the unbound form of the ligand (𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿  in the equation [2-6]) is the 
same as the final docked conformation of the ligand (𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿 ), yielding a final 
contribution 𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿 −  𝑉𝑉𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝐿𝐿−𝐿𝐿  = 0.18 
In all the docking performed with AutoDock 4.2 throughout this thesis, the 
Lamarckian evolutionary algorithm was chosen and all parameters were kept 
default except for the number of genetic algorithm (GA) runs which was set to 200 
to enhance the sampling. The structure of the receptors was always kept rigid, 
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whereas the structure of the ligand was set partially flexible by providing freedom 
to some appropriately selected dihedral angles. 
1.2.2 Autodock Vina 
AutoDock Vina is an open-source program to perform molecular docking. It was 
designed and implemented by Trott et al. at the Scripps Research Institute.4 The 
authors describe the Vina scoring function as more of “machine learning” than 
directly physics-based in its nature, which they justify by its performance on test 
problems rather than by theoretical considerations following some, possibly too 
strong, approximating assumptions.4 
Vina scoring function was mostly inspired by X-score, and, like X-score, was tuned 
using the PDBbind.20 However, some terms are different from X-score, and, in 
tuning the scoring function, Vina’s developers went beyond linear regression.4 As 
optimization algorithm, Vina uses the Iterated Local Search global optimizer21 
similar to that by Abagyan et al.8 In this algorithm, a succession of steps consisting 
of a mutation and a local optimization are taken, with each step being accepted 
according to the Metropolis criterion.22 Vina uses the Broyden-Fletcher-Goldfarb-
Shanno (BFGS)23 method for the local optimization, which is described as an 
efficient quasi-Newton method.4  
BFGS, like other quasi-Newton optimization methods, uses not only the value of 
the scoring function but also its gradient, i.e., the derivatives of the scoring 
function with respect to its arguments. The arguments, in Vina’s case, are the 
position and orientation of the ligand, as well as the values of the torsions for the 
active rotatable bonds in the ligand and flexible residues, if any. Vina can 
concurrently perform several runs starting from random conformations. This fact 
allows Vina to take advantage of multithreading.4 AutoDock Vina tends to be 
faster than AutoDock 4 by two orders of magnitude.  
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1.2.3 GLIDE 
Glide is a commercial docking program provided by Schrödinger.7 It uses a 
hierarchical series of filters to search for possible locations of the ligand in the 
active-site region of the receptor. It has a systematic method to treat ligand 
flexibility, combined with an exhaustive search algorithm.  
The predicting binding affinity and the ranking of the binding pose is performed 
using GlideScore function based on ChemScore function: 
∆𝐺𝐺𝑏𝑏𝑖𝑖𝑏𝑏𝑏𝑏 =  𝐶𝐶𝑏𝑏 + 𝐶𝐶𝑒𝑒𝑖𝑖𝑙𝑙𝑏𝑏�𝑓𝑓(𝑟𝑟𝑒𝑒𝑟𝑟) +  𝐶𝐶ℎ𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏�𝑔𝑔(∆𝑟𝑟)ℎ(∆𝛼𝛼)+ 𝐶𝐶𝑚𝑚𝑒𝑒𝑚𝑚𝑚𝑚𝑒𝑒�𝑓𝑓(𝑟𝑟𝑒𝑒𝑚𝑚) + 𝐶𝐶𝑟𝑟𝑏𝑏𝑚𝑚𝑏𝑏𝐻𝐻𝑟𝑟𝑏𝑏𝑚𝑚𝑏𝑏 [2-7] 
 
The Glide protocol is intuitive and relies on 3 steps: 1) ligand and protein 
preparation; 2) the receptor grid generation, and 3) the docking process. Before 
launching the docking step, Glide has to generate a grid that represents the shape 
and the properties of the receptor, using several different sets of fields that provide 
progressively more accurate scoring of ligand poses. The grid permits to dock only 
the relevant region of the receptor and, thus, saving time calculations.  
Regarding the last point, the full docking VS workflow includes 3 docking stages: 
HTVS (High Throughput Virtual Screening), SP (Standard Precision) and XP (eXtra 
Precision).24 The first stage performs HTVS docking. It is intended for rapid 
screening of very large number of ligands and it has much more restricted 
conformational sampling than SP docking. The second stage performs SP docking. 
It is appropriate for screening ligands of unknown quality in large numbers. The 
third stage is the XP docking and scoring.25 It is a more powerful and 
discriminating procedure using an implementation of a modified and expanded 
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version of the ChemScore scoring function, called GlideScore (equation [2-8]) and 
categorized as an empirical scoring function.  
Glide can be used to perform VS with an accurate binding mode prediction. 
Furthermore, Glide exhibits excellent docking accuracy and high enrichment 
across a diverse range of receptor types. 
∆𝐺𝐺𝑏𝑏𝑖𝑖𝑏𝑏𝑏𝑏 =  𝐶𝐶𝑒𝑒𝑖𝑖𝑙𝑙𝑏𝑏−𝑒𝑒𝑖𝑖𝑙𝑙𝑏𝑏�𝑓𝑓(𝑟𝑟𝑒𝑒𝑟𝑟)+ 𝐶𝐶ℎ𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏−𝑏𝑏𝑒𝑒𝑏𝑏𝑚𝑚−𝑏𝑏𝑒𝑒𝑏𝑏𝑚𝑚�𝑔𝑔(∆𝑟𝑟)ℎ(∆𝛼𝛼)+ 𝐶𝐶ℎ𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏−𝑏𝑏𝑒𝑒𝑏𝑏𝑚𝑚−𝑐𝑐ℎ𝑚𝑚𝑟𝑟𝑎𝑎𝑒𝑒𝑏𝑏�𝑔𝑔(∆𝑟𝑟)ℎ(∆𝛼𝛼)+ 𝐶𝐶ℎ𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏−𝑐𝑐ℎ𝑚𝑚𝑟𝑟𝑎𝑎𝑒𝑒𝑏𝑏−𝑐𝑐ℎ𝑚𝑚𝑟𝑟𝑎𝑎𝑒𝑒𝑏𝑏�𝑔𝑔(∆𝑟𝑟)ℎ(∆𝛼𝛼)+ 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚−𝑚𝑚𝑒𝑒𝑚𝑚𝑚𝑚𝑒𝑒−𝑖𝑖𝑏𝑏𝑏𝑏�𝑓𝑓(𝑟𝑟𝑒𝑒𝑚𝑚) + 𝐶𝐶𝑟𝑟𝑏𝑏𝑚𝑚𝑏𝑏𝐻𝐻𝑟𝑟𝑏𝑏𝑚𝑚𝑏𝑏+ 𝐶𝐶𝑙𝑙𝑏𝑏𝑒𝑒𝑚𝑚𝑟𝑟−𝑙𝑙ℎ𝑏𝑏𝑏𝑏𝑉𝑉𝑙𝑙𝑏𝑏𝑒𝑒𝑚𝑚𝑟𝑟−𝑙𝑙ℎ𝑏𝑏𝑏𝑏 + 𝐶𝐶𝑐𝑐𝑏𝑏𝑏𝑏𝑒𝑒𝐸𝐸𝑐𝑐𝑏𝑏𝑏𝑏𝑒𝑒 + 𝐶𝐶𝑣𝑣𝑏𝑏𝑣𝑣𝐸𝐸𝑣𝑣𝑏𝑏𝑣𝑣+ 𝑠𝑠𝑠𝑠𝑇𝑇𝑠𝑠𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠𝑇𝑇 𝑡𝑡𝑒𝑒𝑟𝑟𝑡𝑡𝑠𝑠 
[2-8] 
 
The lipophilic-lipophilic term and H-bonding term are defined as in ChemScore. 
But the H-bonding term is separated into different weights, depending on whether 
one of the nature of the donor and acceptor i.e. whether they are charged or not. 
The metal-ligand interaction term also uses the same functional form as in 
ChemScore but varies in three principal ways: a) this term considers only 
interactions with anionic acceptor atoms; b) it counts just the single best interaction 
when two or more bounded metal are found; and c) the net charge on the metal ion 
is assessed in the unbound apo–protein. If the net charge is positive, the preference 
for anionic ligand is incorporated into the scoring function. However, if net charge 
is neutral, the preference is suppressed. The sixth term in the function rewards 
situations in which a polar, but non H-bonding, atom is found in a hydrophobic 
region. 
Chapter 2 
   77 
 
The major components in Glide Score equation (2-9) are the contributions from the 
Coulomb and van der Waals energies between the ligand and the receptor.  
𝑋𝑋𝑃𝑃𝐺𝐺𝑇𝑇𝑠𝑠𝑋𝑋𝑒𝑒𝑆𝑆𝑋𝑋𝑠𝑠𝑟𝑟𝑒𝑒 =  𝐸𝐸𝑐𝑐𝑏𝑏𝑏𝑏𝑒𝑒 + 𝐸𝐸𝑣𝑣𝑏𝑏𝑣𝑣 + 𝐸𝐸𝑏𝑏𝑖𝑖𝑏𝑏𝑏𝑏 + 𝐸𝐸𝑙𝑙𝑒𝑒𝑏𝑏𝑚𝑚𝑒𝑒𝑚𝑚𝑝𝑝𝑏𝑏 [2-9] 
Another major component is the introduction of a solvation model and the 
incorporation of the solvation effects. Glide docks explicit waters into the active 
site for each energetically competitive ligand pose and utilize empirical scoring 
terms that assess the exposure of various groups to the explicit waters. 
where, Ehyd_enclosure represents hydrophobic enclosure; Ehb_nn_motif represents the special 
neutral-neutral H-bond motifs; Ehb_cc_motif represents special charged H-bond motifs, 
EPI π-stacking and π-cation interactions; and Ephobic_pair hydrophobic atom-atom pair 
energy term. Ehb_pair term is same as defined in ChemScore scoring function, 
𝐸𝐸𝑙𝑙𝑒𝑒𝑏𝑏𝑚𝑚𝑒𝑒𝑚𝑚𝑝𝑝 =  𝐸𝐸𝑏𝑏𝑒𝑒𝑠𝑠𝑏𝑏𝑒𝑒𝑣𝑣 + 𝐸𝐸𝑒𝑒𝑖𝑖𝑎𝑎𝑚𝑚𝑏𝑏𝑏𝑏_𝑠𝑠𝑚𝑚𝑟𝑟𝑚𝑚𝑖𝑖𝑏𝑏 [2-11] 
where Edesolv represents desolvation penalties, and Eligand_strain contac penalties 
(penalizing strain energy). 
2.1 Simulation of Biomolecules 
Various computational techniques are currently available to describe and predict 
the behavior of molecular biosystems on a wide distribution of length and time 
scales.26 Each method is appropriate for a particular range of length and time 
scales. 
𝐸𝐸𝑏𝑏𝑖𝑖𝑏𝑏𝑏𝑏 =  𝐸𝐸ℎ𝑝𝑝𝑏𝑏_𝑒𝑒𝑏𝑏𝑐𝑐𝑒𝑒𝑏𝑏𝑠𝑠𝑏𝑏𝑟𝑟𝑒𝑒 + 𝐸𝐸ℎ𝑏𝑏_𝑏𝑏𝑏𝑏_𝑚𝑚𝑏𝑏𝑚𝑚𝑖𝑖𝑐𝑐 + 𝐸𝐸ℎ𝑏𝑏_𝑐𝑐𝑐𝑐_𝑚𝑚𝑏𝑏𝑚𝑚𝑖𝑖𝑐𝑐 + 𝐸𝐸𝑃𝑃𝑃𝑃 + 𝐸𝐸ℎ𝑏𝑏_𝑙𝑙𝑚𝑚𝑖𝑖𝑟𝑟+ 𝐸𝐸𝑙𝑙ℎ𝑏𝑏𝑏𝑏𝑖𝑖𝑐𝑐_𝑙𝑙𝑚𝑚𝑖𝑖𝑟𝑟  
 [2-10] 
Chapter 2 
   78 
 
1.2.4 Quantum Mechanics Methods 
Quantum mechanics (QM) is the fundamental theory of physics explaining the 
behavior of atoms and subatomic particles.27 Mathematically, the changes over 
time of such a system are described by the Schrödinger equations: 
𝑠𝑠ħ
∂
𝜕𝜕𝑡𝑡
|ψ(𝐫𝐫,𝑡𝑡)⟩ = 𝐻𝐻�|ψ(𝐫𝐫,𝑡𝑡)⟩ [2-12] 
In this equation, i is the imaginary unit, ħ is the reduced Planck constant, ∂
𝜕𝜕𝑚𝑚
 
indicates a partial derivative with respect to t, the time, Ψ is the wave function of 
the quantum system, r is the position vector, and 𝐻𝐻� is the Hamiltonian operator, it 
characterizes the total energy of the system. 
- Hartree–Fock (HF) method is a method of approximation for the 
determination of the wave function and the energy of a quantum many-body 
system in a stationary state. The Schrödinger equation (equation [2-12]) 
describes the quantum state in an exact way.  
In analogy to classical systems, the Hamiltonian, 𝐻𝐻�, can be seen as the sum of 
the kinetic and the potential energy operators: 
𝐻𝐻� = 𝑇𝑇� + 𝑉𝑉�  [2-13] 
The hardest part in electronic structure calculations is to deal with electron 
correlation, i.e. the repulsion between pairs of electrons. In the HF method, the 
electron correlation is not treated exactly but in an average way. The 
Hamiltonian and the wave function are thus divided into one electron 
contribution and the electron interaction is then added with an integral. This 
method is simpler but does not provide exact solutions to the Schrödinger 
equation.  
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- Density functional theory (DFT) as developed by Kohn and Sham in 1965,28 
is a computational QM modeling method to investigate the electronic structure 
principally at the ground state of atomic systems. In the Kohn-Sham 
formulation, DFT can be viewed as a variant of HF theory in which the 
fundamental variable is the ground state electron density rather than the 
molecular orbitals. The density is then decomposed into Kohn-Sham orbitals in 
which the only restriction is to provide a density that, when integrated over all 
space, should generate the appropriate number of electrons. For most practical 
purposes, the same basis set as in ab initio theory can be applied. From the DFT 
equations, we essentially obtain the electronic energy of the system (as in HF 
theory) corrected for the correlated interaction between electrons. This 
ingredient is missing at the HF level. In order to describe electronic interactions 
corrected for electron correlation, an extra potential term arises in DFT 
compared to HF, referred to as the exchange-correlation potential. The exact 
form of this is not known, but many derivations exist based on theoretical 
physics, chemical parametrization, and other approaches. The mathematical 
entities are termed exchange-correlation functionals, and a plethora of different 
DFT functionals of varying complexity and accuracy exist. An important choice 
is thus which functional to use. When it comes to the study of organic 
molecules, the B3LYP29 functional is the most used.  
In this thesis, Gaussian program was used to perform all quantum mechanics 
calculations i.e. to parametrize new units for further MD simulation. Gaussian is a 
general purpose computational chemistry software package initially released in 
1970 by Pople and coworkers30. It implements packages related to molecular 
mechanics (Amber), semi-empirical quantum chemistry methods (Austin Model 1, 
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PM3), built-in density functional methods (DFT, B3LYP and other hybrid 
functionals), self-consistent field methods (HF), etc.  
1.2.5 Molecular Mechanics and Molecular Dynamics Simulations 
The 3D structure at atomic level of a biological macromolecule can be obtained 
through a number of methods among which X-ray crystallography is the prevalent 
one. In the particular case of a protein, the X-ray crystallographic structure brings 
excellent information about the spatial organization of each of the atoms 
(excluding hydrogens) of the amino acids sequence composing this protein at a 
given crystallized state.31 From this three-dimensional atomic description, one can 
derive structural features such as the secondary structure of its different 
subdomains, their spatial relation one to another, known as the tertiary structure of 
the protein, and the possible arrangement of multiple folded proteins, known as 
the quaternary structure. In addition, binding sites and ligand binding mode can 
be revealed. Other experimental methods to gain insights into the spatial 
organization of the atoms composing a protein are nuclear magnetic resonance 
spectroscopy (NMR) and cryogenic electron microscopy (Cryo-EM).32 Although 
NMR can give information about the molecules in solution and the different 
conformations of a target,33 the motion of a given atom (or a whole structure) 
through time can only be predicted and observed with molecular dynamics 
methods.34  
At the atomic scale, particle’s behavior can be accurately described by the law of 
quantum chemistry considering molecular orbitals and the electron occupying 
them, from which one can derive important chemical properties. However, such a 
precise description of an atomic system is very costly to be computed in systems 
with the size of a protein. Interestingly, the apparent motion of the atoms governed 
by forces that arise from the quantum world can be rather accurately described 
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through classical physics combining mechanical tools (springs, tensors, rotators) 
and electrostatics (Coulomb's law). The use of classical mechanics to model 
molecular system is called molecular mechanics. In this classical description, the 
atoms are represented as charged spheres, which size is usually proportional to the 
van der Waals radius of the atom they describe. These spheres are connected both 
by direct linkage, representing chemical bonds, and by non-bonded interactions, 
comprising van der Waals and electrostatics interactions.35 
𝑉𝑉(𝑟𝑟) = � 𝑘𝑘𝑒𝑒
𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑠𝑠
(𝑇𝑇 − 𝑇𝑇𝑏𝑏)2 + � 𝑘𝑘𝜃𝜃
𝑚𝑚𝑏𝑏𝑎𝑎𝑒𝑒𝑒𝑒𝑠𝑠
(𝜃𝜃 − 𝜃𝜃𝑏𝑏)2
+ � 12𝑉𝑉𝑏𝑏
𝑚𝑚𝑏𝑏𝑟𝑟𝑠𝑠𝑖𝑖𝑏𝑏𝑏𝑏𝑠𝑠
[1 + cos(𝑇𝑇𝜔𝜔 − 𝛾𝛾)]
+ � � 𝐴𝐴𝑖𝑖𝑖𝑖
𝑟𝑟𝑖𝑖𝑖𝑖12
−
𝐶𝐶𝑖𝑖𝑖𝑖
𝑟𝑟𝑖𝑖𝑖𝑖6
+ 𝑞𝑞𝑖𝑖𝑞𝑞𝑖𝑖4𝜋𝜋𝜀𝜀0𝑟𝑟𝑖𝑖𝑖𝑖�𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝑙𝑙𝑚𝑚𝑖𝑖𝑟𝑟𝑠𝑠
 
[2-14] 
 
 
In molecular mechanics, the potential energy of the system is given by equation [2-
14]. This equation takes into account two main contributions, the covalent 
components, (comprising bonds, angles, and torsions), and the noncovalent 
components (containing the electrostatic and the van der Waals interactions). Extra 
terms can be added, for example, one term describing hydrogen bonds. In more 
details, the first term of Equation [2-14] addresses bond stretching (i.e. 
intramolecular motion between two covalently bonded atoms), in which kl is the 
force constant enclosing the energy cost relative to the displacement from the 
equilibrium value, l is the instantaneous bond length and l0 the bond length at 
equilibrium. The second term describes bond angle vibrations (i.e. geometric 
distortions between three covalently bonded atoms A-B-C) written as a harmonic 
potential, with 𝑘𝑘𝜃𝜃 the force constant, θ the instantaneous angle and θ0 the 
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equilibrium angle. The third term represents the dihedral angle potential (i.e. the 
rotation around the central bond B-C in a covalently bonded sequence A-B-C-D). 
In the case that rotation would need to be restricted, e.g. to ensure planarity or to 
maintain the chirality of a certain group, improper torsion can be introduced, 
which is defined between atoms not connected in sequence. Vn is the dihedral 
constant, n the periodicity parameter, ω the instantaneous dihedral angle and γ the 
phase. The fourth term represents non-bonded or ’through-space’ interactions 
between atom pairs, which can be decomposed into Lennard-Jones and Coulomb 
interactions, qi and qj being the respective charges of atoms i and j, rij the distance 
between the two atoms and Aij and Bij parameters for the repulsive and attractive 
components of the Lennard-Jones potential (Figure 1) A graphical representation of 
these components is given in Figure 2. 
 
 
Figure 1: Left) graph of the Lennard-Jones potential function in which regions of repulsion, 
on the left side of the graph, and attraction, on the right side of the graph are explicitly 
described. At lowest temperature distances between atoms tend toward the energy 
minimum. Right) the born ionic-model describing the energy between two non-bonded 
charged partners (e.g. ions) in function of the distance separating them. Both the attraction 
of opposite charges and repulsion of like charges are shown (illustrations adapted from 36). 
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Figure 2: Schematic representation of the molecular mechanics potential function 
components. Atoms are symbolized by black, white, and red spheres and covalent bonds by 
white sticks. 
In molecular dynamics, successive configurations of the system are generated by 
integrating Newton’s equation of motion (equation [2-15]). The result is a trajectory 
that specifies how the positions and velocities of the particles in the system vary 
with time.  
𝐅𝐅 = 𝑡𝑡𝐚𝐚 = 𝑡𝑡 d𝐯𝐯d𝑡𝑡 = 𝑡𝑡 d2𝐪𝐪d𝑡𝑡2  [2-15] 
 
The force F acting upon an atom is equal to the mass m of that atom multiplied by 
the acceleration a of the atom. The acceleration is also the first derivative of the 
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velocity (v) with respect to time �d𝐯𝐯
d𝑚𝑚
� and the second derivative of the position (q) 
with respect to time�d
2𝐪𝐪
d𝑚𝑚2
�. 
In a molecular dynamics simulation, these forces are calculated at a given time 
over a very short period, called the time step (∆t), and the atoms are moved 
accordingly. Then the forces are calculated for those new coordinates and so on, 
until reaching the desired simulated time. ∆t is computed using a simple Taylor 
expansion (equation [2-16]) 
𝐪𝐪(𝑡𝑡 + ∆𝑡𝑡) = 𝐪𝐪(𝑡𝑡) + d𝐪𝐪(t)d𝑡𝑡 ∆t + d2𝐪𝐪d𝑡𝑡2 ∆𝑡𝑡22 + ⋯ [2-16] 
One can see that the position q(t), velocity d𝐪𝐪(t)
d𝑚𝑚
 and acceleration d
2𝐪𝐪
d𝑚𝑚2
, are sufficient 
for the propagation of the molecular system. The acceleration can be computed 
from equation [2-16] in which the force F is obtained by differentiating the energy 
of the system.1 
An MD simulation is set up by assigning initial velocities and positions to all 
atoms in the system. The velocities are usually randomly assigned, whereas the 
positions are typically resolved by one of the methods mentioned above. 
Thereafter, the force acting on each atom is calculated, giving the direction of 
movement. The atoms are moved in this direction, giving news forces on each 
atom, and the procedure is then repeated. Practically, this integration of motion 
can be treated by several methods such as leapfrog, Verlet or velocity-Verlet.37 
A major limitation to an efficient sampling with MD simulations is the discrete 
time step, ∆t. It is desirable to choose a longer time step, which would give longer 
simulations with less computational resources. However, ∆t is limited by the 
fastest motion in the simulated system. For an all-atom system, the fastest motion 
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is the bond vibration between a hydrogen atom and a carbon atom, which limits ∆t 
to about 1fs. Therefore, these bonds are typically constrained in the simulations, 
allowing a 2 fs time step. 
Calculating long-range interactions is very costly and was usually stopped after a 
given cut-off distance introducing important approximation in the calculations. 
This problem is now overcome by the introduction of Ewald summation and 
particle mesh Ewald (PME) methods rendering long-range electrostatic 
interactions significantly more accurate.38 
The temperature of a simulated system is controlled by implementing a thermostat 
within the equation of motions that creates modifications, the common ones being 
modifying velocities (e.g. weak-coupling39), introducing fictitious particles in an 
extended system (e.g. Nosé-Hoover40) and introducing friction (e.g. Langevin 
dynamics). Similarly, the pressure can be controlled by the introduction of a 
barostat which also introduces modifications such as scaling the box dimension 
(e.g. weak-coupling), introducing fictitious particles (e.g. Parrinello-Rahman41) and 
introducing a piston. In addition, the pressure regulation of a simulation needs to 
be handled accordingly to the system under simulation. For example, in a system 
comprising a solute dissolved in a solvent, an isotropic pressure coupling is 
usually the most representative of the reality it aims to describe.  
Molecular Dynamics Force Fields 
Molecular mechanics can be a great tool to understand the behavior of biological 
molecules at atomic scale at the one condition that the force field it uses is accurate 
toward the residues it describes the motion. In summary, the trajectory of a 
molecular dynamics simulation is as representative of the reality as the input 
parameters are accurate. All force fields used throughout this thesis are briefly 
described in this section.  
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Amber ff14SB. The Amber ff14SB force field42 improved protein secondary 
structure balance and dynamics from earlier force fields like ff99, but weaknesses 
in side chain rotamer and backbone secondary structure preferences have been 
identified. For the ff14SB force field, the authors performed a complete refit of all 
amino acid side chain dihedral parameters, which had been carried over from 
ff94.43 The training set of conformations included multidimensional dihedral scans 
designed to improve transferability of the parameters. Improvement in all amino 
acids was obtained as compared to ff99SB. Parameters were also generated for 
alternate protonation states of ionizable side chains. Average errors in relative 
energies of pairs of conformations were under 1.0 kcal/mol as compared to QM, 
reduced 35% from ff99SB.44 Additionally, empirical adjustments were made to the 
protein backbone dihedral parameters as compared to ff99SB. Multiple small 
adjustments of φ and ψ parameters were tested against NMR scalar coupling data 
and secondary structure content for short peptides. The best results were obtained 
from a physically motivated adjustment to the φ rotational profile that 
compensates for lack of ff99SB QM training data in the β-ppII transition region. 
Together, these backbone and side chain modifications not only reproduced their 
benchmarks, but also improved secondary structure content in small peptides and 
reproduction of NMR χ1 scalar coupling measurements for proteins in solution.44 
GLYCAM06, the Amber carbohydrates force field. It was originally developed as a 
set of parameters for MD simulation of carbohydrates in addition to the AMBER 
force field. Later the force field was extended to other classes of molecules and its 
AMBER-dependency was removed.45 GLYCAM06 is a consistent and transferable 
parameter set for modeling carbohydrates, and glycoconjugates.46 When 
combining GLYCAM06 with AMBER parameters for other biomolecules, 
parameter orthogonality is ensured by assigning unique atom types for GLYCAM. 
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In order to facilitate combining GLYCAM06 with other AMBER parameter sets for 
other biomolecules, a variation on the GLYCAM atom types has been introduced 
in which the new name consists of an uppercase letter followed by a second 
character, either a number or lowercase letter. The GLYCAM force field family, 
especially, GLYCAM06, has been extensively employed in simulations of 
biomolecules by the larger scientific community.47 The updated GLYCAM 
parameters and documentation are available for download at the GLYCAM 
website (www.glycam.org). Also available on the website are tools for simplifying 
the generation of structure and topology files for performing simulations of 
oligosaccharides, glycoconjugates and glycoproteins.  
GAFF is the General Amber Force Field for organic molecules. GAFF is designed 
to be compatible with existing Amber force fields for proteins and nucleic acids, 
and has parameters for most organic and pharmaceutical molecules that are 
composed of H, C, N, O, S, P, and halogens. It uses a simple functional form and a 
limited number of atom types, but incorporates both empirical and heuristic 
models to estimate force constants and partial atomic charges. The performance of 
GAFF in test cases was considered encouraging with data comparable to results 
from Parm99/RESP. GAFF can be applied to wide range of molecules in an 
automatic fashion, making it suitable for rational drug design and database 
searching.48 
Lipid 14, the Amber lipid force field. In 2014, Lipid1449 was released as the latest 
Amber lipid force field. Lipid14 represents a major advancement over the previous 
Amber compatible lipid force fields for lipid bilayer simulations in the NPT 
ensemble without the need for an artificial constant surface tension term. Lipid14 
combines the modular framework of Lipid1150 with a number of refinements 
inspired by GAFFlipid. The modular nature of the force field allows for many 
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combinations of lipid head groups and tail groups as well as rapid 
parameterization of further lipid types. In summary, several van der Waals and 
dihedral angle parameters have been refined to fit experimental data and quantum 
energies and new partial charges have been derived for the head and tail groups. 
The force field was validated on six principle lipid bilayer types for a total of 0.5 
microseconds each without applying a surface tension or constant area term. The 
lipid bilayer structural features compare favorably with experimental measures 
such as area per lipid, bilayer thickness, NMR order parameters, scattering data, 
and lipid lateral diffusion. In addition, further validation of the Lipid14 parameters 
has been provided through extensive self-assembly simulation.51 Furthermore, 
Lipid14 was recently expanded to include cholesterol parameters.52 Lipid14 has 
been designed to be fully compatible with the other pairwise-additive protein, 
nucleic acid, carbohydrate, and small molecule Amber force fields, such as ff14SB 
mentioned above. 
 
Molecular Dynamics Protocol 
The simulations reported here, unless specified, are mainly performed with the 
following protocol. Before being submitted to the production run, the system 
undergoes a height steps preparation. The first one consists of 1000 steps of 
steepest descent algorithm followed by 7000 steps of conjugate gradient algorithm 
under a 100 kcal/mol·A2 harmonic potential constraint applied on the non-solvent 
component of the system. The conjugate gradient algorithm minimization 
continues while the harmonic potential is progressively lowered to 10, 5, 2.5 and 0 
kcal/mol·A every 600 steps. The system is then heated from 0 K to 100 K using the 
Langevin thermostat in the canonical ensemble (NVT, number of particles, volume 
and temperature, respectively) while a 20 kcal/mol·A2 harmonic potential restraint 
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is applied on the protein. Finally, the system is heated up, from 100 K to 300 K, in 
the isothermal–isobaric ensemble (NPT, number of particles, pressure and 
temperature, respectively) under the same restraint conditions than the previous 
step, followed by a simulation for 100 ps under no harmonic restraint. At this 
point, the system is ready for the production run, which is performed using the 
Langevin thermostat under NPT ensemble, at a 2 fs time step 
3.1 Virtual Screening 
In the context of drug discovery, virtual screening (VS) techniques have already 
proved to make hit identification more goal-oriented. Virtual screening allows us 
to dock a huge amount of molecules (sometimes more than 100,000) on a target 
structure and to discriminate which of these molecules could bind better. Thus, the 
costs of performing this kind of screening is relatively low than doing it 
experimentally. This computational approach has been subjected to extensive 
attention and revision over the years, from the early perspective of being an 
emerging method,53 until the current time where new challenges are faced.54 The 
availability of the target 3D coordinates is mandatory in order to perform a VS 
protocol. Prior knowledge about the ligand binding site may help in the 
identification of proper binders although, in some approaches, the search for novel 
binding pockets can be an additional interesting and challenging element in the 
drug discovery process.  
Now a day, a number of public and commercial drug-like small molecules 
databases can be found. Each database has unique features that may make them 
more adequate for a particular VS project, and still a relevant number of unique 
compounds is found within each database that makes it worth considering more 
than one library if possible. Duplicate analysis of screening libraries comprising the 
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ones cited below showed that 40%–50% of the totality of structure subjected to 
analysis were structures exclusive to one supplier library Many of them are freely 
available and may possess desirable characteristics such as “drug-likeness”, being 
the most popular the “Lipinski Rule of Five”.55 Others collect chemical structures 
from natural products or approved drugs. Here, a brief description of both 
databases used in this thesis is given: 
- Zinc Database. ZINC (recursive acronym for Zinc Is Not Commercial) is a 
public access database of commercially available compounds developed in the 
Department of Pharmaceutical Chemistry at the University of California, San 
Francisco.56 It contains a constantly growing number of three-dimensional (3D) 
structures ready-to-dock from catalogues of major compound vendors with 
annotated relevant protonation and tautomeric states, and properties such as 
size, calculated logP, number of rotatable bonds, etc. Each molecule also 
contains purchasability and vendor information, making this ZINC’s focus on 
docking and purchasability the main distinctive characteristic from other 
databases. In its latest version, ZINC 16 comprises over 120 million purchasable 
“drug-like” compounds together with information regarding target and 
biological activity, related scaffolds and bioactive and biogenic compounds 
(Tanimoto index of 0.6).57 It also offers other features such as the possibility to 
define target-focused libraries and to download subsets of a physical property 
space (“fragment-like”, lead-like, drug like subsets). 
- Maybridge database. Maybridge Screening Hit Discovery collection (over 
53,000 compounds) is a commercial library of small hit-like and lead-like 
organic compounds of high diversity (Tanimoto Clustering at 0.9), that covers 
ca. 87% of the 400,000 theoretical drug pharmacophores with general 
compliance with the Lipinsky rule of five and of good ADMET properties.58 The 
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HitCreator TM Collection (selection of 14,400 of Maybridge screening 
compounds) aims to represent the diversity of the main collection covering the 
drug-like chemical space. Maybridge also offers a fragment library (30,000 
fragments), a hit-to-lead building block collection, and a Ro3 2500 diversity 
fragment library (2500 fragments) with a Tanimoto similarity index of 0.66 
(based on standard Daylight fingerprinting), assured solubility, optimized  for  
SPR  and  Ro3  compliant. 
1.2.6 Database Processing 
Database processing constitutes a fundamental step in VS approaches. It is crucial 
to generate the proper chemical library, with the adequate geometries, ionization 
states and conformations of the chemical entities. A good database processing will 
assure a rigorous and well-conducted virtual screening, as well as it will decrease 
the required computational time and it will avoid identification of unsuitable drug 
candidates.  
To prepare the databases and include decoys, different softwares were used in this 
Thesis:  
- LigPrep,59 a software by Schrödinger LLC, is a collection of tools designed to 
prepare high quality 3D structures for large numbers of drug-like molecules, 
starting from 2D or 3D structures. LigPrep starts by converting the input structure 
files to Maestro format. LigPrep process consists of a series of steps that perform 
conversions and apply corrections to the structures. It also generates variations on 
the structures (for example, takes into account different tautomers). Finally, it will 
optimize the geometry of the ligands. LigPrep produces a single low-energy 3D 
structure with defined chiralities for each processed input structure and it can also 
produce a number of structures, from each starting geometry, varying ionization 
states, tautomeric forms, stereoisomers, and ring conformations. Additionally, 
Chapter 2 
   92 
 
LigPrep offers the option to eliminate molecules from the collection to be screened 
using various criteria including molecular weight or quantity and types of 
functional groups composing the molecule. 
- AutoDockTools60 is a widely accessible software that has a graphical 
interface implemented within the Python Molecular Viewer. The graphical 
interphase facilitates the formatting of input molecule files, with a set of methods 
that guide the user through protonation, calculation of charges, and specification 
of rotatable bonds in the ligand and the protein. As a brief outline of the 
preparation process, the ligand and the protein are both loaded. AutoDock atom 
types are assigned, polar hydrogens are added, charges are calculated, and 
nonpolar hydrogens are merged with the heavier atoms to which they are 
attached. If the input ligand file presents no charges, ADT will compute Gasteiger 
charges. Regarding the ligand preparation for the virtual screening, it is important 
to treat flexibility of the ligands. For this purpose, ligand flexibility is assigned in 
several steps. First, a root atom is chosen, which will act as the fixed position 
during coordinate transformation in the docking simulation. To find the optimal 
atom, the number of atoms in each branch is evaluated, and the root atom that 
minimizes the size of the largest branch is chosen. However, the ligand flexibility 
can be limited. As a limitation, each step in ADT has to be launched manually, one 
by one, as well as the preparation of each ligand. However, it is possible, with 
simple scripts, to do it automatically. 
1.2.7 Docking Tools for Virtual Screening 
FLAP 
The new molecular modeling tool FLAP (Fingerprints for Ligands and Proteins) 
provides a common reference framework for comparing molecules, using GRID 
Molecular Interaction Fields.61 The MIFs describe the type, strength and direction 
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of the molecular interactions between two biological partners. These MIFs are then 
condensed into discrete pharmacophoric points representing favorable and 
unfavorable interactions using a weighted energy-based and space coverage 
function. Using these discrete points, all four-point quadruplets are generated, and 
the resulting pharmacophore quadruplet fingerprint describes the target of 
interest. In addition to the fingerprints, the GRID MIFs are retained. The targets are 
then aligned by matching quadruplets in Cartesian space and a field similarity is 
computed using the pre-calculated MIFs. Hence, the fingerprints are used to find 
matching pharmacophoric regions and the entire fields are used to score the 
match.62  
FLAP consists of a graphical user interface, and several command-line programs 
which execute the various tasks. FLAP is based on four probes only, H, O, N1, and 
DRY, which characterize the shape, hydrogen-bond acceptor, hydrogen-bond 
donor, and hydrophobic interactions, respectively.  
We used this program to perform structure-based and ligand- based virtual 
screening. The aim of running structure-based VS is that the 3D structure of a 
receptor binding site is known, and can be used as a target for FLAP. When 
performing alignments, the MIFs of a drug candidate are compared with the 
receptor MIFs. These similarities are used to rank the potential interactions of drug 
candidates with the receptor. Notice that the structure-based enrichments are in 
general lower than the ligand-based enrichments. This is most likely due to the fact 
that a structure-based search uses a larger cavity definition (there is more noise). 
Moreover, a ligand-based approach is based on the fact that active compounds 
should be chemically very similar, biasing the search results to favor a particular 
chemical species. The structure-based approach has the advantage that ligands 
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binding different subpockets can be identified, and should not be as closely tied to 
the chemotype of a ligand template.  
Virtual screening employing a Ligand-Based Approach is the best way to select 
potential new candidate drugs from a library of compounds with known three-
dimensional structure but unknown activity against the biological target (the so-
called “decoys”). Having access to a series of compounds with known activity on a 
specific biotarget, FLAP is able to align the molecules from the database (decoys) to 
one specific and chosen active compound (template). It then computes the GRID 
based - MIFs similarity) between decoys and the template assigning a score that 
can be used to rank the most similar compounds The assumption is that the higher 
the similarity with the template, the higher the probability of similar mechanism of 
action at the receptor site. Once scores are produced for each molecule of the 
dataset, it can be necessary to evaluate how well the known active compounds are 
recognized by FLAP through the use of an Enrichment Plot or a ROC curve. 
GLIDE 
The full docking VS workflow in GLIDE includes 3 docking stages: HTVS, SP 
(Standard Precision) and XP (Extra Precision). The first stage performs High 
Throughput Virtual Screening (HTVS) docking. It is intended for rapid screening 
of very large number of ligands and has much more restricted conformational 
sampling than SP docking. The second stage performs SP docking. It is appropriate 
for screening ligands of unknown quality in large numbers. The third stage is the 
XP docking and scoring. It is a more powerful and discriminating procedure using 
an implementation of a modified and expanded version of the ChemScore scoring 
function, called GlideScore and categorized as an empirical scoring function. Glide 
can be used to perform virtual screening, accurate binding mode precision and 
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furthermore, Glide exhibits excellent docking accuracy and high enrichment across 
a diverse range of receptor types. 
2 Homology Modelling 
The availability of the 3D structure of a given protein is a limiting step in the drug 
design and development process. Usually, the 3D structures of the macromolecules 
are elucidated by NMR, X-ray crystallography or electron microscopy techniques, 
and they are deposited in the public database PDB.63 When the 3D structure for a 
protein of interest has not been resolved by experimental techniques, homology 
modelling is very powerful to predict the structure. Enormous efforts have been 
devoted to develop user-friendly servers, and secondary and tertiary structure 
prediction platforms have risen in the recent years to make structure prediction 
more accessible to a wide range of investigators, with the additional attractive of 
being usually freely available. All these servers are based on the Anfinsen´s dogma 
relating the structure of a given protein, and thus its function, to its amino acid 
sequence, and on the principle that the native structure of the protein is the one in 
which the free energy is the lowest.64 In particular, homology modelling methods 
use a homologous protein of known structure as a template to determine the 
structure of the problem protein. The principal steps in a homology modelling 
protocol are template selection, alignment, backbone and side-chain prediction and 
structure optimization. The target protein is aligned to the template sequence, 
which can be found online using BLAST (Basic Local Alignment Search Tool). 
BLAST scoring estimates the quality of the sequence alignment using the 
BLOSUM62 (BLOck SUbstitution Matrix).65 In the score assignment, different 
parameters are taken into account such as the percentage of identity between the 
searched protein or target and the template (a good model has minimum 30% of 
the percentage identity) and the percentage of query cover and the backbone atoms 
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are mapped onto the three dimensional template structure. The non-conserved 
side chains orientations are predicted. Finally, a force field is used to optimize the 
structure, which basically includes the removal of steric clashes and the 
optimization of hydrogen bond network. 
Some examples of homology modelling web servers are presented here. 
ROSETTA66 is a fragment-based method that combines native-like structures of 
unrelated proteins to search the most probable 3D structure for a given amino acid 
sequence. The scoring function includes biological information, like solvation and 
residue-pair interactions, and the 3D structures are generated by combining 
fragments of known structures based on a large number of sequences with known 
structure present in the Protein Data Bank (PDB). Another example is the I-
TASSER server,67 an online resource for automated protein structure prediction 
that uses basically the information stored in the PDB to perform the alignment of 
related sequences. Then, the protein of study is divided into aligned and unaligned 
regions, these regions are connected, and a Monte-Carlo (MC) simulation is 
performed for the assembling and refinement. I-TASSER combines different 
methods to add backbone atoms, side chains, and to refine the final structure. 
SWISS-MODEL68 is also a popular homology modelling web server that presents 
three different modelling protocols, depending on the degree of similarity between 
the input sequence and the template, allowing to predict structures with a very 
low percentage of similarity. Another homology modelling software that uses 
comparative methods is MODELLER.69 
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4.1 Other Programs 
2.2.1 PyMol 
PyMOL molecular graphics and modeling package70 was used to construct and 
modify ligands. Additionally, PyMOL was used for visual analysis of the docking 
outputs, of molecular dynamics trajectories, and to render all molecules pictures 
present in this thesis 
2.2.2 Maestro 
Maestro71 is a molecular modeling and visualizing program for drug design and 
materials science. Here it was mainly used for structure visualization and 
restrained minimization procedure under the OPLS3 force field. Additionally, the 
software was used for AlogP calculation when evaluating ligand solubility 
2.2.3 Antechamber 
Antechamber72 regroups a set of auxiliary programs for MD simulation. Its main 
application in this thesis is to greatly facilitate the creation of new force field entry 
of novel molecules or residues of interest and to support their parameterization. 
Parameters for molecular dynamics simulations were set up with the standard 
Antechamber procedure. Briefly, charges were calculated with Gaussian30 at the 
Hartree-Fock level (HF/6-31G* Pop=MK iop(6/33=2) iop(6/42=6)) from the DFT 
B3LYP optimized structure, then derived and formatted for Ambertools15 and 
Amber 14 with Antechamber assigning the general AMBER force field (GAFF)48 
atom types. Subsequent modifications to the atom types were made when thought 
necessary, e.g. to take advantage of the GLYCAM0645 force field should a 
saccharide fragment of a bigger molecule be already described by the force field. 
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2.2.4 LeaP 
LEaP73, under both its command line format, known as teLeap (run by the tleap 
shell script), and its X-windows graphical user interface enhanced format, known 
as xaLeap (xleap) is the primary program to create a new system in Amber, or to 
modify existing systems. It combines the functionality of prep, link, edit and parm 
from much earlier versions of Amber.74 LEaP serves the major purpose of 
connecting a coordinate file, which contains a spatial description of all the atoms 
contained in a system, with a desired force field, to create a new amber-compatible 
coordinate file and a topology file. The force field file contains all the parameters 
required by the potential function, such as molecule and residue information, atom 
names, atom types, atomic charges, atomics connectivities, atomic coordinates, 
atomic masses, bonded parameters (bond, angle, dihedral) and non-bonded 
parameters (electrostatic and van der Waals). 
LEaP is also a powerful tool for force field modifications and adaptations. For 
instance, when using more than one force field within a unique molecule, such as 
GAFF and GLYCAM06, one needs to define the parameters necessary to describe 
the interface between the two force fields. To do that, modifications were 
introduced within GAFF, GLYCAM06, and AMBERff14. LEaP was used to create 
force field template for new residues. Additionally, LEaP, in a classical pdb to MD 
simulations workflow, is used to define simulation box, solvate the system and 
add ions, among other things. 
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3.1 Introduction 
Galectins are β-galactoside binding proteins involved in many physiological and 
pathological processes. In mammals, they exert a wide range of biological 
functions and play an important role in immune and inflammatory responses, and 
in the cell cycle regulation, among other processes. Also, galectins have been 
identified as key players in cancer and immune pathologies pointing towards these 
proteins as important targets for the development of drugs for cancer therapy and 
immunotherapy.1 Current research confirms the involvement of galectins in tumor 
progression and indicates that galectins could serve as therapeutic targets, and 
have prognostic value.2 In particular, galectins -1, -3, and -7 are adhesion/growth-
regulatory galectins whose functions have been shown to be correlated among 
them in several tumoral processes.3 Galectin-3 (gal-3) participates in the regulation 
of inflammation,4 and mediates important tumor-related functions (tumorigenesis, 
cell adhesion, proliferation, differentiation, angiogenesis, and metastasis), being 
involved in the development and malignancy of several types of tumor.5 Therefore, 
synthetic gal-3 binders have been pursued for the understanding of the molecular 
regulation of gal-3 expression and for the development of new antitumoral 
therapeutic strategies.6 Galectin-1 (gal-1) also acts in cellular adhesion, mobility 
and invasion, tumor-induced angiogenesis, and apoptosis. Although the 
mechanisms of these processes are not yet well understood, and less is known 
about gal-1 pathways compared to gal-3,7 the overexpression of gal-1 in cancer 
progression indicates a significant role for gal-1.8 In fact, both galectins, -1 and -3, 
seem to be main players in cancer biology as it can be deduced from significant 
studies. Regarding Galectin-7 (gal-7), it is one of the galectins least studied. The 
available information about altered gal-7 expression between normal and tumor 
types is also mostly limited to single reports. In addition, some findings resemble 
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the differences in gal-3 expression with respect to cancer subtype and cellular 
localization. These observations further exemplify that galectin localization might 
be used to distinguish between histological subtypes.1a  
The possibility of differential targeting of galectins has been sought as an 
interesting aim in the glycomimetics field. Selective galectin binders could help in 
cellular assays to unravel the mechanisms regulated by galectins and their 
different (and sometimes opposite roles). Moreover, selective galectin ligands with 
improved affinity would also be interesting molecules with therapeutic 
applications. Although it is known that galectins bind carbohydrates through a 
carbohydrate recognition domain (CRD), a deeper knowledge of the interactions 
that take place and the search of new binding pockets to anchorage putative 
modulators, are key factors for the development of galectin modulators.6a Different 
strategies have been followed to obtain glycomimetics targeting galectins with 
improved affinity and selectivity. Given that galectins specifically recognize β-
galactosides, an evident starting point has been the modification of the galactose 
moiety to produce different monosaccharides. In particular, changes on the 
anomeric position and position 3 of the galactose ring have been performed. 
Nevertheless, the most used strategy has pursued the modification of disaccharide 
scaffolds, mainly the lactose. Chemical modifications include: the substitution of 
the glycosidic linkage in order to improve the glycolytic stability; the insertion of 
relatively long linkers on position 1 in order to have multivalent systems; the 
introduction of substituents in position 3 of the galactose moiety and/or positions 2 
and 3 of the glucose moiety; and the use of other disaccharide scaffolds, such as the 
digalactose9. To date, a large number of gal-1 and gal-3 inhibitors have been 
synthesized, although it is scarce the information about selective gal-7 inhibitors. 
In general terms, there are three types of described gal-1 and gal-3 that can be 
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classified as monosaccharide, disaccharide and non-carbohydrate inhibitors. Most 
of monosaccharide derived inhibitors are based on galactose, since it is the natural 
moiety galectins can bind, and on mannose or talose, since they are epimers of 
galactose in carbons 2 and 4. Substitutions on carbon 1 or 3 of these glycans, in 
order to maintain the nature of the galectin-carbohydrate interaction, are the most 
common substitutions in the galectin inhibitors design field. The vast majority of 
these substitutions are joined to the desired glycan through an ether, amide or 
triazol linkers. Disaccharide inhibitors are based mostly on lactose and LacNac, 
due to the higher affinity compared to monosaccharide ligands, but also on seleno 
and diseleno glycans, given that the use of these compounds can improve the 
bioavailability of the resulting binder. For both mono and disaccharide inhibitors, 
the modifications on different carbons of the sugar are based on aromatic 
substituents, due to the presence of different arginine residues in the adjacent 
pockets, in the case of gal-3, that can interact with this type of substituents through 
a cation-π interaction. Different modifications of these types have been explored, 
based in benzene, naphthalene, quinolones, steroids, etc. Simultaneous 
modifications have also been explored in both mono and disaccharide inhibitors, 
combining C3 and C1 modifications, in order to reach to more pockets and thus 
increase the affinity. In the case of non-carbohydrate ligands, there have been 
described only peptide and peptidomimetics as inhibitors of galectin-1, although 
their binding mode has not been elucidated. 
In rational drug design it is evident that structural information is of paramount 
importance.10 The first X-ray structure of Gal-3/Lactose complex was the starting 
point of the rational drug design of galectin inhibitors because the groove 
extending from galactose O3’ was perfect spot to accommodate new chemical 
entities and enhance affinity and selectivity. Another example is , the knowledge of 
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the conformational change of Arg144 in gal-3, in presence of aromatic ring 
establishing a cation-π interaction, has permitted the synthesis of several gal-3 
inhibitors.11 However, to the best of our knowledge, there are no computer-aided 
studies for the design of galectin ligands with improved selectivity and affinity. In 
particular we are interested in the identification of novel scaffolds able to lead to 
second generation of lactose derivatives with different selective binding properties 
towards human galectins -1, -3, and -7 that would be helpful for the study of 
galectin mechanism and would be interesting as putative galectin modulators. We 
here report the design, synthesis and biophysical studies of the binding properties 
of a series of lactose derivatives with improved selectivity and affinity towards 
galectins 1-, 3-, and 7-. The computer-aided design of the galectin ligands has 
followed two steps: i) a fragment-based virtual screening to identify the best 
moieties able to be accommodated in the adjacent pocket to the  CRD of each 
galectin, and ii) a computational study of the designed lactose derivatives to select 
those candidates for synthesis with better predicted binding properties. Several 
compounds have been synthesized and studied by ITC and NMR techniques. Our 
studies have led to the design of novel ligands with improved predicted binding 
affinity, and, putative selectivity towards gal-1, -3 and -7. These studies can assist 
in the further development of synthetic glycans with potential therapeutic 
applications. 
3.2 Results 
Design of selective galectin ligands. From the study of galectins is very easy to 
underlines how CRD could be very similar among protein of the same family. 
They shared some common features such as the presence of an arginine, a histidine 
and a tryptophan. So we start to explore the adjacent binding site of the CRD 
which is already known to have some conformational changes depending on the 
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ligand interacting with them, such as the conformational change of the Arg144 in 
the galectin 3 in the presence of a ligand with an aromatic portion.12 So, we focus 
the attention in particular on galectin -1, -3 and -7 which seem to be very 
interesting as therapeutical targets. The necessity to aim to a specific galectin is 
mandatory. Given that β-galactose is the molecular pattern characteristic of the 
specific recognition of all galectins, this moiety is usually maintained in the 
reported synthetic glycomimetics aiming to target galectins. Moreover the 
common natural ligand for galectins is a lactose or lactosamine. Therefore, we 
focused our attention in the adjacent pocket of the CRD in order to explore the 
possibility to identify specific moieties with good binding properties. We explore 
this region through binding site pocket finder software (SiteMap) (Figure 1).13  
 
   
Figure 1: Surface representation of gal-1 (PDB ID 1GWZ, green), gal-3 (PDB ID 3ZKJ, 
cyan) and gal-7 (PDB ID 4GAL, magenta). 
Protocol for the design 
We follow a protocol summarized in Figure 2 that can be divided into the 
following steps. 
Virtual screening of fragments in the vicinal pocket. 
The Maybridge fragment library was screened in the vicinal pocket of all available 
galectins. We aimed to identify the best anchored fragments in this pocket for each 
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of the seeked galectines -1, -3 and -7. Additionally, pocket X of galectins 2, 4, 8, 9, 
and 10, were also screened to discard fragments with high affinity towards these 
“unwanted” galectins, focusing only on those fragments with the highest possible 
affinity and selectivity towards the X pocket of galectins 1, 3 and 7. The Maybridge 
fragment library provides structural diversity and drug-like profile, including 
experimental solubility.14  
 
Selection of the best fragments for each galectin X pocket 
More than 300 fragments were filtered as the best possible fragments in term of 
binding energies, and analysed to finally yield 25, 32, and 30 selected fragments for 
each galectin (1, 3, and 7 respectively).   
 
Docking of the designed lactose derivatives 
Based on the selected fragments, 106 different OMe-lactose derivatives were 
docked into the carbohydrate binding domain of the eight galectins. Analysis of 
the docking results allowed the final selection of 25 compounds as candidates to be 
synthesized. 
 
Synthesis and biophysical binding studies 
The synthesis of some of them was performed in collaboration with Prof. 
Menéndez (UCM, Madrid, Spain) and Prof. Oscarson (UCD, Dublin, Irlanda). 
Biophysical assays were performed by us (ITC, at the CIB-CSIC with collaboration 
of Prof. Margarita Menéndez from IQFR-CSIC) and in collaboration with Prof. 
Jiménez-Barbero (NMR at CIC bioGUNE). 
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Figure 2: Left: Scheme of the protocol applied for the virtual screening on each galectin. 
Right: Cartoon representation of gal-3, bound to lactose. Yellow sphere represents the 
merge of two pockets used to perform virtual screening with the Maybridge database. 
Virtual screening of fragment library. Keeping the lactose as in the crystal 
binding pose, we performed a structure-based virtual screening in the adjacent 
region using two different protocols (FLAP and Glide). In particular, we used the 
area delimited by Ser29-Lys63-Tyr119 for gal-1, Arg144-Lys176-Lys233 in gal-3 and 
Lys6-Arg31-Lys64 for gal-7. The surface area of these pockets was approximately 
1200 Å3. The fragment library used in this work was the Maybridge data base, 
which contains more than one thousands drug-like fragments. The choice of the 
fragments was dictate from the best scoring marks.  
From FLAP virtual screening, two amino acids per galectin were chosen to 
determine the centre of two different pockets that were merged together, in order 
to study the complete adjacent pocket. Pocket extension and thickness were 8 and 
26 for all the cases, respectively, and high accuracy performance option was 
chosen. Best fragments, i.e. fragments with a GlobScore of more than 0,9 (26 for 
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gal-1, 32 for gal-3, and 30 for gal-7), were considered to build the methyl-lactose 
(OMe-Lac) based ligands. In the case of Glide, VS protocol comprises 3 levels of 
performance: High-Throughput Virtual Screening (HTVS), Standard Precision (SP) 
docking and Extra Precision (XP) docking. In every step, only 30% of the fragments 
were kept. By applying this protocol, 26 fragments were asked to Glide to be 
selected for each galectin -1, -3 and -7, starting from the Maybridge database. An 
average of 25% of the fragments was repeated in more than one galectin by both 
FLAP and Glide VS protocols. 
In total, taking into account both results from FLAP and Glide, and alternative 
binding poses and possible linkage connections with the lactose moiety, more than 
300 possible fragment poses were analyzed in order to build the full OMe-Lac 
ligands based on these fragments. Only fragments with the appropriate orientation 
and position were considered, i.e. binding pose of the fragment near the lactose 
binding site and the linkage position oriented towards position 3 of galactose 
residue (Figure 3). Finally, 106 fragments were selected to build OMe-Lac based 
ligands.  
   
Figure 3: Representative results of the fragment-based virtual screening in gal-1 (PDB ID 
1GWZ, green), gal-3 (PDB ID 3ZKJ, cyan) and gal-7 (PDB ID 4GAL, magenta). 
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Docking of the designed methyl-lactose derivatives 
We designed the ligands based on the OMe-Lac scaffold and more than one 
hundred (106) structures were built using the best binding fragments. The three-
dimensional structures were then prepared (minimized and charged) to docking 
purpose. To validate the protocol and to estimate an improvement of affinity we 
firstly perform docking studies by means of AutoDock4 with OMe-Lac. Then the 
new 106 ligands were docked in gal-1 (PDB ID 1GZW), gal-3 (PDB ID 3ZSJ and 
1KJR) and gal-7 (PDB ID 4GAL). Moreover, the designed compounds were 
submitted to the same docking protocol with the other human galectins (gal-2 PDB 
ID 5DG2, gal-4 PDB ID 4XZP, gal-8 PDB ID 4BMB, gal-9 PDB ID 3NV4 and gal-10 
PDB ID 1G86) to discard those ligands with putative affinity towards other 
galectins. Overall, we found that the designed compounds presented worst 
theoretical binding energies for galectins different t gal-1, 3-, 1-, and 7-.  
Focusing on galectin -1, -3 and -7 we compared the predicted docked poses for 
each designed compound with each galectin. For each compound the lowest 
energy lactose-like binding pose was taken into consideration. The choice of best 
candidates for synthesis was dictated by different criteria. Among lowest-energy 
binding poses we chose those with an improvement of energy in comparison with 
the predicted binding energy of the OMe-Lac for the same galectin and with a 
worsening of the binding energy for the other galectins, comparing with the OMe-
Lac predicted binding energy. Among the best candidates, we chose compounds 
J013, J228 and J683 given the synthetic accessibility of the corresponding moiety to 
be condensed to the amino-lactose (Figure 4). Reference compounds L2 and L312 
and J009 were synthesized, whose fragments were commercial available. The 
compounds were modelled and the docking calculations were performed. These 
compounds were used as a “control”.  
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Figure 4: 2D representation of three of the best candidate compounds obtained by crossing 
the two VS protocols (FLAP and Glide). 
According to the docking study the compound J013 show an improvement of the 
affinity due to the ionic interaction between the ammonium group with Arg123 
and Arg125 (Gal-1). The docking study of the compound J013 with galectin-1 
shows a considerable improvement of the predicted affinity due to the ionic 
interaction between the ammonium group present in the piperazine and the 
carboxylic group of Asp124 and Asp126 (Figure 5). The presence of the lactose 
moiety keeps the “classical” interactions with the protein. In particular the stacking 
interaction between the galactose ring and the Trp69, and the hydrogen bonds 
established by the polar groups of the glucose and galactose with His53, Arg49, 
Glu72, Asn47, His45, and Asn62. 
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Figure 5: Docked pose of compound J013 into galectin-1. 
These interactions in fact, are conserved during all the MD simulation and they 
strongly contribute to the binding, as possible to note from the MMPBSA 
calculation (Figure 6). 
 
Figure 6: Representation of the contributions to the free binding energy of the gal-1/J013 
complex based on MMPBSA calculations. 
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The compound J228 shows selectivity for the galectin-3 due to the cationic-π 
interaction with the Arg144, which suffers a conformational change due to the 
presence of the aromatic portion in the ligand. The docking study of the compound 
J228 shows a selectivity of this ligand for the galectin-3 in particular for the 
presence of an aromatic portion in the new fragment that establishes a cationic-π 
interaction with the Arg144, which suffers a conformational change due to the 
presence of the aromatic portion in the ligand (Figure 7). This kind of behaviour 
was already observed with previous ligand that presented an aromatic portion 
attached to the position 3 of the galactose.12 Actually all the dockings were 
performed in the two different crystal conformation of the Arg144 and the 
predicted binding energies were compared. 
 
Figure 7: Docked pose of compound J228 into galectin-3. 
 Apart of the new interactions established by the new fragment, the lactose moiety 
still conserves the interactions observed in the crystal structures. In particular, the 
stacking interaction between the galactose moiety and Trp181 and the polar 
interactions between the OH groups of the sugars and the side chains of Arg162, 
Arg144 
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His158, Glu184. Also from the MMPBSA calculation is evident how these 
interactions are important for the binding (Figure 8). 
 
Figure 8: Representation of the contributions to the free binding energy of the gal-3/J228 
complex based on MMPBSA calculations. 
The compound J683 shown an improvement of the affinity due to the ability to 
achieve a polar portion delimited by three asparagines (3, 36, 52) and the Arg31 in 
the adjacent pocket (Gal-7). The compound J683 shown an improvement of the 
affinity due to the ability to achieve a polar portion delimited by three asparagine 
(23, 36, 52, Figure 9) and the Arg32 in the adjacent pocket (Gal-7). Nevertheless also 
the lactose moiety interacts with the principal binding pocket through CH-π 
staking with the Trp70 and polar interactions between the OH groups of the 
galactose and glucose with the polar groups of the side chain of the Arg32, Arg54, 
His50 and Glu73. These residues mainly contribute to the binding as shown from 
the MMPBSA calculation (Figure 10). 
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Figure 9: Docked pose of compound J683 into galectin-7. 
 
 
Figure 10: Representation of the contributions to the free binding energy of the gal-7/J683 
complex based on MMPBSA calculations. 
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NMR and ITC results 
For compound J013 a difference in terms of binding has been register. In fact, 
depending on method use to evaluate the affinity the results were different. From 
the STD experiments (data not shown), this compound shows a very good affinity, 
4.5 times better than lactose, whilst the measure by ITC shows an affinity 
improved of 1.5 times in comparison with lactose (data not shown). Also the 
selectivity profile changes depending on the technique. In fact with NMR no major 
differences among the three galectins were observed. On the contrary, ITC 
measurements show that J013is very selective towards galectin-3. This result could 
be explained by a CH-pi interaction between the phenyl group and the Arg144 side 
chain. In fact, the STD results clearly show the involvement of the fragment moiety 
in the binding. According to the docking calculations, the compound J228 shows 
an improvement in the affinity/selectivity profile for galectin 3. This improvement 
is basically due to the presence of the tiophene ring which can establish a CH-pi 
interaction with Arg144 side chain. The involvement of the fragment in the binding 
is clearly shown in STD experiment (data not shown). Nevertheless the binding 
towards galectins 1, and 7 is still very good, although this molecule binds 
preferentially to galectin 3 (not very selective). Regarding compound J683, this 
ligand does not show selectivity but, interestingly, shows an improved affinity 
towards galectin 7 in comparison to lactose. This is an interesting property not 
gained for any reported galectin 7 modulator to the best of our knowledge. 
3.3 Conclusions 
Selective modulators of galectins 1, 3 and 7 have been computationally designed 
based on a lactose core from a fragment-based virtual screening protocol. NMR 
and ITC experiments show results clearly indicating improved affinity and 
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selectivity for some of them in comparison with the lactose reference compound. 
These novel compounds can be useful in cellular assays for the understanding of 
the cellular roles, especially in cancer, of these important galectins. 
3.4 Material and methods  
Computational Methods. 
Protein Preparation. More than 150 X-ray crystallographic structures of human 
galectins are available at the Protein Data Bank15: 27 structures for gal-1, 4 for gal-2, 
40 for gal-3, 12 for gal-4, 15 for gal-7, 28 for gal-8, 15 for gal-9, and 4 for gal-10. For 
our studies we used the X-ray structures with the following PDB IDs: 1GZW for 
gal-1, 5DG2 for gal-2, 3ZSJ and 1KJR for gal-3, 4XZP for gal-4, 4GAL for gal-7, 
4BMB for gal-8, 3NV4 for gal-9, and 1G86 for gal-10. In the case of gal-3, two 
different structures were used in order to take into consideration the 
conformational change of the Arg144. As shown in Figure 11, the presence of a 
ligand with an aryl group in position 3 of the galactose moiety induces a change in 
the conformation of the Arg144 side chain and the establishment of CH-π 
interaction, increasing the affinity of the ligand towards the protein.28 
The proteins were prepared using the Protein Preparation Wizard tool included in 
Maestro.16 Water molecules, co-factors of crystallization and ligands were 
removed, missing atoms and cap termini were added, side chains and loops were 
filled by Prime, and hydrogens were added with Epik17 at physiological pH. For 
the preparation of the proteins, the protonation of the main histidine in the CRD 
considered as HID. The final structure of the proteins was minimized with OPLS 
2005 force field as implemented in Maestro with implicit solvent (water). The final 
minimized structures were used for docking purposes.  
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Figure 11: X-ray crystal structures of gal-3 (in green) with different ligands. Left: gal-3 
complexed with lactose (represented in purple sticks, PDB ID 3ZSJ). Right: gal-3 
complexed with L3 (represented in yellow sticks, PDB ID 1KJR). Arg144 in both crystal 
structures is shown in sticks. 
Virtual Screening of Maybridge database. To perform the virtual screening in galectins 
-1, -3 and -7 Maybridge database was imported. Maybrige database consists of 
1002 different drug-like fragments of different chemical composition and 
properties. Additional entries were added for the L2 benzene fragment, L3 
tetrafluorated benzene fragment and a naphthalene fragment as reference 
fragments with reported experimental data.12 The protonation state of every 
fragment at physiological pH was calculated by Epik. Two different virtual 
screening protocols were applied by means of two VS programs: FLAP18 and 
Glide.19  
VS Protocol with FLAP program. The pocket point radius was 2.0 Å and high 
accuracy performance was chosen. To explore only the adjacent accessory pocket 
of each galectin, we took in consideration the “lactose space” setting as 
macromolecule the complex of each galectin with lactose. Table 1 shows the two 
aminoacids chosen as the centre of the pocket of each galectin. The pocket 
extension and thickness were 8 and 26 for all the cases, respectively. 
Chapter 3 
126 
 
Protein Galectin-1 Galectin-3 Galectin-7 
Centric 
aminoacids 
Val31/Asn33 Arg144/Asp148 His34/Arg32 
Table 1: Chosen aminoacids for the pocket centre to perform virtual screening in galectin -
1, -3 and -7 
The VS protocol was validated using Chembl database.20 For the validation 
protocol we use the gal-3. In Chembl database we found 62 known as active gal-3 
binders and 48 as inactives. So, we performed a VS in the pocket centred in the 
Trp181 with extension and thickness of 15 and 5, respectively.  
Building of the designed compounds. To build the designed compounds, OMe-Lac 
(Galβ1-4Glcβ-OMe) scaffold was used (Figure 12). The OMe-Lac moiety was 
obtained by means of GLYCAM21 carbohydrate builder tool. The selected 
fragments from VS studies (32, Glob-Prob score up to 0.9 for FLAP + Glide) were 
attached through an amidic bond to the position 3 of the galactose. These 106 new 
ligands were then minimized with MMFFs force field with Macromodel22 and 
Gasteiger charges were added with AutoDockTools.23  
O
HO
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Figure 12: General structure of the designed compounds 
Validation of the docking protocols. Different docking protocols were applied 
(described below): AutoDock4,23 VINA24 and Glide.19 In order to validate the 
docking protocol, we docked lactose in gal-3, obtaining results in full agreement 
with the X-ray crystallographic binding pose with the three docking programs 
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AutoDock4 (RMSD = 0.727 Å), Vina (RMSD = 0.906 Å) and Glide (RMSD = 0.686 
Å). 
Docking with AutoDock4. The same grid box coordinates and size for all the ligands 
were used in the same protein. The box size chosen was big enough to ensure that 
all ligands could be docked. A three-dimensional grid was defined (68 x 60 x 40 Ǻ) 
centred on the centroid of the key residues from the CRD (Trp, His and Arg). In 
particular, Trp181, His158 and Arg162 were chosen for gal-3, Trp68, His44 and 
Arg48 for gal-1, and Trp69, His49 and Arg53 for gal-7. The grid spacing was 0.375 
Ǻ, and a distance-dependent dielectric constant was used. The original Lennard-
Jonnes and hydrogen-bonding potentials provided by AutoDock4 were also used. 
After docking, the 200 solutions were clustered in groups with root-mean-square 
deviation less than 1.0 Ǻ. The clusters were ranked by the lowest energy 
representative of each cluster.  
Docking with VINA. The same gridboxes used with Autodock4 were employed also 
for VINA protocol. Twenty conformers for each ligand with each protein were 
generated.  
Docking with Glide. The ligands were prepared by means of LigPrep tool in 
Maestro. Ligand minimization was performed with OPLS 2005 force field. The 
specified chiralities were retained as well as the ionization state. The same grid 
boxes in terms of size and centre were generated. Van der Waals scaling factor and 
partial charge cutoff were kept as default, which is 1.0 and 0.25, respectively. 
Unlike AutoDock4 and VINA, first a number of conformers were generated; the 
best poses were kept and posteriorly docked into the proteins. Standard precision 
Glide Docking was performed, maintaining all the default parameters except the 
partial charge cutoff of van der Waals radii, which was set in 0.5, to enhance the 
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contribution of the Trp interaction to the global binding energy. The output file 
was generated writing 5 poses per ligand conformation and the RMSD for the 
clustering was set in less than 2 Å. Calculations with Glide were only able to 
reproduce the crystallographic pose for lactose when two crystallographic water 
molecules were kept: the one close to Glu184 and Arg186, and the one close to 
Arg144 and Arg162. van der Waals scaling factor and partial charge cutoff were 
kept as default, which are 1.0 and 0.25, respectively. The other parameters were 
kept as default as well. The key residues from the CRD were used to generate the 
box centre position, and box size was 20x26x20 grid point, being the spacing 
between points of 1 Å. The output file was generated writing 5 poses per ligand 
conformation and the RMSD for the clustering was set in less than 2 Å. 
MD simulation. The best docked solutions for each ligand were considered as 
starting geometries to perform the MD simulations. GLYCAM06, gaff, and ff14SB 
were used as force fields. All MD simulations were carried out by using the sander 
module in AMBER14. Counterions (Na+ and Cl-) were added to neutralize the 
system. Each system was then solvated by using TIP3P waters in a cubic box with 
at least 10 Ǻ of distance around the complex. The shake algorithm was applied to 
all hydrogen containing bonds, and 1 fs integration step was used. Periodic 
boundary conditions were applied, as well as the smooth particle mesh Ewald 
method to represent the electrostatic interactions, with a grid space of 1 Ǻ. Each 
system was gently annealed from 100 to 300 K over a period of 25 ps. The system 
were then maintained at temperature of 300 K during 50 ps with a solute restraint 
and progressive energy minimizations, gradually releasing the restraints of the 
solute followed by a 20 ps heating phase from 100 to 300 K, where restraints were 
removed. Production simulation for each system lasted 50 ns. Coordinate 
trajectories were recorded each 2 ps throughout production runs, yielding an 
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ensemble of 5000 structures for each complex, which were finally analysed. Finally, 
the relative binding free energies of the ligand-galectin complexes were calculated 
by the MMPB/GBSA approach provided in the Amber14 suite. In the preparation 
of the MMPB/GBSA calculations, 500 snapshots were collected from the 50 ns MD 
simulations. From the trajectory file all counterions and water molecules were 
stripped and a salt concentration of 0.1 M. Poisson-Boltzmann (PB) model and 
three Generalized Born (GB) models were used to calculate the solvation free 
energy  
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4.1 Introduction 
This chapter of the thesis was performed in collaboration with Prof. Anna 
Bernardi, at the Università degli Studi di Milano.  
DC-SIGN is a transmembrane C-type lectin expressed at the surface of dendritic 
cells. It plays a key role in the recognition of several pathogens and in the 
development of various infections, including Dengue and the HIV virus.1 Over the 
past decade, several glycomimetic ligands were designed to act as antagonists of 
DC-SIGN mediated viral infections using as template the pseudo-dimannoside (ps-
diMan) scaffold (Figure 1), composed of a mannose ring connected to a 
conformationally locked cyclohexane diol.2  
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Figure 1: Left) Scaffold present in the literature for the design of DC-SIGN inhibitors. 
Right) Our proposal of modification in carbon 2, instead of carbon 6. 
Here, we have identified by means of fragment-based virtual screening an 
alternative pocket adjacent to the mannose binding site where positively charged 
fragments are nicely hosted. This pocket can harbor fragments that can be linked to 
the carbon 2 of the mannose residue in order to design ligands derived from 
dimannoside, with improved affinity towards DC-SIGN (Figure 1). Thus, instead 
of modifications in carbon 6 of the mannose, here we have explored the possibility 
to perform modifications on carbon 2 (Figure 1). Designed pseudo-dimannoside 
compounds have been docked in several DC-SIGN protein structures, and some of 
them are proposed to be synthesized and tested as novel DC-SIGN inhibitors. 
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4.2 Results 
Virtual fragment screening of Maybridge database3 (more than 1000 thousand 
drug-like fragments) was performed using Glide on the 2XR5 DC-SIGN X-ray 
structure2b, keeping in place the ligand from the X-ray crystallographic structure. 
More concretely, we focused on the region besides the mannose binding site, 
comprising residues Asn344, Glu358, Ser360, Asn365, Asp367, Phe313, Leu371 and 
Lys373. We chose that region because, after a deep observation and study of the 
protein, we realized that oxygen of carbon 2 of the mannose residue could act as a 
linker, given the pocket that is present between it and Phe 313 (Figure 2). Actually, 
this pocket also binds several natural oligomannosides.4 
 
Figure 2: Representation of the X-ray structure of DC-SIGN/ps-diMan complex (PDB ID 
2XR5). Alternative pocket (Grey) adjacent to the mannose binding site of DC-SIGN is 
shown in blue. Phe313 is highlighted and ps-diMan is depicted in green sticks. 
Around 50 fragments resulted from this VS protocol, with predicted binding 
energies from -6.5 to -3.8 kcal/mol. Most of the fragments presented ammonium 
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groups in their structure, given the polar and negatively charged nature of the DC-
SIGN binding pocket. Actually, the ammonium group is placed in a way that 
interacts with Glu358 through ionic interactions, Ser360 through H-bonds and with 
Phe313 through a cation-π interaction. Aromatic fragments are always present in 
the VS results, some containing nitrogen or sulfur in their structure. These 
fragments are close to residues like Phe313 and Asn344, stablishing π-π 
interactions. Although some fragments were predicted to bind in different parts of 
the protein, they were discarded for synthetic and accessibility reasons (Figure 3). 
 
Figure 3: A) Selected fragments from the virtual screening. B) Selected superimposed 
fragments from the VS into DC-SIGN: fragments 23 (cyano), 250 (green) and 261 
(magenta). Bound pseudo-dimannoside (from PDB ID 2XR5) is represented in grey sticks. 
Based on the VS results, the suggestions in terms of synthetic accessibility and the 
availability of commercial fragments, we design 88 ligands with the scaffold of the 
pseudo-dimannoside molecule. The fragments were joined to the carbon 2 of the 
mannose residue through three types of linkers: alpha aminoacid linker (48 
fragments), beta-aminoacid linker (22 fragments) and triazole linker (18 fragments) 
(Figure 4, annex figures 1-3). 
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Figure 4: Designed ligands to be docked in DC-SIGN based on fragment-based VS. 
In order to validate our docking protocol, the reference molecules for each type of 
ligand (i.e. the pseudo-dimannoside plus the linker with the ammonium group) 
were docked in order to discriminate if a possible increase in the binding affinity is 
due to the presence of fragment or the linker. In all three cases, the reference 
ligands interact with DC-SIGN in a very similar way than the reported crystal 
structures.2b, 5 The mannose moiety is the major responsible of the binding, 
interacting with the calcium atom present in the binding site of DC-SIGN through 
oxygens of carbons 3 and 4, while the cyclohexane moiety is more exposed to the 
solvent. In interacts, though, with Val351. The results showed no appreciable 
difference in the binding energy between the reference structures (-2.6 kcal/mol for 
the α-aminoacid reference; -2.7 kcal/mol for the β-aminoacid reference; and -3.0 
kcal/mol for the triazole reference) and the crystal ligand of 2XR5 crystal structure 
were docked as a validation of the docking protocol and to compare the predicted 
binding energies (Figure 5). 
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Figure 5: Docking results of the reference compounds of the α-aminoacid (A), the β-
aminoacid (B) and the triazole (C) based compounds. Docked ligands and residues Phe313, 
Val351, Lys368 and Glu358 are highlighted in sticks. Calcium atom is shown as a green 
sphere. 
We also performed the docking of compound Man069. Man069 is a compound 
designed by Bernardi and her coworkers based on our fragment-based design that 
showed a high binding affinity towards DC-SIGN (ITC results, data not shown). It 
is a triazole based compound with two hydroxymethyl-phenyl moieties attached 
to carbons 4 and 5 of the cyclohexane. The predicted binding pose was very similar 
than the crystal structure that they have also reported. Main differences can be 
observed in both hydroxymethyl-phenyl moieties, since the sugar part of the 
ligand is interacting with the protein like the reference compound. The differences 
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in the hydroxymethyl-phenyl moiety could be caused by possible disruptions of 
the structure in the crystal due to the interaction of this moiety with other DC-
SIGN (Figure 6) 
 
Figure 6: A) Structure of Man069 ligand. B) Superimposition of docked pose of Man069 
(green) in DC-SIGN and the crystallographic pose from PDB ID 6GHV (yellow, PDB 
entry on hold until publication). Calcium atom is shown as a green sphere. 
All these compounds were docked on DC-SIGN. Since there were two crystal 
structures of DC-SIGN protein on the PDB (2XR5 and 2IT5)2b, 5, we decided to dock 
all ligands in both proteins. Although there are no major differences between these 
two crystal structures, subtle changes in the some aminoacids orientation can be 
found in the carbohydrate binding region (Figure 7). For example, Lys368, which is 
exposed to the solvent in the case of 2XR5, is oriented towards the ligand in 2IT5 
crystal structure. This different orientation could lead to changes in the pose and in 
the predicted binding energy of the docking (Figure 7, top). Besides that, we also 
performed a molecular dynamics simulation of the free state of 2XR5 protein for 
two main reasons: to explore different conformations of the binding site and to 
identify the major conformation of Val351. Val351 is very close to the binding site 
and seems to interact with the 2XR5 crystal ligand but, in the crystal structure, 
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there are two possible conformation of this residue. After 20ns, we observed an 
aperture of the ammonium pocket, mainly due to the displacement of Phe313 
(Figure 7, bottom). So, the docking was performed using these three proteins. 
 
Figure 7: Superimposition of 2XR5 (pink) and 2IT5 (cyan) crystal structures (up) and 
2XR5 with the average structure of 2XR5 MD simulation (2XR5_dyn, yellow, down). 
Calcium atom is shown as a green sphere. 
Although in all three protein structures the desired conformation of the reference 
ligand (i.e. a pose with oxygens 3 and 4 of the mannose residue interacting with 
the calcium atom in the proper orientation) was achieved, best results in terms of 
energy were obtained on the average structure of the 2XR5 MD simulation (Annex 
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tables 1-3). The aperture of Phe313 seems to give more space for the binding of the 
ligands. 
From all docked results, we selected as a good predicted poses the ones which the 
pseudo-dimannoside is placed and interacts with the protein in the same way than 
in the 2XR5 crystal structure. 
From the docking results we suggested that the best candidates in terms of 
predicted binding energy would be the triazole based ligands, since its predicted 
binding energy is lower. Common features between all docked poses can be 
observed. Oxygens of carbons 3 and 4 of mannose residue are interacting with the 
calcium atom present in the binding site while the cyclohexane is clearly more 
exposed to the solvent, although an ionic interaction through its carboxymethyl 
moieties with Lys368 can be observed. The mannose moiety has another anchorage 
site, since its oxygen of carbon 4 stablishes a dual H-bond with the side chains of 
Glu347 and Asn349. On the other hand, the triazole moiety has the perfect size not 
only to fit into the ammonium pocket, but to expose the ammonium group to 
Phe313 and Glu358. Figure 8 show the example of compound 29R, one of the best 
predicted binders. The pseudo-dimannoside moiety is binding to 2XR5 in a very 
similar way than reference ligand, as well as the triazole and the ammonium. The 
pyridine fragment, due to the R conformation of the chiral carbon of the linker, 
reaches another part of the protein and interacts through a π-π stacking with 
Asn344. Best predicted ligands, apart from 29R, where ligands 26R_F and 28R_S, 
which a binding pose very similar to ligand 29R (Figure 8).  
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Figure 8: Examples of docked poses of compounds 28R_S (A), 29R (B) and 26R_F (C). 
Residues that participate in the interaction are highlighted in sticks. Calcium atom is 
shown as a green sphere. 
MD simulations of the DC-SIGN complex with the reference ligand were 
performed. The mannose residue is kept in the staring bound orientation, while the 
cyclohexane moiety, more exposed to the solvent, changes its orientation during 
time. The ammonium moiety was kept in the same pocket, interacting with the 
initial residues Phe313 and Glu358 during the whole simulation, confirming to be a 
proper scaffold to hold the charged groups to bind in that pocket. 
We also performed molecular dynamics simulation of both pseudo-dimannoside 
and man069 ligand on 2XR5 crystal structure. After 20ns, no major changes in both 
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ligand and protein can be observed. Mannose residues in both ligands remain 
stable and oxygens of carbon 3 and 4 interact during the whole simulation with the 
calcium atom present in the binding site. In the case of pseudo-dimannoside, the 
cyclohexane moiety rotates and changes its orientation compared to the mannose 
residue, but his results was expected because that part of the ligand is exposed 
completely to the solvent. This behavior is clearly observed in man069, where both 
4-hydroxy-methyl-phenyl moieties are completely exposed to the solvent and the 
change in their orientation during time is relatively high.  
4.3 Conclusions 
In this chapter, we have studied the DC-SIGN protein in diverse levels. First of all, 
we have performed a fragment-based virtual screening of the Maybridge database 
in the 2XR5 crystal structure of DC-SIGN in order to identify additional pockets to 
design novel DC-SIGN inhibitors. With the results of the VS, we have designed 88 
ligands based on a pseudo-dimannoside core with three different linkers: α-
aminoacid, β-aminoacid and triazol linker. Then, we have docked these designed 
ligands into three structures of the DC-SIGN protein: the two conformations from 
the X-ray crystal structures (PDB IDs 2XR5 and 2IT5) and the average structure 
resulting from the MD simulation 2XR5 DC-SIGN conformation, representing the 
average from the conformational ensemble. These three conformations of the 
protein have revealed subtle changes between them that have been crucial in the 
understanding of how the designed ligands bind to DC-SIGN. We have revealed 
that Val351 side chain rotation has an important role in the recognition of DC-
SIGN binders and that the motion of Phe313 enlarges the adjacent pocket. This 
enlargement is the reason why the designed ligands bind better to the average 
structure of the MD simulation. From the docking studies, we have selected some 
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compounds to be synthesized with novel scaffolds as glycomimetics with high 
affinity and DC-SIGN inhibitor activity. 
4.4 Materials and Methods 
Protein Preparation. 2XR5 and 2IT5 DC–SIGN crystal structures were extracted 
from the PDB. The proteins were prepared using the Protein Preparation Wizard 
tool included in Maestro. Water molecules, co-factors of crystallization and ligands 
were removed, missing atoms and cap termini were added, and hydrogens were 
added with Epik at physiological pH. Calcium atoms were left, since at least one of 
them is crucial for the binding of the ligands. The final structure of the proteins 
was minimized with OPLS3 force field as implemented in Maestro with implicit 
solvent (water). The final minimized structures were used for docking purposes. 
Virtual screening. Virtual screening was performed using GLIDE VS Workflow.6 
1000 drug-like fragment Maybridge database was screened on DC-SIGN 2XR5 
crystal structure. The center of the grid box was placed at the middle point 
between Phe313, Glu358 and Asn365. Inner box size was 8x8x8 Å and the outer 
box size was 19x19x19 Å, including the whole adjacent pocket of the calcium 
binding site, the so-called “ammonium binding pocket”.  No excluded volumes 
were used in the grid preparation. Since the Maybridge database was previously 
optimized by our group, no ligand preparation was performed prior to the VS 
protocol. Scaling factor and partial charge cutoff were set as default (0.8 and 0.15, 
respectively) and Epik state penalties for docking were used. 20 % of the poses 
were kept in the first stage (High Throughput Virtual Screening, HTVS), 50 % in 
the second step (Standard precision, SP) and 50 % in the last step (Extra Precision, 
XP),  
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Docking. Docking of constructed ligands was performed using Autodock4 
software.7 Docking settings were set as default. The box size chosen was big 
enough to ensure that all ligands could be docked. A three-dimensional grid was 
defined (54 x 50 x 56 Ǻ) centered on the centroid of residues Glu347, Glu354 and 
Asn365, which are at the center of the binding site . The grid spacing was 0.375 Ǻ, 
and a distance-dependent dielectric constant was used. The original Lennard-
Jonnes and hydrogen-bonding potentials provided by AutoDock4 were also used. 
After docking, the 200 solutions were clustered in groups with root-mean-square 
deviation less than 2.0 Ǻ. The clusters were ranked by the lowest energy 
representative of each cluster.  
Parameters Derivation. Parameters for molecular dynamics simulation of the new 
units were set up with the standard Antechamber procedure. Charges were 
calculated with Gaussian at the Hartree-Fock level (HF/6-31G* Pop=MK 
iop(6/33=2) iop(6/42=6)) from the solvated DFT B3LYP optimized structure, then 
derived and formatted for Ambertools14 and AMBER14 with Antechamber 
assigning the general AMBER force field (GAFF) atom types.  
MD simulation. GLYCAM06, gaff, and ff14SB were used as force fields.8 All MD 
simulations were carried out by using the sander module in AMBER14. 
Counterions (Na+ and Cl-) were added to neutralize the system. Each system was 
then solvated by using TIP3P waters in a cubic box with at least 10 Ǻ of distance 
around the complex. The shake algorithm was applied to all hydrogen containing 
bonds, and 1 fs integration step was used. Periodic boundary conditions were 
applied, as well as the smooth particle mesh Ewald method to represent the 
electrostatic interactions, with a grid space of 1 Ǻ. Each system was gently 
annealed from 100 to 300 K over a period of 25 ps. The system were then 
maintained at temperature of 300 K during 50 ps with a solute restraint and 
progressive energy minimizations, gradually releasing the restraints of the solute 
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followed by a 20 ps heating phase from 100 to 300 K, where restraints were 
removed. Production simulation for each system lasted 100 ns. Coordinate 
trajectories were recorded each 2 ps throughout production runs, yielding an 
ensemble of 5000 structures for each complex, which were finally analyzed. 
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4.5 Annex 
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Annex Figure 1: α-aminoacids based fragments. 
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Annex Figure 2: β-aminoacids based fragments. 
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Annex Figure 3: Triazole based fragments. 
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Annex Table 1: Predicted binding energies obtained with Autodock4 of the α-aminoacids 
based compounds on 2XR5 crystal structure (Up), 2IT5 crystal structure (Middle) and 
2XR5_dyn average structure (Down). PBE =predicted binding energy in kcal/Mol 
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Annex Table 2: Predicted binding energies obtained with Autodock4 of the β-aminoacids 
based compounds on 2XR5 crystal structure (Up), 2IT5 crystal structure (Middle) and 
2XR5_dyn average structure (Down). PBE =predicted binding energy in kcal/Mol 
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Annex Table 3: Predicted binding energies obtained with Autodock4 of the triazole based 
compounds on 2XR5 crystal structure (Up), 2IT5 crystal structure (Middle) and 
2XR5_dyn average structure (Down). PBE =predicted binding energy in kcal/Mol. 
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5.1 Agonist synthetic peptides RS01 and RS09 
In this part of the work we have studied the binding of two reported agonist 
peptides of TLR4. Shanmugam et al. reported a series of agonist peptides designed 
by means of phage display combinatorial peptide technology.1 Phage display is 
used as a technique to study protein-protein interactions, mainly. It was first 
described by Smith in 1985.2 In this technique, a gene encoding a protein of interest 
is inserted into a phage coat protein gene. That causes the phage to display the 
protein on its surface, while containing the gene for the protein, resulting in a 
connection between genotype and phenotype. Then, those phages can be screened 
against other proteins in order to detect interaction between them. 
The authors used a commercial library containing phages that express a variety of 
7 amino acid length peptides. The library was screened against an anti-LPS 
antibody, in order to discriminate which of the peptides could mimic the LPS 
structure. Among the 12 initially reported peptides that interact with the antibody, 
RS01, RS03 and RS04 showed a strong LPS activity at 10µg/mL, comparable to the 
activity of LPS. On the contrary, RS02, RS05-07, RS08 and RS10 did not trigger 
TLR4 activation. Finally, RS09, RS11 and RS12 showed a partial agonist activity. 
We chose two of these peptides (RS01 and RS09) to investigate their binding pose 
to TLR4/MD-2 and try to shed light into their agonist mechanism.  
 5.1.1 Modelling of RS01 and RS09 Peptides 
Agonist peptides RS01 (Gln-Glu-Ile-Asn-Ser-Ser-Tyr) and RS09 (Ala-Pro-Pro-His-
Ala-Leu-Ser) were built using PyMol software. Both peptides were minimized 
using Maestro, and the resulting structures were used to perform docking 
calculation in TLR4/MD-2. Since these peptides mimicked LPS, according to the 
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phage display experiments, the grid of the docking was placed occupying the full 
hydrophobic pocket of MD-2, as well as the rim of the pocket. According to 
GlideScore, best predicted binding energies for RS01 and RS09 were very similar,   
-11.1 kcal/mol and -10.9 kcal/mol, respectively. However, differences in term of the 
predicted binding site could be observed, as RS01 was predicted to bind at the rim 
of MD-2 pocket while the prediction for RS09 was to be inserted into the pocket.  
 
Figure 1: Structures of A) RS01 peptide (Gln-Glu-Ile-Asn-Ser-Ser-Tyr). B) RS09 peptide (Ala-Pro-Pro-His-Ala-Leu-
Ser). Non polar hydrogens are not shown. 
This different predicted binding mode could be due to the predominant 
abundance of aliphatic residues in RS09 peptide (two Alanines, two prolines and a 
Leucine) in comparison to RS01 (only one Isoleucine). Thus, RS09 was docked with 
the N-terminal region inside the MD-2 pocket, with both prolines interacting with 
Ile63, Leu61, Ile117 and Tyr65. RS09-His is as well in the MD-2 pocket and interacts 
with Phe119. Val, Leu and Ser of RS09 peptide are located at the rim of the pocket. 
Leucine interacts with Ile117 and hydroxyl group of RS09-Ser interacts with the 
CO group of the Val93 backbone. On the contrary, RS01 was docked completely at 
the rim of MD-2, with none of its residues inserted in the MD-2 pocket. The NH 
group of RS01-Gln establishes an H-bond with the CO group of Lys122 backbone, 
while the side chain of RS01-Asn interacts with the backbone of Ser120 through a 
H-bond. Close to the C-terminal region of RS01, the side chain of the RS01-Ser1 
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interacts with side chain of Glu92 through a hydrogen bond and another hydrogen 
bond with the RS01-Ser2 is formed with the Val93 backbone CO. Note that in the 
case of RS01, more polar contacts between the peptide and MD-2 were predicted 
than in the case of RS09. Another important feature of the RS01 predicted binding 
pose is the fact that RS01 interacts with residues not only from MD-2 but also from 
TLR4, like Arg239, which stablishes a hydrogen bond with the RS01-Ser2, and 
Asn314, which interacts with the backbone of the RS01-Tyr.  
Since only from the docking we could not discriminate why RS01 is a better 
agonist than RS09, we decided to perform a MD simulation of both complexes. 
After 40ns of MD simulation, both complexes remained stable, but only RS01 
peptide was able to maintain the agonist conformation of the Ile124-Phe126 loop 
(with the Phe126 side chain towards the inner region of MD-2, Figure 2). RS01 
peptide was kept at the rim of MD-2 during the whole simulation, with a minor 
displacement through the rim of MD-2. MD-2 hydrophobic pocket seems to 
collapse slightly, leading to a displacement of the C-terminal region of the peptide, 
allowing the RS01-Phe to interact with TLR4 residues like Asn314 and Lys337. 
Moreover, Arg90 and Tyr102 of MD-2 came also in contact with the peptide, 
through a ionic interaction with the side chain of RS01-Glu and a H-bond with the 
side chain of RS01-Ser1, in the case of Arg90, and a H-bond with the RS01-Ser2 
backbone. Lys120 also stablishes a H-bond with the side chain of RS01-Asn and 
with the CO backbone of RS01-Ile. Finally, RS01-Ser2 side chain stablishes a H-
bond with the side chain of Glu92 of MD-2 and the backbone CO of RS01-Ser2 
interacts with the side chain of Ser 118 of MD-2 (Figure 3). 
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Figure 2: Docking and MD simulation RS01 and RS09. A) Docked pose (cyan) and 100ns 
MD simulation structure (pink) of RS01 peptide. B) Docked pose (salmon) and 100ns MD 
simulation structure (yellow) of RS09 peptide. Ile124 and Phe126 are highlighted in sticks. 
In the case of RS09, the complex with TLR4/MD-2 remained stable as well. The 
overall structure of MD-2 did not suffer major changes with the exception of the 
Ile124-Phe126 loop. These residues changed their position to the so-called 
antagonist conformation.3 Phe126, initially buried inside the MD-2 pocket, exposes 
its side chain to the solvent at the very beginning of the dynamics. Ile124, partially 
exposed to the solvent at the beginning, enters to the MD-2 pocket and occupies 
the initial place of Phe126. This is one of most important feature that determines 
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the agonist of antagonist behavior of a TLR4 ligand. As said before, the peptide 
does not suffer major changes during the dynamics, as it kept buried deep inside 
the MD-2 pocket (Figure 2).  
 
Figure 3: MD simulation of RS01 peptide (grey): average geometry from the last 
nanosecond. TLR4 is represented in salmon. MD-2 is represented in yellow. 
To complement these findings, we also performed a MM-ISMSA protocol to 
determine the strength of the binding of both peptides to TLR4/MD-2 complex. 
The average binding energy predicted to RS01 during the dynamics was -67.7 
kcal/mol, while the energy to RS09 was -53.44 kcal/mol, indicating a stronger 
interaction of RS01 peptide than RS09. Overall, these findings are in agreement 
with the experimental data suggesting that RS01 a better agonist that RS09.  
Therefore, we have here proposed a binding mode for these reported peptide 
agonists in agreement with their biological activities. 
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5.2 Antagonist Peptide MDMP 
In another work published by Duan et al. in 2010, a synthetic MD-2 mimetic 
peptide with antagonist activity on TLR4 is reported.4 They designed that peptide 
based on the LPS and TLR4 binding motifs present in the structure of MD-2, called 
MDMP. LPS binding motif is formed by amino acids between Phe119 and Lys1323, 5 
and TLR4 binding motif is composed by residues from Cys95 to Cys105.6 It is 
important to highlight the importance of the disulfide bond between these two 
residues, due to its formation promotes the adoption of a tertiary structure that is 
crucial for the binding to TLR4.7 Thus, the final sequence of the designed peptide 
was CHGHDDDYSFCFSFEGILFPKGHYR, with a disulfide bond between both 
cysteines in the structure. In the paper, they conclude that this peptide binds 
efficiently to TLR4 and block the binding of MD-2 to TLR4, resulting in an effective 
and promising TLR4 antagonist.4 
In this part of the work, we try to give some answers related to the binding mode 
of this peptide to TLR4, to understand the mechanism of action and to propose 
modifications that could lead to an increase in the antagonist activity. 
5.2.1 Modelling of MDMP 
Since we wanted to study the ability of MDMP to bind to TLR4, we started by 
working with the TLR4 binding domain, i.e. the region comprised from Cys95 to 
Cys105 of the MD-2 sequence. In order to get the 3D structure of this region, we 
extracted it from the MD-2 of 3FXI crystal structure. From this starting geometry, 
we performed a conformational analysis to get the lowest energy conformations of 
the peptide.  
The resulting structure is shown in Figure 4.  
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Figure 4: 3D structure of the TLR4 binding motif in MDMP peptide. Non polar hydrogens 
are not shown. 
As it can be seen, the peptide adopts an almost circular (closed) structure, due to, 
mainly, the disulfide bridge present in it. We also performed a 100ns MD 
simulation of the peptide, to explore more possible conformations that could affect 
to the docking results. As it can be seen in Figure 5, the peptide remains stable after 
75 ns of MD simulation, with no major changes in its secondary structure after that 
time. We took the average structure of the last nanosecond as starting geometry to 
perform a docking in TLR4. The docking was performed with AutoDock4 and the 
center of the box was placed on the residues that interact with MD-2 in the 3FXI 
crystal structure, i.e. Arg234, Asn265 and Arg264. The backbone torsional angles 
were kept fixed, in order to preserve the secondary structure during the docking. It 
is important to mention that this backbone conformation was obtained from 
previous conformational analysis. 
The cluster with higher number of poses after the docking contains the poses that 
are more similar to the TLR4 binding motif of MD-2. The Tyr and Asp1 MDMP 
residues interact with Arg264, and MDMP-Ser side chain stablishes a H-bond with 
Glu266 and Asn265 (Figure 6, A). With these results in hand, we performed a 
100ns MD simulation of the complex, in order to see if the pose remains stable. 
Figure 6 shows the results of the simulation. RMSD of both MDMP and TLR4 did 
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not show relatively important changes during time. In fact, the peptide adopts a 
conformation which is more similar to the MD-2 pose on 3FXI at the end of the 
simulation than the docked pose.  
 
Figure 5: A) RMSD graph of 100ns of MD simulation of the TLR4 binding motif of 
MDMP. B) Ribbon representation of the average secondary structures during the 
simulation. Green = Initial structure; Salmon = 25ns; Blue = 50ns; Pink = 75ns; Yellow = 
100ns. The cysteine bridge is represented in sticks. 
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Figure 6: Docking and MD simulation of TLR4/MDMP complex. A) Docked pose of 
MDMP (blue sticks) in TLR4 (salmon). Interacting residues in TLR4 are highlighted in 
sticks. A) Superimposition of docked TLR4/MDMP complex with the TLR4/MD-2 from 
PDB 3FXI (yellow). C) RMSD graph of MDMP (black line) and TLR4 (red line) during 
the MD simulation of the TLR4/MDMP complex. D) Superimposition of the average 
structure TLR4/MDMP of the last nanosecond of the simulation (blue) with the 
TLR4/MD-2 from PDB 3FXI (yellow). 
5.3 Bacteroides vulgatus LPS 
This section of the chapter was done in collaboration with Prof. Molinaro and Prof. 
Silipo at University of Naples Federico II.  
In a previous study, our collaborators characterized a member of the phylum 
Bacteroidetes, Bacteroides vulgatus mpk, a symbiotic commensal of the mouse 
intestine, providing high genome plasticity and strong immune-modulating 
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properties leading to prevention of colitis-induction in several mouse models for 
experimental colitis.8 In fact, not only the presence, abundance or proportion of 
certain live microbial species contributes to such microbiota-mediated effects. 
Indeed, also the structure and, consequently, the toxicity of Gram-negative bacteria 
lipopolysaccharides determine the outcome of inflammation in a mouse model for 
experimental colitis.9 
The group of Prof. Molinaro has characterized the structure of Bacteroides vulgatus 
LPS (LPSBV). It revealed that LPSBV is actually a mixture of a tetracylated and 
pentacylated LPS and has a unique core OS composition. Briefly, the core region 
was built up of a hexa-saccharide bearing a phosphorylated Kdo unit, in turn, 
substituted at position O-5 by a rhamnose (Rhap) residue. This latter was found to 
be a branched monosaccharide bearing a β-galactofuranose unit (Galf) at its 
position O-3 and, at position O-4, a β-galactopyranose (Galp) unit. This latter was, 
in turn, di-substituted by α-fucose (Fucp) and, finally, by a β-glucose (Glcp) which 
was established to be the residue substituted by the first rhamnose of the O-chain. 
The O-chain structure was built up of repeating units of β-mannose (Manp) and α-
rhamnose (Figure 7). The lipid A part has only one phosphate on the galactose unit 
and the FA chains have between 15 and 17 carbons, in contrast with E. coli LPS, 
which have only chains with 14 carbons.  
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Figure 7: A) Elucidated 2D structure of the pentacylated LPSBV. FA chain that is not 
present in tetracylated is marked in red. B) Schematic representation of the Core OS of 
LPSBV. 
Our workers proved that the administration of live Bacteroides vulgatus in colonic 
inflammation mouse models reduced drastically the inflammation and the 
administration of the mixture of LPSBV alone mimics the effect of the 
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administration of live bacteria. Moreover, LPSBV protective role seems to be 
associated with a weak activation of dendritic cells, acting as an immunoprotector. 
Given that the active principle of live cells is the LPSBV, it is presumable that TLR4 
could have a role in the activity of LPSBV. 
Here we provide a model of the binding mode of both tetra and pentacylated 
LPSBV on TLR4/MD-2, trying to provide a 3D perspective to the activity. 
5.3.1 Modelling of LPSBV  
We performed computational studies using both docking and molecular dynamics 
(MD) simulation approaches. Given that the structural analysis of LPSBv revealed a 
mixture of species that are actually present in the sample employed to 
experimentally evaluate LPSBv lipid A activity, we decided to use the two most 
representative and abundant structures of the mixture for our computational 
study, namely the mono-phosphorylated tetra- and penta-acylated LPSBv 
compounds (referred to here on as LPSBv-tetra and LPSBv-penta). 
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Figure 8: Docking calculations of LPSBv–tetra and LPSBv–penta into TLR4/MD-2. Residues in contact 
with LPSBv are displayed in wireframes (A, B, C, and D). A) Superimposition of selected docked poses of 
LPSBv-tetra and LPSBv-penta in mTLR4/MD-2. B, C, D, E) Detail of representative binding poses of 
both LPSBv-penta and LPSBv-tetra. (B) and (C) correspond to poses 02 and 09 of LPSBv-penta, 
respectively. Pose 02 (B) corresponds to a type-A orientation and presents the five FA chains inserted 
into the MD-2 pocket. Pose 09 (C) corresponds to a type-B orientation and one of its FA chains is 
located at the MD-2 channel. (D) and (E) correspond to poses 15 and 10 of LPSBv-tetra, respectively, 
both corresponding to a type-A orientation (no docked type-B orientations were predicted in this case). 
Pose 10 (D) presents one FA chain at the MD-2 channel. 
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We performed docking calculations to predict putative binding modes for both 
ligands inside the murine TLR4/MD-2 system (mTLR4/MD-2), to be subsequently 
submitted to MD simulations to study the stability and dynamics of the predicted 
bound complexes. Reported X-ray crystallographic structures for similar 
compounds show that the fatty acid (FA) chains are inserted into the MD-2 pocket, 
while the oligosaccharide portion establishes polar interactions with 
complementary residues from the TLR4 and also from the partner TLR4* when a 
heterodimer is formed (PDB ID 3FXI 3VQ2). In the case of E. coli hexa-acylated 
LPS, five of the FA chains are inserted into the MD-2 pocket and the sixth one is 
placed in a groove or channel of MD-2 delimited by residues Arg90 and Phe126, 
thus allowing the conformation of the Phe126 side chain to be kept towards the 
inner part of MD-2. This disposition has been established as the agonist bound 
conformation for LPSEc (PDB ID 3FXI), while the antagonist conformation presents 
the Phe126 exposed to the solvent and the Ile124 occupies the Phe126 initial 
position (PDB ID 2E59). Our previous molecular modeling studies for different 
LPSs or synthetic glycolipids also predicted binding modes similar to the X-ray 
crystallographic binding poses.  
As for the docking of LPSBv-tetra and LPSBv-penta, different docked poses with 
favorable predicted binding energy were obtained: some of them with the FA 
chains inserted into the MD-2 pocket (most of the poses), and other poses with one 
FA chain placed in the channel delimited by residues Arg90 and Phe126, and the 
other FA chains inside the MD-2 pocket, similarly to LPSEc in human (h-) and 
murine (m-) TLR4/MD-2/TLR4*/MD-2* heterodimers (PDB ID 3FXI and 3VQ2). The 
oligosaccharide moiety was predicted to establish polar interactions with the TLR4 
with high similarity to the binding poses found for LPSEc in the X-ray crystal 
structures of h- and mTLR4/MD-2/LPSEc/TLR4*/MD-2*/LPSEc* (Figure 8). 
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The phosphate group at the GlcRID was found to be oriented towards the side chain 
of Tyr102 of MD-2 for LPSBv-tetra and most of the docked poses of LPSBv-penta. 
This orientation is similar to that found for E. coli LPS in the PDB IDs 3FXI and 
3VQ2, and for tetra-acylated lipid IVA, a biosynthetic precursor of E. coli lipid A, in 
mTLR4/MD-2/TLR4*/MD-2* (PDB ID 3VQ1), accounting for their agonist activity, 
and it will be referred here on as orientation “type-A”. For LPSBv-penta, 
additionally, a 180°-rotated orientation (“type-B”) was also found in few docking 
solutions, with the phosphate group at GlcRID oriented towards the guanidinium 
group of Arg90 of MD-2. This type-B orientation is also found for lipid IVA when 
bound to hTLR4/MD-2 (PDB ID 2E59) in the antagonist bound pose. Lipid IVA is, 
indeed, widely known for acting as an antagonist on hTLR4/MD-2 as X-ray 
crystallographic studies of the compound in complex with hTLR4/MD-2 showed 
that all its four acyl chains are placed inside the MD-2 binding cavity in a manner 
that does not permit dimerization and subsequent activation of the downstream 
signaling.  The phosphate group linked to Kdo, in both compounds, establishes 
polar interactions with the side chains of residues Lys263, Arg337 or Lys360, 
depending on the pose, which are key residues in the recognition of LPSs by the 
TLR4/MD-2 complex, according to the literature data.24 In all the poses of both 
LPSBv-tetra and LPSBv-penta, also other interactions from the different sugar 
moieties (depending on the binding pose) with the side chains of particular 
residues are identified: Gln339 (TLR4), Ser120 (MD-2) and Tyr102 (MD-2). These 
residues are also present in the interactions network involving the oligosaccharide 
of LPSEc in the reported X-ray crystal structures (PDB IDs 3FXI and 3VQ2). 
From the docking results, we selected 13 different TLR4/MD-2/LPSBv complexes 
(from 8 and 5 selected docked poses of the LPSBv-penta and LPSBv-tetra 
compounds, respectively) to be submitted to 20ns MD simulations. Different 
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aspects were monitored along the simulation (Annex figures 1-3): i) stability of the 
LPSBv ligands and the TLR4/MD-2 system, ii) stability and values of the ligand 
binding energies, iii) stability of the FA chains kept inside the MD-2 pocket (or one 
of them in MD-2 channel), iv) stability of the Phe126 and Ile124 side chains 
towards the inside and outside of MD-2, respectively (agonist conformation). 
 
Figure 9: MD simulations of different complexes of TLR4/MD-2with LPSBv–penta and 
LPSBv–tetra. (a, b and c) Superimposed geometries for TLR4/MD-2/LPSBv complexes along 
the MD simulation (initial geometry in cyan, brown, and grey; after 20ns of MD 
simulation in deep blue, yellow, and black). (a) TLR4/MD-2/LPSBv-penta complex from 
docked pose 09. (b) TLR4/MD-2/LPSBv-penta complex from docked pose 19. (c) TLR4/MD-
2/LPSBv-tetra complex from docked pose 10. Red squares highlight Ile124 and Phe126 
shifting during the MD simulation. (d) 3D Structure of the TLR4/MD-2/LPSBv-
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tetra/TLR4*/MD-2*/LPSBv-tetra* heterodimer complex from MD simulations (from pose 
10, average after 20 ns simulation time). Front (top) and lateral (bottom) views. (f) Detail 
of the polar interactions of the core OS with TLR4. (g) Detail of the interactions taking 
place at the dimerization interface between MD-2 and the partner TLR4*. Representative 
interactions are: the FA chain at the MD-2 channel stablishes a hydrophobic interaction 
with Leu442* of the partner TLR4*; the phosphate group of GlcNRID interacts with the 
guanidinium group of Arg434* side chain; the Pro88 of MD-2 stablishes a π-π interaction 
with the Phe436 side chain from TLR4*.An additional docked pose (pose 15) was also 
selected, and two different models of the TLR4/MD-2/LPSBv-tetra/TLR4*/MD-2*/LPSBv-
tetra* heterodimer were built. 
In the case of LPSBv-penta, after the 20ns MD simulation time, five of the eight 
selected poses kept the agonist conformation of Phe126, while the other three 
suffered a partial rotation of the Phe126 side chain towards the outer part of MD-2, 
even allowing Ile124 side chain to occupy the initial position of Phe126 side chain 
in few cases, but without observing complete rotation towards the antagonist 
conformation. From the RMSD of LPSBv (Annex Figure 1), it can be observed that 
the major changes took place in the core OS, due to the accommodation of the 
polar interactions, while lipid A moiety remained stable in all cases. Among the 
eight TLR4/MD-2/LPSBv-penta complexes, and taking into account the stability 
along the MD simulation, we selected two of them with type-A orientation (from 
docked poses 02 and 19) and two with type-B orientation (from docked poses 04 
and 09) as the best complexes to build four models of the full TLR4/MD-2/LPSBv-
penta/TLR4*/MD-2*/LPSBv-penta* heterodimer (Figure 9). 
In the case of compound LPSBv-tetra, five docked poses were selected as the best 
ones, being all of them with type-A orientation. Only one of these five selected 
poses (from docked pose 10) kept the agonist conformation of Phe126 after the MD 
simulation (Annex Figure 2). 
We finally constructed six TLR4/MD-2/LPSBv/TLR4*/MD-2*/LPSBv* full heterodimer 
models which were submitted to 20ns MD simulations: four from the LPSBv-penta 
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docked poses (two type-A oriented and two type-B oriented), and two from the 
LPSBv-tetra (type-A oriented) (Figure 9). A similar analysis to that performed to the 
previous MD simulations of the monomers was performed. Except for the model 
from pose 09 of LPSBv-penta, which suffered a geometry change due to the 
approaching of N-terminal and C-terminal domains, coming in close contact, no 
significant changes were observed during the simulations (with very stable RMSD 
values), and the Phe126 side chain remained in the partially rotated agonist 
conformation, in a similar position to that found in the previous models, while Ile 
124 side chain is stable towards the inner part of MD-2 (Annex figure 3). 
Interestingly, the model from pose 10 of LPSBv-tetra maintained the agonist 
conformation of both Phe126 and Ile124 side chains. 
5.4 Cardiolipin 
This part of the work was performed in collaboration with Prof. Fukase, at the 
University of Osaka, Japan.  
Cardiolipin (CL) is an important component of the inner mitochondrial membrane, 
constituting the 20% of the total lipid composition of this organelle. The name 
cardiolipin is derived from the fact that it was first isolated from animal hearts, 
more concretely, from a beef heart.10 CL contains two phosphatidylglyceride 
backbone molecules and therefore contains also four fatty acids (Figure 10).11 
Different fatty acids bound to all four positions give rise to a highly diversified CL 
pool in most mammalian tissues. CL is involved in many essential functions linked 
to mitochondrial membranes, including mitochondrial morphology, mitochondrial 
metabolism, and respiration. Accordingly, defects in the biosynthesis and 
remodeling of CL have been linked with severe disorders such as Sengers disease 
and Barth syndrome.10, 12  
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In the recent years, some works have linked CL to TLR4.13 There is strong evidence 
in the literature that CL can bind to TLR4, but it is not clear still the exact role of 
this fatty acid in the activation of TLR4, since the bibliography in this field has a 
variety of results. Prof. Fukase and his coworkers observed a possible synergistic 
effect of murine CL with LPS (data not published). When they incubated HekBlue 
Cells with LPS and low concentrations of CL (50 and 500ng/mL), they observed a 
higher secretion of IL-6 compared to the cells that were only treated with LPS and 
CL separately. Moreover, at higher concentrations of CL, the synergistic effect 
disappeared. With these results in hand, they suggested that, at lower 
concentrations of CL, the TLR4 dimer is formed by one monomer containing LPS 
bound to the MD-2 pocket and the other monomer containing CL. On the other 
hand, at high concentration of CL compared to LPS, both MD-2 pockets are 
occupied and, thus, the activation of TLR4 is lower. Based on these results, we 
wanted to study the binding mode of CL in TLR4/MD-2, which is not known, and 
to propose a mechanism for the observed synergistic effect.  
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Figure 10: Structure of murine CL. Label of the fatty acid chain is indicated. 
5.4.1 Modelling of Cardiolipin 
The molecule of murine CL was constructed using Maestro and, after a round of 
minimization, was docked using AutodockVina on the agonist conformation of 
TLR4/MD-2 (PDB ID 3FXI). Among all the docked poses (20 in total), we only took 
into account the ones with all four FA chains inserted into the MD-2 hydrophobic 
pocket. Only six poses presented the FA chains inserted in this way. All these 
poses presented common features. The phosphate backbone was predicted to bind 
at the rim of MD-2, interacting with the polar residues present in that region. For 
example, in the best docked pose (pose 1, Figure 11), phosphate group of FA chain 
A, is interacting with Arg 90 of MD-2, while the other is exposed to the solvent. 
Arg 264 of TLR4 stablishes a hydrogen bond with the oxygen present on the ester 
bond of chains B. The hydroxyl group of the backbone is oriented and interacting 
with Arg90 and Glu92 side chains of MD-2. On the other hand, the FA chains are 
buried inside MD-2 pocket, partially mimicking the interactions of LPS with the 
hydrophobic residues of MD-2. In fact, thanks to the larger FA chains in CL 
compared to E. coli LPS (18 against 14), CL is able compensate it lower number of 
FA chains (4 against 6) and mimic the orientation of the FA chains of LPS (Figure 
9). 
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Figure 11: Docking of CL. A) Docked pose 1 of CL (blue) on TLR4/MD-2(salmon/yellow). 
Polar interacting residues are highlighted in sticks. B) Superimposition of E. Coli LPS 
(green) with CL docked pose 01 (blue). 
Actually, the observed differences between the binding poses are mainly due to the 
position of the phosphate backbone, since the FA chains are placed in a very 
similar way in all cases. Thus, the backbone, which is always predicted to be 
oriented and interacting with the polar residues of the rim of MD-2, seem to have 
more freedom of movement in the binding pose of CL to TLR4. 
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We examined with detail the best six docked poses, and we chose pose 1 to 
perform MD simulation, since apart of being the pose with the best predicted 
binding energy, presented a binding mode similar to that for LPS. Thus, pose 1 of 
Cl in complex with TLR4/MD-2 was submitted to 100ns MD simulation, to 
determine if CL could retain the agonist conformation of MD-2. In fact, after 100ns 
MD simulation, the complex remained stable and the agonist conformation of 
Phe126 of MD-2 was retained. The FA chains did not suffer major changes during 
the simulation, since they were buried inside MD-2 pocket and with very stable 
interactions.  
 
Figure 12: Hydrophobic interactions at the end of 100ns MS simulation of CL docked pose 
1 on TLR4/MD-2. 
For example, chain B1 interacts with Tyr65, Ile63, Phe76 and Phe147, while chain 
B2 interacts with Phe121, Phe126 Phe76 and Ile80. On the other hand, chain A1 
interacts with Phe121, Ile80 Cys133 and Phe141 and chain A2 with Ile80, Phe737, 
Ile632 and Phe 126 (Figure 12). Regarding the phosphate backbone, it changes 
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subtly its orientation (Figure 13). Phosphate A, which was interacting initially with 
Arg 90, at the end of the simulation is placed on the other side of MD-2, interacting 
with the side chain of Lys122. Phosphate B, in contact with Lys 337 of TLR4 at the 
beginning of the simulation, relocates and keeps in contact with Arg676. Arg239 of 
TLR4 also has an important role in the binding of CL to TLR4, since its interaction 
with the carboxy group of the backbone is kept during the whole simulation. Thus, 
in agreement with our results, cardiolipin can bind to the TLR4/MD-2 complex and 
is able to maintain the agonist conformation of the protein. 
 
Figure 13: MD simulation of CL docked pose 01. Initial pose is represented in blue lines. 
Binding pose after green lines. 
In order to explore the mechanism of the observed synergic effect, we constructed 
a mixed heterodimer of LPS and CL i.e. a TLR4 dimer complex with a LPS 
molecule inserted in MD-2 of one monomer and CL inserted in MD-2 of the other 
monomer. The docked Pose 01 was superimposed to one of the monomers of 
TLR4/MD-2 complex in 3FXI crystal structure. Then, the template monomer was 
removed, in order to finally obtain the mixed dimer. The mixed dimer was 
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submitted to 100ns MD simulation. In both monomers, the agonist conformation of 
Phe126 side chain was maintained. The overall structure of TLR4/MD-2 dimer was 
maintained and no major changes in LPS pose can be observed. In the case of CL, 
the phosphate backbone suffers a minor relocation, but the interactions between 
MD-2 and the partner TLR4, like Arg90 with Gln436 and Lys125 with Glu422, are 
not affected. Thus, we propose that CL and LPS can form a stable TLR4/MD2 
heterodimer  
5.5 Conclusion 
In this chapter, we have studied several reported (and yet to be reported) agonist 
and antagonists of the TLR4/MD-2 system were very distinct chemical nature.  
In the case of agonist peptides RS01 and RS09, we proposed a binding mode to the 
MD-2 protein. RS01 was binding at the rim of the pocket, while RS09 was more 
buried inside, due to the presence of hydrophobic residues in its structure. 
Furthermore, after an MD simulation, only RS01 was able to maintain the agonist 
conformation of MD-2, while Phe126 of the TLR4/MD-2/RS09 complex changed its 
orientation towards the antagonist conformation. These results were in agreement 
with the experimental data stating that RS01 was a more potent agonist than RS09.  
The binding mode of the antagonist peptide has been also elucidated. This peptide 
was a mimic of TLR4 binding motif of MD-2. After docking and MD simulations, it 
was shown that the predicted binding site in TLR4 is the same as for MD-2, thus 
mimicking the same MD-2 binding motif. In fact, its TLR4 bound conformation 
was kept in a similar way to that for MD-2. Modifications of the structure of this 
peptide could lead to the design of a more potent antagonist. 
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On the other hand, Bacteroides vulgatus LPS was an interesting case of study, 
because it is a mixture of two actually different LPS: tetracylated and pentacylated. 
Our molecular modelling studies indicate that both LPSBv-tetra and LPSBv-penta 
can bind to the TLR4/MD-2 system in a similar pose to that for LPSEc (type-A 
orientation), with some variations on the FA chains and core OS binding, 
promoting slight differences in the resulting TLR4/MD-2 conformations. The 
predominance of a conformation close to the agonist conformation of the Phe126-
Ile124 MD-2 switch, from our molecular dynamics results, indicates that this LPSBv 
mixture could trigger changes at a molecular level that are in the frontier between 
an agonist and antagonist conformation and this could explain the weak agonist 
behavior of LPSBv. 
Finally, we have demonstrated that CL binds to TLR4/MD-2. The molecular 
modelling reveals that the FA chains are inserted in the MD-2 hydrophobic pocket 
while the phosphate polar head is located at the rim of MD-2, interacting with 
residues from both TLR4 and MD-2. The FA chains buried in the pocket are stable 
during the simulation time and the phosphate groups have more freedom of 
movement, but without affecting the overall binding pose. Moreover, we have 
shown that a heterodimer of TLR4/MD-2 with a molecule of CL in one monomer 
and a molecule of E. coli LPS in the other monomer can be formed, and that fact 
could explain the synergistic effect observed in vitro. 
5.6 Materials and methods 
Building of the ligands and the macromolecule. Compounds LPSBv-tetra and 
LPSBv-penta, peptides RS01 and RS09 and cardiolipin, were constructed using 
Maestro interface. The 3D coordinates of E. coli LPS from PDB ID 3FXI were used 
as template. The resulting structures were minimized using OPLS3 force field, 
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water as a solvent and steepest descent as the method of minimization, with a 
maximum of 10000 iterations. The 3D structure of the murine mTLR4/MD-2 
complex was obtained from the X-ray crystal structure with PDB ID 3VQ2. The 3D 
structure of human TLR4/MD-2 was obtained from the 3FXI crystal structure. 
Water molecules, LPS and glycans attached to the structure were removed. 
Missing hydrogens were added and protonation state of ionizable groups was 
computed using Protein Preparation Wizard of Maestro. The complex was 
minimized with 10000 steps of steepest descent method and optimized with OPLS3 
force field. 
Parameters derivation. Parameterization of new units was performed using 
Gaussian09 by optimizing the geometries with 6-31G basis set at the Hartree-Fock 
level of theory. Charges were derived by applying the RESP methodology 
implemented in Antechamber, assigning the general Amber14 force field (GAFF) 
atom types. 
Docking calculations. Docking of compounds LPSBv-tetra and LPSBv-penta and CL 
inside the mTLR4/MD-2 system was performed using AutoDock Vina.24 Agonist 
peptides RS01 and RS09 were docked with Autodock4. Grid box was centered at 
the centroid defined among the α-C atoms from Arg 90, Glu 92 and Phe 121 of 
MD-2, occupying the full MD-2 pocket and part of the TLR4/MD-2 dimerization 
interface, and 1 Å of grid spacing was set (default value in AutoDock Vina). The 
spacing in the case of Autodock4 was set to 0.375Å. Box size was set to 34.5 Å in 
the x-axis, 26.25 Å in the y-axis and 35.25 Å in the z-axis. In the case of AutoDock 
Vina, exhaustiveness was set as default (200) and 20 predicted binding poses, the 
maximum allowed in AutoDock Vina, were extracted. The original Lennard-
Jonnes and hydrogen-bonding potentials provided by AutoDock4 were also used. 
After docking, the 200 solutions were clustered in groups with root-mean-square 
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deviation less than 2.0 Ǻ. The clusters were ranked by the lowest energy 
representative of each cluster. 
Molecular dynamics (MD) simulations. All the MD simulations were carried out 
using Amber14. Several steps of equilibration were performed before running the 
MD simulation. The first one consisted of 1000 steps of steepest descent 
minimization followed by 7000 steps of conjugate gradient minimization; a 100 
kcal·mol−1·A−2 harmonic potential constraint was applied to the proteins and the 
ligand. In the four subsequent steps, the harmonic potential was progressively 
lowered respectively to 10, 5, and 2.5 kcal·mol−1·A−2) for 600 steps of conjugate 
gradient minimization each time, and then the whole system was minimized 
uniformly. In the following step, the system was heated from 0 to 100 K using the 
Langevin thermostat in the canonical ensemble (NVT) while applying a 20 kcal· 
mol−1·A−2 harmonic potential restraint on the proteins and the ligand. The next step 
heated up the system from 100 to 300 K in the isothermal−isobaric ensemble (NPT) 
under the same restraint condition as in the previous step. In the last step, the same 
parameters were used to simulate the system for 100 ps but no harmonic restraint 
was applied. At this point, the system was ready for the production run, which 
was performed using the Langevin thermostat under NPT ensemble, at a 2 fs time 
step. 
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Annex Figure 1: RMSD values along the 20ns MD simulations of eight TLR4/MD-
2/LPSBv-penta complexes. RMSD (Å) values (y-axis) of TLR4/MD-2/LPSBv-penta 
complexes from docking predicted binding poses 01 (a), 02 (b), 04 (c), 07 (d), 09 (e), 15 (f), 
18 (g) and 19 (h) along 20ns of MD simulation (x-axis). First column represents the 
RMSD of TLR4 (black line), MD-2 (red line) LPSBv (green line), Phe 126 (blue line) and Ile 
124 (yellow line). Second column represent the RMSD of LPSBv separated in core OS (black 
line) and lipid A (red line). All RMSD were calculated with ptraj. Each frame has been 
collected every 20 ps of the simulation. Hydrogens were not included in the calculation in 
all cases and in the case of TLR4 and MD-2 values, only α-carbons were considered in the 
calculation. 
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Annex Figure 2: RMSD values along the 20ns MD simulations of five TLR4/MD-
2/LPSBv-tetra complexes. RMSD values of TLR4/MD-2/LPSBv-penta complexes from 
docking predicted binding poses 02 (a), 03 (b), 10 (c), 15 (d) and 18 (e). First column 
represents the RMSD of TLR4 (black line), MD-2 (red line) LPSBv (green line), Phe 126 
(blue line) and Ile 124 (yellow line). Second column represents the RMSD of LPSBv 
separated in core OS (black line) and lipid A (red line). All RMSD were calculated with 
ptraj. Each frame has been collected every 10 ps of the simulation. Hydrogens were not 
included in the calculation in all cases and in the case of TLR4 and MD-2 values, only α-
carbons were considered in the calculation. 
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Annex Figure 3: RMSD values along the 20ns MD simulations of the six TLR4/MD-
2/LPSBv/TLR4*/MD-2*/LPSBv* full heterodimer models. RMSD values of both LPSBv-penta 
and LPSBv-tetra full heterodimer models after 20ns of MD simulation. The models were 
constructed from an average structure of the monomers MD simulation and using 3VQ2 
crystal structure as template.  (a) LPSBv-penta pose 02; (b) LPSBv-penta pose 04; (c) LPSBv-
penta pose 09; (d) LPSBv-penta pose 19; (e) LPSBv-tetra pose 10; (f) LPSBv-tetra pose 15. 
First column represents the RMSD values of the first monomer (TLR4/MD-2/LPSBv, 
residue number 1-735) and the second column represents the RMSD values of the second 
monomer (TLR4*/MD-2*/LPSBv*, residue number 736-1470).  Black line, TLR4; Red line, 
MD-2; Green line, LPSBv; Blue line, Phe 126; Yellow line, Ile 124. All RMSD were 
calculated with ptraj. Each frame has been collected every 10 ps of the simulation. 
Hydrogens were not included in the calculation in all cases and in the case of TLR4 and 
MD-2 values, only α-carbons were considered. 
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6.1. Introduction 
Identification of drug-like molecules with potential therapeutic applications for the 
treatment of TLR-related diseases has attracted considerable interest due to their 
clinical potential. TLR modulators have the potential to be used with different 
biomedical applications, especially in the field of infection,1 inflammation2 and 
autoimmune diseases,3 and also in cancer4 and in central nervous system (CNS) 
disorders such as Alzheimer´s disease.5 Even though several inhibitors of the 
TLR4/MD-2 complex acting on MD-2 were found in the literature, only a minority 
shows promising characteristics to become an available drug. Eritoran for example 
showed promising results in phase I and II clinical trials, but in phase II failed in 
showing better properties than existing treatments for sepsis.6 In fact, just few 
candidates are currently under clinical development due to the difficulty to find 
molecules with appropriate physic-chemical properties and low toxicity.7  
Therefore, it is imperative to find new chemical entities, and not necessary with 
LPS-like structure, as TLR modulators with drug-like properties in order to 
facilitate their development as drugs. There are some small molecules that 
exemplify this possibility. For example, some pyrimido[5,4-b]indoles that have 
shown to stimulate TLR4 and could potentially be used as adjuvants or immune 
modulators;8 synthetic analogues of natural product euodenine A have exhibited 
potent and selective agonist towards TLR4;9 and synthetic peptides to mimic the 
TLR4/LPS interaction have also been reported.10 Also several small non LPS-like 
molecules with TLR4 antagonist activity have been developed, such as ethyl 4-oxo-
4-(oxazolidin-3-yl)-butenoate derivatives (OSL07),11 benzothiazole-based 
inhibitors,12 ethyl phenyl-sulfamoylcyclohexenecarboxylate derivatives (TAK-242 
or resatorvid),13 and β-amino alcohol derivatives.14  
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In the context of drug discovery, virtual screening (VS) techniques have already 
proved to make hit identification more goal-oriented, allowing the access to a huge 
number of chemically diverse binders (from public and commercial databases) 
with a relatively low-cost in terms of time and materials (see Chapter 2, section 3). 
This computational approach has been subjected to extensive attention and 
revision over the years, from the early perspective of being an emerging method,15 
until the current time where new challenges are faced.16 These VS approaches 
constitute a current strategy in drug design for the identification of novel chemical 
entities with a given binding ability.17 
We could say that TLRs are not standard receptors which could be approached 
following classical strategies in drug design. The complexity of the system and the 
characteristics of their complexation with the pathogen associated molecular 
patterns (PAMPs) make them especially difficult to tackle following classical 
procedures in drug design and discovery. This is why TLRs constitute a special 
case study in this context. Specifically, on the field of TLR4 research, VS studies 
have been recently reported leading to novel ligands with drug-like properties, 
trying to overcome the solubility problems associated with LPS mimetics (see 
Chapter 1, section 1.4.1). Among these works, Joce et al.18 have developed a novel in 
silico screening methodology including molecular mechanics and implicit solvent 
methods to incorporate the evaluation of binding free energies and have screened 
the Enamine database collection.19 The resulting clusters were filtered by selecting 
the representative compounds that were submitted to fast molecular docking for 
the generation of binding poses and subsequent MD simulations to rank the ligand 
poses according to their predicted binding affinities. Final filtering led to the 
identification of compounds T5342126 and T6071187 (Figure 5.1) as small drug-like 
inhibitors of the TLR4/MD-2 protein-protein interactions. Their biological activity 
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and selectivity were tested in vitro, and their TLR4/MD-2 antagonist activity was 
confirmed. In other study, Švajger et al.20 performed parallel ligand-based and 
structure-based VS in order to identify novel TLR4 antagonists targeting the 
TLR4/MD-2 interface, by using the ZINC drug-like subset (~11.3 million drug-like 
compounds) from the ZINC database.21 The identified ligands after ligand-based 
VS resulted in being either insoluble in water, or inactive, or presented cytotoxicity 
on HEK293 cells. However, the structure-based VS identified 40 putative 
TLR4/MD-2 ligands that were assessed in vitro. After the first assays, only 14 
compounds were sufficiently water-soluble and completely non-cytotoxic at 100 
μM. These compounds received further biological evaluation, and finally, three 
compounds with promising antagonistic activities were discovered: 
ZINC25778142, ZINC49563556 and ZINC3415865 (Figure 1). 
O O OH
N
N
N
Cl
HO
O
N
H
O
O
O
ENAMINE code: T5342126
TLR4/MD2 antagonist
ENAMINE code: T6071187
TLR4/MD2 antagonist
O
OH
O
N
N
N
NH2
N
H
F
ZINC25778142
TLR4/MD2 antagonist
N
S N
N
NN
NH2
NH
N
N
S
O
N
N
H
O
N
O
ZINC49563556
TLR4/MD2 antagonist
ZINC3415865
TLR4/MD2 antagonist  
Figure 1: Novel TLR4/MD-2 modulators identified by VS approaches. 
On the other hand, despite the enormous effort of spent time and money on 
research and development, the number of new drugs brought to market drastically 
decreases each year.22 Significant investments by pharmaceutical companies for 
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optimizing the drug discovery pipeline have been undertaken, and new techniques 
such as structure-based drug design, combinatorial chemistry and high 
throughput screening (HTS) techniques have emerged. However, the impact of 
these innovations has not been as important as it was expected both in short and 
long term.23 Drug repositioning (also known as drug repurposing, drug 
redirecting, or drug reprofiling) is a process of discovering new uses outside the 
scope of the original medical indication for existing drugs. Before 2004, no traces of 
this process have been found in the literature,24 but it has gained an increasing 
attention within the international drug development community over the last few 
years, and represents a new promising direction.25  
Different terms are used to describe drug repositioning, but all mean a way to find 
new indications for existing drugs or potential drug candidates, including those in 
clinical development where mechanism-of-action is relevant to multiple diseases: 
drugs that have failed to demonstrate efficacy for a particular indication during 
Phase II or Phase III trials but with no major safety concerns; drugs that have been 
discontinued for commercial reasons; marketed drugs for which patents are close 
to expiry; and drugs candidates from academic institutions and public sector 
laboratories that have not been fully pursued yet, are also took into account. In this 
way, drug repositioning represents unique translational opportunities, and is 
believed to offer great benefits over the de novo drug discovery, reducing the 
development risks and timeline to potentially 3-12 years,25f substantially increasing 
the probability of success to brought drugs into market due to existing knowledge 
about the drugs, and providing relatively inexpensive solutions as therapies for 
rare and neglected diseases26 that frequently offer limited potential revenue to 
pharmaceutical companies. Successful repurposing examples, discovered by 
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serendipity, are sildenafil (Viagra®), acetyl salicylic acid (Aspirin®),27 and 
thalidomide.28 
In this work, we aimed to identify novel TLR4 modulators with non LPS-like 
structure by means of virtual screening following a “computed-aided drug 
repositioning” approach. We have screened almost 3,000 approved drugs and 
drug-like molecules, and identified several compounds with TLR4 antagonist 
activity. This approach has shown to be a promising and efficient tool for 
discovering new uses from existing drugs and holds the great potential for 
precision medicine in the age of big data. 
6.2 Results and Discussion 
-Receptors 
There are several available 3D structures of TLR4, as hetero/homo-dimers, and in 
complex with some ligands (agonists and antagonists) and/or co-receptors.29 In the 
case of the agonist conformation of the hTLR4/MD-2 monomer complex, 3D 
coordinates from TLR4/MD-2 heterodimer were obtained from the PDB (PDB-ID: 
3FXI).30 In the case of the antagonist conformation, since the full crystallographic 
structure of the hTLR4/MD-2 complex is not available, a model built by us was 
used. This model was built using the human MD-2 protein in antagonist 
conformation (PDB-ID: 2E59)31 superimposed onto the MD-2 subunit of the agonist 
full complex (PDB-ID: 3FXI chain C) through PyMOL (see Chapter 3). Also in 
order to consider different antagonist conformations of TLR4, we used PDB-ID: 
2E56 (only in the case of SPECS and Log P 1000 databases). 
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-Databases 
Database processing constitutes a fundamental step in VS approaches. It is crucial 
to generate the proper chemical library, with the adequate geometries, ionization 
states, conformations, etc. Furthermore, it is very important to discard any 
molecule that will not be a good candidate in the further steps of the VS study in 
relation to the particular system on hand. A good database processing will assure a 
rigorous and well-conducted VS, as well as it will avoid computational cost and 
identification of unsuitable drug candidates.  
Different commercial, public and in-house databases have been used: Log P 1000, 
SPECS and ZINC as commercial databases, and as in-house databases, a diversity 
collection of compounds from laboratories of Prof. Péter Mátyus (PM) from 
Semmelweis University (Budapest), Prof. Jose Carlos Menéndez32 (JCM) from 
Complutense University of Madrid, Prof. J. R. Pedro (JRP),33 and Prof. A. Marco 
(AM)34 from the University of Valencia.  
Commercial databases 
ZINC15 (ZINC Is Not Commercial 2015)21, 35 is a public access database and tool 
set, developed to enable ready access to compounds for VS, ligand discovery, 
pharmacophore screens, benchmarking, and force field development. Nowadays 
ZINC15 database contains over 120 million purchasable compounds. For the 
purpose of this work, we were only interested in the approved compounds which 
represented, that time, a total of 2459 structures categorized under the substance 
subset called WORLD that is standing for approved drugs in major jurisdictions, 
including the FDA. Being a computational drug repositioning study, the 
compounds present in the ZINC15 database were filtered by clinically approved 
drugs. Thus 2459 from the WORLD subset over 100 million compounds in total 
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were kept for the repurposing study. These compounds were submitted to a 
preparation process and the number of compounds increased from 2459 to 2949.  
Log P 1000 dataset36 a small diverse subset of the ZINC database.21, 37 The 
subset was obtained by a similarity search based on 128 molecular VolSurf+ 
descriptors38 covering biologically relevant properties such as shape, surface, 
volume, molecular weight, polar surface area, hydrogen bonding capacity, 
lipophilicity and solubility. This was followed by an additional elimination of 
permanently charged compounds and compounds with a molecular weight lower 
than 150 Da, resulting in a diverse set of drug-like compounds. 
SPECS dataset is a database of commercially available drug-like 
compounds.39 Due to the large number of compounds (almost 300000) and 
computational limitations, a reduction of the final screening set was necessary. The 
MOE software40 was used to perform a cluster analysis on which a diverse subset 
was created. Therefore the fingerprint of each molecule was calculated in form of a 
bit-packed version of the molecular access system (MACCS) structural keys 
(BIT_MACCS),41 encoding 166 unique features. The Tanimoto coefficient was used 
as a measure of similarity between fingerprints.42 A similarity of 85% was used for 
the cluster search. This resulted in a reduced diverse subset of SPECS comprising 
23774 compounds that were used for screening. 
In-house databases 
We selected in-house collections with a wide range of chemical structures from 
different collaborators expert in different types of chemistry. It is important to 
mention that these chemical libraries are available to perform the biological assay, 
in the case of these compounds give very good results in the VS studies. 
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First, we used the diversity collection of heterocyclic compounds, based on their 
interesting structural characteristics, from PM database with around 1 964 
molecules; a second in-house dataset with quinoline, quinazoline and acridine 
structures from JCM database, with 68 compounds; and a third in-house collection 
of 25 and 85 compounds from JRP and AM, respectively, including pyrroles, 
indoles, naptholes, heterocyclic derivatives from JRP and analogues of natural 
products colchicine and pironetin from AM library. All of them had the available 
samples to be tested in case there were successfully screened. It is important to 
mention that, given that paclitaxel had shown antagonistic activity in human 
TLR4, while agonistic activity in mouse TLR4, showing the species-specific ligand 
recognition by MD-2, we were prompted to include tubuline binders in our VS 
approach. Prof. Marco is a well-recognized synthetic chemist specialized in the 
synthesis of natural products analogues, being analogues to tubuline binders 
among them.  
The binding of paclitaxel to TLR4 had been demonstrated, however not the 
induction of the cytokine response. Based on these reported results, we included 
other tubulin binders and related compounds as putative TLR4 ligands in order to 
discover novel TLR4 modulators. We chose a family of compounds analogue to 
natural products colchicine and pironetin (Figure 2). Regarding their antitumoral 
activity, and their ability to bind to tubulin components and microtubules, 
paclitaxel is a tubulin-interacting drug that stabilizes microtubules, while 
colchicine causes disruption of microtubules, and pironetin derivates bind to α- 
tubulin, inhibiting tubulin assembly. These opposite effects are due to the different 
tubulin sites with which they interact. We also included compounds derived from 
stilbene, like resveratrol since they are studied for their antimitotic properties and 
their antitumor activity, all of them included in the AM database.  
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Figure 2: Colchicine, pironetin and euodenine A structures. 
Filtering 
In order to prepare the databases for the VS, different tautomers were considered 
according physiological pH leading to the corresponding increase in the total 
number of screened compounds (see Materials and Methods). Finally, in this 
study, a database composed by around five hundred thousand compounds was 
built, including known binders (data from the literature) and decoys.  
We have considered the following filters: 
1- Lipophilicity of the molecules: a maximum logP of 6 were considered, 
taking into account that the natural LPS and reported synthetic glycolipids 
have a logP very high: 29.14 ± 0.83, 14.35±0.73 and 13.53±0.47 for lipid IVa, 
P01 and ONO-4007 respectively. This limit is a reasonable margin above the 
value of 5 according to Lipinski´s rules (oral bioavailability). 
2- Molecular weight (MW): we considered a wide range between 300 and 700 
Da given the MW of glycolipids targeting TLR4, with a reasonable margin 
above the value of 500 according to Lipinski´s rules. 
3- pH: only possible tautomers at physiological pH were considered within a 
range of 7± 0.5. 
4- Prediction of favorable binding from at least two docking programs and in 
two different conformations of TLR4. 
Searching for TLR4/MD-2 Modulators: Virtual Screening 
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-General overview of the VS protocol 
Molecular docking screening was performed against the different databases based 
on both, the agonist conformation of hTLR4/MD-2 complex from PDB-ID: 3FXI, 
and our modeled antagonist conformation of hTLR4/MD-2 complex. Ligand Based 
(LBVS) and Structure Based (SBVS) VS were carried following the protocols 
showed in the Figure 5.3. Log P 1000 and SPECS databases were submitted to 
LBVS (step III) and SBVS (step I) with the FLAP tool. WORD (subset ZINC 
database) and in-house databases were submitted to SBVS with the combined 
Glide/AutoDock/VINA approach (step II). The resulting screened compounds (189 
in total) were re-docked (step IV) by means of FLAP and Glide programs, finally 
yielding the selection of 27 compounds that were experimentally tested (step V). 
Seven compounds were identified as TLR4 antagonists. 
 
Figure 3: Flow chart of the VS protocol. 
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-Performance of the VS study 
STEP I. Structure-Based Virtual Screening (SBVS) with FLAP  
The investigated compounds from Log P 1000, SPECS datasets are drug-like 
molecules and not glycolipids like the known binders lipid A, lipid IVa or eritoran. 
The lipid chains in those glycolipids contain a vast number of free bonds which 
would increase the docking time exponentially. An additional complication would 
probably arise from the circumstance that most scoring functions are calibrated on 
drug-like molecules and would likely have difficulties evaluating the interactions 
correctly, especially in the entropic term, due to the many degrees of freedom and 
the large hydrophobic surface.43  
The literature defines three categories of compounds that may inhibit MD-2.44 The 
first class consists of inhibitors that compete with LPS for the binding in the 
hydrophobic pocket but without being able to trigger the final dimerization; 
Paclitaxel is one example for this class of inhibitors.45 Molecules of the second 
category bind covalently to the residue Cys133; compound JTT705 is one 
example.46 The final class of inhibitors does not enter the hydrophobic pocket 
completely but binds in the opening region of the cavity and prevent LPS from 
entering the pocket; representatives of this category are compounds JSH, 
curcumin, xanthohumol and isoxanthohumol (Figure 4).47 The majority of the side 
chains of the residues form the MD-2 pocket are hydrophobics (Leu, Ile, Phe and 
Val), but the rim of the cavity, on the other hand, contains almost no hydrophobic 
residues. The surface contains many positively and negatively charged amino 
acids which are important for the interaction between TLR4 and MD-2. 
FLAP’s SBVS method was used to perform target based VS on the TLR4/MD-2 
receptor with SPECS and Log P 1000 databases. As a benchmark, the method was 
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applied initially to the set of known active compounds. The result is shown in 
Table 1 with the ligands ranked according to their Glob-Sum score. This score is a 
global similarity score calculated by summing the four single contributions: shape 
(H), hydrogen-bond acceptor (N1), hydrophobic (DRY), and hydrogen-donor 
acceptor (O) descriptors; Glob-Sum is the global sum of all four energy values. Note 
that the scores of the single contributions are derived from the individual best 
conformation for this type of score, which might be different, while the Glob-Sum 
score comes from the one conformation for which the sum of scores is maximal. 
 
Table 1: Known antagonists of MD-2, ranked descending by Glob-Sum score obtained from 
structure-based virtual screening (SBVS). 
Since the Glob-Sum score does not reflect any experimental binding affinity, the 
results of the known ligands allow having an idea at which value a screened ligand 
can be considered as a potential hit. The highest score was obtained by paclitaxel 
(Glob-Sum=3.245) which was then used as a cutoff value for the screened unknown 
ligands. From Log P 1000 and SPECS libraries, 26 and 2012 compounds were 
obtained, respectively, having a score equal to or higher than 3.245. The highest 
contribution to the global score is given by the hydrophobic score which can easily 
be explained by the high hydrophobicity of the target pocket and the screening 
model that is obtained from it. 
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To better understand the interactions of the potential inhibitors retrieved by 
LBVS and SBVS with TLR4/MD-2, a molecular re-docking approach was carried 
out. In order to narrow down the number of compounds to dock, only molecules 
were selected which obtained a good score in the LB and the SBVS approaches. 
From the SBVS, in total, 2038 compounds (26 from Log P 1000 and 2012 from 
SPECS) obtained a score higher than the cutoff value of 3.245. Since an analogous 
cutoff value was not available for the LBVS approach, the same number of 
compounds was chosen here, i.e. the top ranked 26 and 2012 compounds from Log 
P 1000 and SPECS, respectively.  
Of the Log P 1000 set 3 common compounds were found in the top ranks of 
both LBVS and SBVS, while SPECS shared 556 top-ranked compounds. This total 
number of 559 compounds still seemed large, considering the time-consuming 
FLAP docking program. For this reason only the top 100 highest scoring ligands 
were taken for the final re-docking (step IV). This selection procedure was found to 
be in agreement with examples from the literature.48 
STEP II. Structure-Based Virtual Screening (SBVS) with Glide, AutoDock and VINA  
WORD database from ZINC and in-house databases (PM, JCM, JRP and AM) were 
docked into both agonist and antagonist protein conformations, using three 
docking programs, Glide, AutoDock and VINA, to avoid the limitation of one 
scoring function. The receptor grid was set up in order to fully contain the E. coli 
LPS, allowing small molecules to interact with the entire MD-2 pocket, as well as 
its rim and its entrance (see Materials and Methods). During the docking process, 
all the ligands were kept to facilitate visual inspections, comparisons and selections 
between the three docking programs. 50 poses per ligand were generated with 
AutoDock, 20 poses per ligand with VINA (which is the maximum for the 
program), and only one pose per ligand was generated with Glide, using HTVS, SP 
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and XP protocols in order to also facilitate the comparisons, choosing Glide as the 
main docking software. For the docking program validation analysis, either with, 
Glide, AutoDock or VINA, the scoring results for all the compounds were 
consistent and correlated to each other. However, the correlation between 
AutoDock and VINA is stronger than between Glide and AutoDock or VINA. The 
docked compounds, as well as all their corresponding predicted binding poses, 
were visually analyzed to detect any computational errors. The docking scores, 
defined by the average score of all the poses from one ligand for each docking 
program, were analyzed. Among all the compounds, according to each scoring 
function, only the top 25% from each docking program has been kept for the next 
analysis step.  
Among the databases, 23, 18, 16 and 32 compounds were selected respectively, 
being ranked at the top 25% for at least two docking programs at the same time 
and for one or both conformations, prioritizing a correlation with Glide, were kept 
for visual cluster rank analysis.  
II.a Molecular Docking Using Glide 
The molecules were subjected to a grid-based ligand docking with energetics 
(Glide, Schrodinger, version 6.9)49 using the Virtual Screening Workflow protocol 
(See Materials and Methods). Regarding the docking step parameters, Epik state 
penalties for docking were used, and the non-polar part of the ligand potential 
were soften by scaling the van der Waals radii of ligand atoms with small partial 
charges. The full workflow includes three docking stages, each step differing from 
the preceding step in the amount of time taken to dock each molecule and the 
scoring system used to evaluate each pose. The first stage performs HTVS (High 
Throughput Virtual Screening) docking. The ligands that are retained are then 
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passed to the next stage, which performs SP (Standard Precision) docking. The 
survivors of this stage are passed onto the third stage, which performs XP (eXtra 
Precision) docking, a more powerful and discriminating procedure. The Dock 
flexibility method was used for HTVS, SP and XP dockings allowing us to penalize 
non-planar conformation for amide bonds. A post-docking minimization was also 
performed, as well as constraints for the docking stages. One pose per compound 
state was generated and 100% of the best compounds that passed the HTVS, SP 
and XP docking have been kept. For HTVS and SP docking, all states have been 
retained, but only the best scoring state for the XP docking. 
II.b Molecular Docking Using AutoDock and VINA 
Docking was also performed independently with both VINA50 and AutoDock.51 In 
AutoDock the Lamarckian evolutionary algorithm was chosen and all parameters 
were kept default except for the number of genetic algorithm (GA) runs which was 
set to 50 to sample more docked poses.  
VINA (Vina Is Not AutoDock) uses an Iterated Local Search global optimizer52 
based on Broyden–Fletcher–Goldfarb–Shanno (BFGS) algorithm which 
approximates Newton's method and the number of docking poses was set to 20, 
which is the maximum for the program. TLR4/MD-2 receptors were kept rigid and 
the ligands were set partially flexible (i.e. maximum of 32 dihedral angles) for 
AutoDock and totally flexible for VINA.  
II.c Screened Compounds from Combined Glide/AutoDock/VINA Results 
Selected screened compounds from each docking program (steps II.a and II.b) 
were visually inspected and those binding outside the MD-2 were discarded. 
Finally, only the top 10% in the case of WORD and PM databases, and 20% from 
JCM, JRP and AM databases, were kept. Among them, 89 compounds were ranked 
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at the top for at least two docking programs at the same time, and were predicted 
to bind into one (at least) of the two TLR4 conformations (agonist/antagonist). 
These 89 compounds were then submitted to the following analysis step: (step IV) 
re-docking with AutoDock and Glide. 
STEP III. Ligand-Based Virtual Screening (LBVS) with FLAP  
Only in the case of the Log P 1000 and SPECS commercial database, we also 
performed LBVS with the FLAP tool.53 The FLAP LBVS method uses the common 
reference framework to align a set of candidate molecules to the template binder, 
to find the optimal overlap according to the GRID MIFs. The similarity between 
the fields is quantified by the Tanimoto coefficient. In the output table the user can 
see the individual scores obtained by the single MIF contributions (Glob-Prod), as 
well as a global score representing the sum (Glob-Sum) for each compound.  
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Figure 4: Known antagonists of the MD-2 reported in the literature. 
 
For the LBVS with FLAP, a set of known active antagonists of MD-2 was built 
based on a literature search (Figure 4). The two datasets Log P 1000 and SPECS 
were screened on each known active separately and ranked by their obtained Glob-
Sum scores. 
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LBVS was here performed individually by using the 14 known ligands as 
templates for the screening. The best ranked results are shown in Table 2. The 2D 
representations of the compounds of Log P 1000 and SPECS can be found in Annex 
Figure 1 and 2, respectively. The similarity between template and test molecule of 
the single contributions is a value between 0 (no similarity) and 1 (high similarity).  
The four single contributions are shape (H), hydrogen-bond acceptor (O), 
hydrogen-bond donor (N1) and hydrophobic (DRY) potential. The global score 
value that was used as result for the screening analysis is the Glob-Sum which is the 
global sum of all four energy values.54 Note that the scores of the single 
contributions are derived from the individual best conformation for this type of 
score, which might be different, while the Glob-Sum score comes from the one 
conformation for which the sum of scores is maximal.  
 
Template Compound Glob-
Sum 
H N1 DRY O 
6-shogaol 152 1.326 0.663 0.508 0.224 0.239 
481 1.742 0.598 0.271 0.254 0.702 
Xanthohumol 568 1.269 0.699 0.283 0.340 0.124 
19907 1.912 0.703 0.368 0.508 0.359 
Paclitaxel 383 0.847 0.505 0.175 0.134 0.337 
20513 1.022 0.565 0.171 0.105 0.321 
1D10G 368 1.152 0.579 0.203 0.181 0.310 
20700 1.857 0.654 0.306 0.260 0.734 
JSH 492 1.165 0.598 0.359 0.229 0.144 
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21315 1.421 0.515 0.371 0.304 0.329 
Isoliquiritigenine 42 1.181 0.637 0.364 0.195 0.010 
120 1.706 0.750 0.431 0.343 0.294 
Isoxanthohumaol 138 1.054 0.638 0.234 0.308 0.010 
28 1.493 0.634 0.430 0.304 0.305 
CAPE 575 1.149 0.625 0.242 0.181 0.243 
22298 1.528 0.587 0.230 0.159 0.700 
Curcumin 548 1.041 0.631 0.242 0.204 0.010 
23010 1.562 0.519 0.264 0.173 0.623 
Sulforaphane 46 1.104 0.650 0.361 0.166 0.000 
3203 1.184 0.684 0.296 0.000 0.000 
Cinnamaldehyde 40 1.489 0.684 0.581 0.383 0.000 
23599 1.500 0.580 0.673 0.273 0.000 
OSL7 35 1.007 0.648 0.295 0.128 0.000 
1171 1.285 0.702 0.445 0.191 0.000 
C34 187 1.142 0.506 0.205 0.137 0.512 
10959 1.428 0.560 0.216 0.102 0.903 
JTT705 439 1.033 0.539 0.391 0.188 0.010 
14650 1.127 0.592 0.347 0.188 0.000 
Table 2: Best ranked compounds of Log P 1000 (blue) and SPECS (white) set for each 
known ligand (black). 
Table 2 shows that for each of the known actives the best scoring SPECS 
compound scored higher than the best scoring one from the Log P 1000 database. 
This could be explained by the sole fact that the SPECS set contain a much higher 
number of compounds than Log P 1000. Consequently the probability is higher to 
find a good scoring compound. 
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Regarding the single contributions of the four similarities, the shape similarity (H) 
seems to have the highest impact on the global score in most of the cases. In four 
cases (6-shogaol, CAPE, Curcumin, C34) the hydrogen-bond acceptor and in one 
case the hydrogen-bond donor (N1) similarity made the biggest contribution to the 
global score.  
All five compounds are from the SPECS set. The reason why the influence of 
hydrophobic (DRY) similarity is comparatively low might be the relatively small 
size of the compounds. While strong hydrogen-bond similarities can be derived 
from single donor or acceptor atoms, the hydrophobic potential needs larger 
apolar surfaces to show a strong impact.  
STEP IV. Re-docking with FLAP and Glide 
The screened compounds from the above steps (189 compounds in total) were re-
docked by means of FLAP and Glide programs, finally leading to the selection of 
27 compounds. This selection was based in: i) the agreement in the most probable 
clusters from both programs; and ii) in the visual analysis of the best clusters from 
both docking programs with special attention to the ligand/receptor interactions 
(discussed below).  
The finally selected compounds were: 1 compound from Log P 1000 (ID-5382), 2 
compounds from SPECS (AG-690/11203225, and AF-399/1512855) (Table 3); 5 
compounds from WORD database (compounds 146, 157, 177, 179, and 208) (Annex 
Table 1); 8 compounds from PM (PM1097, PM1811, PM1779, PM567, PM1090, 
PM810, PM1758, and PM1200) (Annex Table 2), 8 from JCM (MS14, MS20, MS21, 
MS32, MS35, MS40, MS45, and MS49) (Annex Table 3) and 3 compounds from 
JRC and AM (JRP07, JRp07p, and JRP10) (Annex Table 4). 
Regarding the three ligands from the Log P 1000 and SPECS datasets, those were 
initially screened with FLAP, had an S-score equal to or higher than the threshold 
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of 1.074, obtained by the best-scoring known inhibitor sulforaphane. The 
compounds, their 2D description and the respective scores are listed in Table 3. 
The highest scoring compound is ID-5382 from the Log P 1000 set, with an S-score 
of 1.231. The two compounds of the SPECS set AG-690/11203225 and AF-
399/15128553 obtained a score of 1.114 and 1.074 respectively.  
Compound S-score Structure 
ID-5382 1.231 
N N
O
S
N
O
O
Cl
 
AG-690/11203225 1.114 S
Cl
O
O
O
NH
N O
 
AF-399/15128553 1.074 
N
N
N
S
O
N
 
Table 3: 2D description and the respective scores from ID-5382, AG-690/11203225 and 
AF-399/15128553. 
When studying the docked poses, in the three cases (ID-5382, AG-690/11203225 
and AF-399/15128553) the docked ligand is located at the entry of the hydrophobic 
pocket of MD-2 adopting similar poses. The principal interactions are hydrophobic 
and polar ones. The three compounds show polar interactions with Arg90 and 
Lys122. The hydrophobic interactions are more wide spread and not with the same 
set of amino acids for the three compounds. It is observed that compound ID-5382 
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is in close contact with the hydrophobic residues Ile46, Leu61, Leu78, Phe121, 
Ile124, Val135 and Phe151. Compound AG-690/11203225 interacts with the 
residues Ile52, Phe76, Leu78, Ile80, Val82, Glu92, Phe121, Ile124, Val135 and Ile153. 
Finally, the hydrophobic interactions of AF-399/15128553 were established with 
Ile46, Leu61, Ile80, Val82, Leu87, Phe121, Ile124, Tyr131 and Phe151 side chains. 
(Figure 5) 
 
Figure 5: Redocked ID-5382 in TLR4/MD-2. 
The two amino acids, Arg90 and Lys122, are able to build salt bridges with the 
compounds ID-5382 and AG-690/11203225 due to their sulfonyl group. This would 
explain why the polar score is significantly higher for these two ligands than for 
compound AF-399/15128553 which possesses no sulfonyl groups. The latter one 
only forms hydrogen-bonds between Arg90 and Lys122 side chains and the basic 
nitrogen atoms from the triazol ring. Interactions with Cys133, as those reported in 
the literature,55 could not be observed, due to the inability to predict/model 
covalent bonds with FLAP.  
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From JRP and AM databases, the selected compounds stablished stacking 
interactions with Phe76, and CH-π interactions are observed with the side chain of 
Cys133, Phe151, Phe104 and Leu61. Other interactions observed are hydrophobic 
ones with the residues Val24, Ile32, Ile44, Val48, Ile52, Leu78, Ile80, Ile94, Ile117, 
Phe119, Val135 and Ile153. 
Regarding the compounds from PM databases, they stablish π-π interactions with 
Phe104 and Phe151, also CH-π interactions with Phe76 and Phe121. Other 
interactions observed are hydrophobic with Ile32, Ile52, Leu61, Ile117, Val135, 
leu149 and Ile153. 
 
Figure 6: Redocked MS-21 (A) and MS-32 (B) in TLR4/MD2. 
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Finally, in the case of the compounds from JCM databases, the principal 
interactions observed are: π-π interactions with Phe76 and Phe151 and also 
hydrophobic interactions with Ile32, Ile52, Leu61, Leu63, Ile94 and Val135 (Figure 
6). 
In summary, it is possible to say that for the Log P 1000, SPECS, and the in-house 
databases (JCM, PM, JRP and AM), the docked ligands are located at the entry of 
the hydrophobic cavity of TLR4/MD-2 in similar poses. The principle interactions 
are hydrophobic with the inner region of MD-2, and polar ones at the rim of MD-2. 
All the compounds show polar interactions with Arg90 and Lys122. The 
hydrophobic interactions, however, are more wide spread and not with the same 
set of amino acids for all the compounds. Arg90 is assumed to participate in 
interactions with sulforaphane, JTT705, isoxanthohumol, isoliquiritigenin, CAPE 
and JSH. Lys122 interacts with OSL07 and cinnamaldehyde.  
Some of the identified side chains are also participating in the interaction with 
known ligands. Ile80 for example interacts with xanthohumol, JSH, OSL07, 
cinnamaldehyde and 6-shogaol. The side chains Phe121 and Ile124 interact with all 
known ligands. Hydrophobic interactions with the ligand are basically with 
aromatic cycles. 
Regarding drug repurposing results (WORD subset from ZINC database), the 
analysis revealed 5 compounds outperforming the remaining ones (Annex Table 
1): compounds 146, 157, 177, 179, and 208. Surprisingly, compared to the previous 
analysis done only with the best Glide pose step II), compounds 157 and also 
compound 212 did not show good results in the last analysis. Indeed, having a 
more wide number of poses in Glide permitted to see, for these two compounds, 
that the first pose was not part of the most probable cluster, or any cluster at all, for 
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both conformations. Moreover, it has been shown that the most probable clusters 
for these two compounds were ranked in a low energy position, and with a 
medium total percentage of interaction against the main residues. Compound 208, 
previously identified in the first analysis, having a good cluster position, was 
observed to have medium total percentage of interaction against the main residues. 
Compounds 157, 208 and 212 were kept as a query for future structure similarity 
search. 
In ascending order of better predicted binding, compounds 146, 177 and 179 
outperformed all the compounds. Compounds 146 and 177, already revealed by 
the first cluster analysis, have shown having in each pose, interactions with almost 
all the main residues. Moreover, in about 50% of the poses, they were able to make 
2 hydrogen bonds at the same time, and in about 70% of the poses, able to make 2 
salt bridge interactions simultaneously. Regarding compound 179, it was predicted 
having the highest affinity potential with all the main residues. It interacts with all 
the main residues with high affinity, making in 80% of the poses, up to 3 hydrogen 
bonding and a salt bridge in 50% of the poses. Compounds 146, 177 and 179 were 
also kept as queries for future structure similarity search.  
Regarding compound 146, it is known as Diphenoxylate. It is a meperidine 
congener used as an antidiarrheal, usually in combination with atropine. At high 
doses, it acts like morphine. Its unesterified metabolite difenoxin has similar 
properties and is used similarly. It has little or no analgesic activity. According to 
DrugBank it is categorized as: analgesics, opioid, antiperistaltic agents, alimentary 
tract and metabolism, antidiarrheals, intestinal anti-inflammatory/anti-infective 
agents, and antipropulsives. Because TLR pathways can be related to 
inflammatory and microbial pathologies, it can be conceivable that Diphenoxylate 
could have a certain affinity for TLR4. It has also been shown that Diphenoxylate 
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can regulate NF-kβ,56 a protein present downstream in the TLR pathway. 
Moreover, some studies have proven the binding between morphine and TLR4,57 
suggesting also a conceivable effect of Diphenoxylate to TLR4. 
Compound 177 is known as Ono-Rs 411 or Pranlukast. It is a cysteinyl leukotriene 
receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally 
in asthmatics, by an allergic reaction to accidentally or inadvertently encountered 
allergens. It is classified as: anti-asthmatic agents, respiratory system, drugs for 
obstructive airway diseases, leukotriene receptor antagonists, cytochrome P-450 
CYP2C9 inhibitors, cytochrome P-450 CYP2C9 inducers, and CYP3A4 inhibitors. 
Besides, some studies have shown that Pranlukast can inhibit NF-kβ activation,58 a 
protein present downstream in the TLR activation pathway. It has also been shown 
that it indirectly induces cytoplasmic membrane depolarization of Gram-negative 
bacteria, promoting E. coli outer membrane detachment,59 which some are 
recognized by TLR4. 
Compound 179 is known as Vemurafenib, a V600 mutant BRAF enzyme inhibitor 
for the treatment of late-stage melanoma.60 Vemurafenib inhibits the active form of 
the kinase,61 firmly anchoring itself in the ATP-binding site. By inhibiting only the 
active form of the kinase, it selectively inhibits the proliferation of cells with 
unregulated BRAF, normally those that cause cancer. It is classified as: 
antineoplastic agents, protein kinase inhibitors, antineoplastic and 
immunomodulating agents, cytochrome P-450 CYP1A2 inhibitors, cytochrome P-
450 CYP1A2 inducers, CYP2D6 inducers, CYP2D6 inducers (strong), and CYP3A4 
inhibitors. Up to date, it has been shown that TLR4 and its signaling pathway 
promote the migration of human melanoma cells,62 but no studies showing an 
effect from Vemurafenib to TLR4 have been done yet. 
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All hit structures show a very common scaffold and binding pattern: two 
hydrophobic moieties separated by a polar linker. The larger hydrophobic part 
occupies the hydrophobic MD-2 cavity, while the smaller one is placed in the same 
hydrophobic side region where also one of the lipid A alkyl chains is located in the 
bound X-ray structure. Key interactions are those stablished with residues Arg90, 
capable of making salt bridges and hydrogen bonds, Phe121, able to make strong 
hydrophobic interactions, and situated closely to Phe126, and Tyr131, also able to 
make hydrogen bonds. These interactions were common for all the compounds, 
and conferred them a strong predicted binding energy. The polar linker seems to 
be interacting with two of the positively charged amino acids Arg90 and Lys122 at 
the entry region of the pocket which have already been described in the literature 
to interact with known active compounds. The literature reports a covalent 
interaction between Cys133 of MD-2 and some of the known actives. This 
observation could be reproduced with some of the known actives. The identified 
screening hits, however, represent an interesting scaffold for a new class of 
possible inhibitors for the TLR4/MD-2 complex.  
STEP V. Biological testing 
After molecular docking and VS would have allowed us to predict the binding and 
the affinity of putative TLR4 modulators, we subsequently tested them in HEK-
Blue cells transfected with hTLR4, to check the ability of acting as TLR4 agonists or 
antagonists, and in J744 macrophage cells to check their ability to decrease TNF-α 
secretion. These studies were performed in collaboration with Belén de Andrés 
(CNM-ISCIII) and Manuel Fresno (UAM/CBM-CSIC). 
The ability of molecules to interfere with LPS-triggered TLR4 activation in HEK-
Blue hTLR4 cells model was investigated. This HEK293 cell line is stably 
transfected with human TLR4, MD-2, and CD14 genes. In addition, HEK-BlueTM 
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cells express a secreted Alkaline Phosphatase (SEAP) produced upon activation of 
NF-kβ. LPS binding activates TLR4 and NF-kβ leading to SEAP secretion, which is 
detected by an alkaline phosphatase substrate in cell culture media (Figure 5).  
 
Figure 7: Cell-based colorimetric assay for the detection of biological active endotoxin 
(figure extracted from https://www.invivogen.com/hek-blue-lps-detection-kit). 
In this assay, HEK293 cells transfected with human CD14 and TLR4/MD-2 were 
treated with increasing concentrations of synthetic molecules and then stimulated 
with LPS (LPS, 100 ng/ml). TLR4 activation is monitored as SEAP production. The 
results are normalized to activation by LPS alone and expressed as the mean of 
percentage ± SD of three independent experiments. The screened 27 compounds 
were tested and, from them, compounds B (ID-5382), F (MS21), H (MS32), I 
(MS35), X (PM1090) and Z (PM1200) inhibited TLR4 activation in a dose-
dependent way (Figure 6).  
As a negative control, compounds were tested in Null cell line (InvivoGen), 
transfected with the same plasmids as HEK-Blue but without TLR4, MD-2, and 
CD14 genes, and no effect was observed.  
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The toxicities of all compounds are being assaying by MTT assay and no inhibitory 
effects on cell viability have being observed in the concentration range used for 
biological characterization.  
 
Figure 8: Results are expressed in % of TLR4 activation (positive control: LPS 20ng/mL). 
We finally identified the following TLR4/MD-2 antagonist non LPS-like 
compounds: 
Compound Structure 
LogP 
ChemSketch 
LogP 
Molinspiration 
ID-5382 (B) 
 
ClN
N
O
S
O
O
N
H3C  
2.77+/- 0.49 4.13 
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MS21 (F) 
NCl
HN
OCH3
 
5.89+/- 0.40 6.331 
MS32 (H) 
NCl
HN
OCH3
OCH3
 
4.20+/- 0.83 6.434 
MS35 (I) 
NCl
OCH3
HN
N
 
4.68+/-0.84 
 
 
6.728 
 
 
PM1090 (X) 
F
N
CH3
N
N
N
N
CH3
O
 
5.70+/- 0.89 6.063 
PM1200 (Z) 
O
H3C N
N
H
NCH3
HH
H
 
6.29+/- 0.45 6.116 
Table 4: Non LPS-like compounds identified with TLR4/MD-2 antagonist activity. 
We also tested the activity of these compounds on J744 macrophage cells, in order 
to detect the amount of TNF-α secreted by the cells in presence of the compounds. 
Moreover, in order to test the toxicity of selected compounds, MTT assay was 
performed on the same cell line (Figure 9). Compound H showed an strong TNF-α 
production inhibition at both concentrations and no cytotoxicity effect was 
observed. These results make compound H one of the most promising scaffolds. 
Compound F showed also an inhibitory activity at 1ug/mL, but high levels of 
cytotoxicity were observed at 5ug/mL. On the other hand, compound X inhibits the 
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production of TNF-α markedly at 5ug/mL, while no cytotoxic effect was observed 
at both concentrations. Compounds B, J, I and Z did not show any inhibitory effect 
and compound I showed a high cytotoxicity even at 1μg/mL.  
 
Figure 9: % of expresion of TNF-α secretion (black bars) and cell viability (white bars) in 
J744 cell line upon the treatment with screened compounds B, F, I, J, X and Z.  
 
6.3 Conclusions 
In this work, we have applied VS and computational repositioning strategies for 
the finding of novel TLR4 modulators. Our computational protocol has made use 
of different conformations of TLR4/MD-2, and included ligand-based and 
structure-based VS and deep ligand/receptor analysis. Our protocol has shown to 
be a robust approach for the identification of seven non LPS-like compounds with 
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TLR4/MD-2 antagonist activity. Compounds B (ID-5382), F (MS21), H (MS32), I 
(MS35), X (PM1090) and Z (PM1200) inhibited TLR4 activation in a dose-
dependent way as putative of TLR4 modulators. In addition, compounds F and H 
showed an antagonist activity in J744 cell line, with no signs of cytotoxicity. The 
computationally identified hits represent interesting non LPS-like scaffolds for a 
new class of possible inhibitors for the TLR4/MD-2 complex. 
6.4 Materials and Methods 
-Computational Methods  
Library Preparation 
Importation. All the databases were saved as a SD File and imported in Maestro 
software (Schrodinger, version 10.4),63 which is an all-purpose molecular modeling 
environment. During the importation process, the chirality and the atom type of 
each compound has been checked.  
Ligand Preparation using LigPrep. LigPrep (Schrodinger, version 3.6)64 is a 
program specialized in preparing all-atom 3D structure of drug like molecules, 
was used for many purposes: to refine the geometry of the ligands imported from 
the databases; to generate accurate, energy minimized 3D molecular structures; to 
expand tautomeric, ring conformation, and stereoisomers in order to produce 
broad chemical and structural diversity from each input structure and to predict 
protonation states. The 3D structures were minimized using OPLS 2005;65 to 
generate ionization states, Epik66 was used, in order to simulate the physiological 
pH. In many cases, the compounds contain water molecules or ions, these extra 
molecules were removed with Desalt option.  
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The generating tautomer options were also used in order to generate up to 8 
tautomers per input structure. Regarding the setting stereoisomer options, the 
choice of retaining the specified chiralities to keep this information from the input 
file and fixed these chiralities for the entire calculation has been made. The number 
of stereoisomers generated was limited up to 32 per ligand. From a 2D structure, it 
is not immediately obvious which ring conformations give the lowest energy or are 
preferred for binding to an active site. Therefore it was decided to generate one 
low energy ring conformation per ligand with LigPrep. The final output was in 
Maestro format to keep the total information calculated for all the compounds. For 
the VS, the compounds were selected according to their molecular weight and their 
lipophilicity, between 300 Da and 700 Da, and between 4 and 6 respectively, using 
the property calculation tool from the Maestro software.  
Protein Preparation 
In the case of the agonist conformation of the TLR4/MD-2 monomer, 3D 
coordinates from TLR4/MD-2 heterodimer were obtained from the PDB (PDB-ID: 
3FXI).30 By contrast, in the case of the antagonist conformation, since the full 
crystallographic structure of the TLR4/MD-2 complex is not available, a model 
built by us was used. This model was built using the human MD-2 protein in 
antagonist conformation (PDB-ID: 2E59)31 superimposed onto the MD-2 subunit of 
the agonist full complex (PDB-ID: 3FXI chain C) through PyMOL. Then, 
coordinates from the TLR4 chain of the 3FXI adjacent to the superimposed MD-2 
(PDB-ID: 3FXI chain A) and the superimposed MD-2 in antagonist conformation 
were retained, forming the TLR4/MD-2 monomer in antagonist conformation. 
Finally, both agonist and antagonist the structures were subjected to 10000 cycles 
of steepest descent energy minimization under the Amber force field via Maestro 
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(see Chapter 3). Also PDB-ID: 2E56 were used to consider different antagonist 
conformation of MD-2. 
Receptor Grid Preparation 
Glide. For preparing the receptor grids for the two protein conformations, Glide 
software (Schrodinger, version 6.9) was used.49 All the parameters from the 
software were kept at their default values. We only determined where the scoring 
grids will be positioned and their sizes. The coordinates of the box were set up to 
fully contain E. coli LPS. Glide software uses two "boxes" that can be parametrized 
to organize the calculation: the inner box, which can be monitored in the advanced 
panel, and where the ligand center is allowed to move within that box during the 
site point search; and the outer box, which is the box within all the ligand atoms 
must be contained. Its size is function of the inner box, and the inner box has to be 
included within the outer box. For the inner box, the center was set up at residue 
serine 120 and the lengths of the boxes for both protein conformations were the 
following ones: 33 Å in X, 40 Å in Y and 35 Å in Z. For the outer box, 10 Å has been 
chosen, that is to say 10 Å bigger than the inner box (43 Å in X, 50 Å in Y and 45 Å 
in Z). 
AutoDock, FLAP and VINA. As the receptor grids were already set up with Glide, 
the same grids have been chosen for the softwares. Glide coordinates were kept for 
VINA, but were converted in AutoDock coordinates using scaling calculation tool. 
In the case of FLAP, the pockets of MD-2 were identified and defined by FLAP's 
pocket search algorithm. 
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Docking 
Structure Based Virtual Screening (SBVS) with FLAP 
The FLAP software explicitly distinguishes between the so-called SBVS method 
and docking.67 While in FLAP docking is primarily used for pose prediction and a 
more precise quantification of binding energies, SBVS is a tool for large-scale 
virtual screenings. Even though docking is often used as a structure based virtual 
screening technique,68 the term SBVS will hereafter refer only to FLAP’s 
correspondent screening program.  
The SBVS program first creates MIFs of the receptor’s binding site. During 
screening, the MIFs of the ligand are compared with those of the binding site. Time 
consuming calculations describing each atom-atom interaction are not needed 
here. One downside of this method is that there is no energetic penalty for atom 
clashing with the target. In some scenarios however, this might even be an 
advantage, since it overcomes the rigidity of the target to some extent.  
The SBVS in FLAP was performed on the 3D structure of the human co-receptor 
MD-2. The structure was obtained from the PDB (PDB-ID: 2E56)31 and the MOE 
software was used to prepare the protein by removing water molecules, adding 
hydrogens and missing atoms and side chains.40 The optimized structure was 
loaded into FLAP and the Search for pockets function was used to define the binding 
area. The results are then treated in analogy to the LBVS approach. 
SBVS with Glide 
The molecules were subjected to a grid-based ligand docking with energetics 
(Glide, Schrodinger, version 6.9)49 using the Virtual Screening Workflow protocol. 
It is designed to run an entire sequence of jobs for screening large collections of 
compounds against one or more targets. However, as the compounds and the grids 
Chapter 6 
236 
 
had already been prepared, in this case, only the docking steps of the program 
have been used. The compound files and the receptor grid files were imported into 
the Virtual Screening Workflow program. Regarding the docking step parameters, 
Epik state penalties for docking were used, and the non-polar part of the ligand 
potential were soften by scaling the Van der Waals radii of ligand atoms with small 
partial charges. To do so, the scaling factor was 0.80, and the partial charge cutoff 
was 0.15. The full workflow includes three docking stages, each step differing from 
the preceding step in the amount of time taken to dock each molecule and the 
scoring system used to evaluate each pose. The first stage performs HTVS (High 
Throughput Virtual Screening) docking. The ligands that are retained are then 
passed to the next stage, which performs SP (Standard Precision) docking.  
The survivors of this stage are passed onto the third stage, which performs XP 
(eXtra Precision) docking, a more powerful and discriminating procedure. 
The Dock flexibility method was used for HTVS, SP and XP dockings allowing us 
to penalize non-planar conformation for amide bonds. A post-docking 
minimization was also performed, as well as constraints for the docking stages. 
One pose per compound state was generated and 100% of the best compounds that 
passed the HTVS, SP and XP docking have been kept. For HTVS and SP docking, 
all states have been retained, but only the best scoring state for the XP docking. 
Ligand re-docking using Glide  
The shortlisted molecules were submitted to a re-docking procedure using Glide. 
All the parameters were kept as mentioned in the docking paragraph using Glide, 
except for the docking poses which were set to 50 per molecule. 
Molecular re-docking using FLAP 
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The FLAP software implements a fragmentation-based docking algorithm, called 
FLAPdock, which works as follows. MIFs are calculated for the target binding site, 
in a similar manner to the SBVS approach but with more points to describe the site 
in more detail (Reference manual for FLAP 2.0, © 2014 Molecular Discovery Ltd). 
A set of ligand conformations is generated using a stochastic search and a 
customized implementation of the MM3 force field69 with a cutoff of 30 kcal mol-1 
to remove high energy and duplicate conformations respectively. The ligands are 
then split into fragments with only 1-3 rotatable bonds. For each fragment 
conformation, GRID MIFs are calculated. The first fragment is docked into the 
binding site and the best scoring solutions, according to the global S-Score, are 
retained for the next iteration. In the next step, the next fragment, is attached to the 
first one and scored in the same way. The S-Score is a scoring function that 
includes terms from the GRID MIF similarities (Hydrogen-bonding and 
hydrophobic interactions as well as shape matching), Lennard-Jones and 
electrostatic interactions.  
It was validated, amongst other targets, on those of the Astex and DUD datasets.67b, 
70 In each iteration, the best scoring solutions are kept and filtered by RMS 
clustering. Once the reconstruction of the ligand has finished, the final pose can be 
optionally optimized by minimization and the final score is recalculated. The 
benefit of FLAPdock towards the SBVS method lies in the more detailed chemical 
interactions that are considered for docking and the respect of steric clashes that 
are not regarded in the SBVS method. In order to obtain score reference values, a 
set of known MD-2 inhibitors was docked, followed by the docking of compounds 
from the Log P 1000 and the SPECS dataset. 
Biological characterization 
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HEK-Blue TLR4 assay. HEK-Blue TLR4 cells (InvivoGen, Toulouse, France) and 
parental cell line HEK-Blue Null 2 (InvivoGen) were HEK-Blue cells were used to 
test the agonist or antagonist effect of different compounds. This cell line expresses 
TLR4, MD-2 and CD14 and do not express any other TLR. The activation of TLR4 
leads to the expression of SEAP, a protease that enzymatically hydrolyze a 
molecule present in the media. The amount of hydrolyzed molecule can be 
measured using colorimetric methods. These cells were cultured according to 
manufacturer’s instructions. Briefly, cells were cultured in DMEM high glucose 
medium supplemented with 10% fetal bovine serum (FBS), 1% glutamine, 1% 
penicillin/ streptomycin, 1X Normocin (InvivoGen). Experiments were performed 
when 70-80% of confluence was reached. Cells were detached by the use of PBS, 
tapping the flask and the cell concentration was estimated using. Four different 
compound concentrations were used: 0.1, 1, 5 and 10 μg/mL. 20 μL of compound 
dilution were added in a 96-well plate, in triplicate (3 wells for each concentration), 
seeded in multiwall plate at a density of 2 x 104 cells/well in 200 μl. LPS was used 
as positive control (20ng/mL final concentration) and PBS 1x was used as negative 
control. Cells were detached using 4mL of PBS and 140000 cell/mL solution was 
prepared using Detections Media. 180 μL of this solution were added into each 
well (25000 cells/well). After a 30 min incubation, 20 μL of LPS solution were 
added in each well (final LPS concentration: 20 ng/mL) (LPS was diluted in PBS as 
well). Plates were incubated for 16 h in the dark at 37 °C, 95% of humidity and 5% 
of CO2 and then, the plate reading was assessed using a spectrophotometer at 620 
nm. The results were normalized with positive control (LPS alone) and expressed 
as the mean of percentage ± SD of at least three independent experiments. 
TNF-α detection. An adherent murine macrophage cell line J774.2 was grown in 
75 cm2 cell culture flasks in Dulbecco’s Modified Eagle Medium supplemented 
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with 5% Fetal Bovine Serum and 1% Penicillin/Streptomycin. Approximately 2x106 
cells were plated in individual wells of a 12-well plate. Cells were stimulated with 
LPS from Escherichia coli (Sigma Aldrich) at a final concentration of 2ng/mL. 
5 μg/mL and 5 μg/mL of the respective compound were added with 1ng/mL of 
LPS. As positive control, LPS (1ng/mL) with DMSO was used. Two wells per 
compound and control were used. Plates were incubated for 24h at 37ºC and 5% of 
CO2. Cell supernatants collected after 24 h stimulation assays were analyzed for 
TNF-α. Commercial enzyme-linked immunosorbent assay kits were used (Mouse 
TNF-α DuoSet ELISA, rndsystems). ELISA was performed in 96 well plates, and 
plates were read at 450 nm in a microplate reader. 
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Annex Figure 1: Top scoring compounds obtained by LBVS on the Log P 1000 database. 
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Annex Table 1: 2D Chemical structure of predicted TLR4 modulators identified by 
computational drug repurposing, and kept for future structure similarity search. 
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2D structure 
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Annex Table 2: 2D Chemical structure from PM databases obtained from SBVS. 
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Annex Table 3: 2D Chemical structure from JCM databases obtained from SBVS. 
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Annex Table 4: 2D Chemical structure from JRP and AM databases obtained from SBVS. 
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7.1 Introduction 
Cell membranes, also known as plasma membrane or cytoplasmic membrane, 
consist of a lipid bilayer that separates the cytosol from the extracellular fluid.1 
Substances can cross the membrane by passive diffusion, active transport or 
through transport proteins (forming protein channels) and information, useful for 
the survival of the cell, is transmitted both ways through embedded proteins. Toll-
like receptor 4 (TLR4), as a pattern recognition receptor (PRR), perceives the 
presence of both damage-associated and pathogen-associated molecular patterns 
(DAMPs and PAMPs respectively), e.g. bacterial lipopolysaccharides (LPSs), on the 
outside of the membrane and transmit this signal inside the cell initiating the 
activation of defense mechanisms.1  
The nature of the lipids composing biological membranes is important for many 
physiological processes. A number of diseases such as cancers, diabetes, 
Alzheimer’s disease, HIV entry, and atherosclerosis, have been associated to 
changes in expression levels of individual lipid species.2 A typical plasma 
membrane is formed by hundreds of amphipathic lipids.3 Phospholipids, together 
with glycolipids, are the most abundant and the large majority of non-lipid 
membrane components are sterols.4 The fatty chains (FA) in phospholipids and 
glycolipids may be saturated or unsaturated and usually contain an even number 
of carbon atoms, typically between 16 and 20, being 16- and 18-carbon FAs the 
most common ones. The polar head groups are exposed to water and the nonpolar 
lipid tail groups from the upper bilayer interact with the ones from the lower 
bilayer, forming a hydrophobic block.5 The presence of unsaturation in the FA 
chains is correlated with liquid-disordered (Ld) phases whereas the absence of 
unsaturation in the FA chains of the lipids and the presence of cholesterol are 
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associated with liquid-ordered (Lo) phases. In biomembranes Lo is known as lipid 
rafts and plays a crucial role during protein signaling.6 Regarding their 
composition, mammalian membranes contain phosphatedylcholine (PC), 
sphingomyelin (SM), and gangliosides (GM) in the outer leaflet and 
phosphatidylethanolamine (PE), phosphatidylserine (PS), and other charged lipids 
in the inner leaflet; in addition eukaryotic plasma membranes contain between 20 
to 50% sterols.7  
The study of the dynamics of the TLR4/MD-2 complex requires the consideration 
of different membrane environments, since the membrane constituents are directly 
involved in the dimerization processes and thus governing the activation.6 We 
aimed at deepening the understanding of this dimerization process at atomic level 
using various computational techniques. We studied independently each TLR4 
subdomains, namely the ectodomain (ED), the transmembrane domain (TD), and 
the intracellular domain (ID), aiming at proposing full TLR4/MD-2 models 
accounting for its mechanism of activation. We here report MD simulations of the 
ED in its dimeric and monomeric forms, in complex with MD-2 engaged by E. coli 
LPS. The TD was simulated in Lo and Ld membrane phases to account for the 
recruitment of TLR4 in lipid-rafts over activation.8 Building our way up to a more 
complex model, we performed MD simulations of the TD attached to the ID, 
attempting to explain the reported importance of the long linker joining the two 
domains. A model for the ID/ID dimer has also been addressed. Our final goal is, 
from the information gathered in the previous modelled, to propose a full 
TLR4/MD-2 dimer model that explain most of the molecular information known to 
date regarding TLR4 activation. 
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7.2 Computational studies on the TLR4/MD-2 receptor complex  
TLR4 ectodomain. 
The structure of the agonist form of TLR4 in complex with its accessory protein 
MD-2 engaged by the most potent agonist known to date, E. coli LPS, was resolved 
by X-ray crystallography (PDB ID 3FXI).9 Here we report MD simulations of both 
the inactivated monomeric form and the activated dimeric form of the ED of TLR4, 
both in complex with MD-2 engaged by E. coli LPS. In the simulation of the dimer, 
both TLR4s undergo little deviation from their original locations, in relation to 
MD-2, at the beginning of the simulation and stabilize for the rest of the simulation 
(Annex Figure 1, left panel, blue and red lines). In the simulation of the monomer, 
TLR4 keeps deviating from its original location, in relation to MD-2, along the 
entire simulation, indicating that the monomeric TLR4/MD-2/E. coli LPS complex is 
not as stable as the dimeric (TLR4/MD-2/E. coli LPS)2 complex (Annex Figure 1, left 
panel, right line). This suggests that the presence of a second TLR4/MD-2/E. coli 
LPS unit stabilizes the first, and vice versa, which may be due to the polar 
interactions taking place at the dimer interface. The ligand, E. coli LPS, displays 
similar deviation pattern in both the simulation of the monomer and the dimer, as 
indicated by the RMSD plot (Annex Figure 1, right panel). However a subtle loss of 
symmetry between the two LPSs in the dimer simulation can be observed 
(comparing blue and red lines of Annex Figure 1, right panel) due the high 
flexibility of the OS-core of LPS, which adopts different conformations in both 
monomers. The lipid A moiety, buried in the MD-2 pocket, behave similarly along 
the simulation in both monomers, only a subtle difference in the disposition of the 
R3’ lipid chain can be observed: in one monomer the chain stays within the MD-2 
channel, as it is in the crystal structure, and in the other monomer the chain moves 
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towards the MD-2 pocket. Nevertheless, critical interactions of this chains with 
residues like Phe440* and Phe126 are maintained in both cases.  
 
Figure 1: Full view of the dimeric (TLR4/MD-2/E. coli LPS)2. 
MD-2 shows similar amplitude of conformational deviation in both simulations 
(Annex Figure 2, left panel). Phe126, known as the switch ON/OFF of the receptor 
complex,10 remains in an agonist-like conformation in both simulations 
characterized by an arbitrarily selected angle (Annex Figure 3) plotted in Annex 
Figure 2, right panel. 
7.3 Computational considerations about membrane models. 
To understand the dynamics of the bilayers themselves before including the TLR4 
we constructed a number of symmetric models: POPC, POPE:POPC [1:1], 
CHL:POPC [1:1], DPPC:POPC [1:1], DPPC:POPE [1:1] (Annex Table 1). Each of 
these membrane systems were simulated for 50 ns under anisotropic pressure 
coupling conditions at a temperature of 303 K. The area per lipid over the 
simulation time is reported in Annex Figure 4 left panel, in order of decreasing 
compactness our models can be ranked as follows: DPPC:POPE > POPE:POPC > 
DPPC:POPC > POPC >> CHL:POPC. The electron-density was calculated over the 
last nanosecond of simulation and is shown in Annex Figure 4 right panel. Based 
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on this analysis we can rank the membrane models based on their thickness in 
ascending order: CHL:POPC < POPC < DPPC:POPC < POPE:POPC < DPPC:POPE. 
The importance of membrane domains, known as rafts, for proteins signaling and 
trafficking has been extensively reported.11 The recruitment of TLR4 into lipid rafts 
domain has also been reported.12 To better represent the activation of TLR4, and 
based on our previous membranes models, we introduce two new models, namely 
a liquid-ordered (Lo) membrane model, representing a membrane raft, and a 
liquid-disordered (Ld) models. Each layer of the Ld model is composed of 64 units 
of DOPC and each layer of the Lo model of a mixture of 38 DPPC and 26 CHL, 
approximating a 60:40 ratio. Both membrane models were simulated for 50 ns. The 
electron density plot from the simulations gives a rough membrane thickness 
estimates of 45 Å for the Lo model and of 24 Å for the Ld model, similar to the 
POPC model previously reported (Annex Figure 5, right). The area per lipids is 
around 68 Å2 for the Lo model, also similar than the one of the POPC model, and 
around 70 Å2 for the Ld model (Annex Figure 5 left). 
7.4 TLR4 transmembrane domain and hydrophobic region 
The transmembrane domain of TLR4 (TD) is predicted to span from Thr632 to 
Tyr652 and to consist of an α-helix of lipophilic residues, with few polar residues. 
In addition, the amino acid sequence directly following this domain, called 
hydrophobic region (further abbreviated HR), lower delimitated by Lys666, has 
been largely argue to also actively interact with the membrane, either extending 
the TD α-helix or interacting with the head group of the lipids.13 Very recently, 
Mineev et al. reported a NMR study of both the TD and the HR of TLR4.13a The 
interpretation of the NMR data points to a helical conformation of the HR in 
DMPG/DHPC bicelles (PDB ID 5NAM). They further performed protein-protein 
docking experiments and selected a dimeric model based on NMR data. However, 
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it is important to keep in mind that membrane protein secondary structure and 
membrane protein-protein interactions are highly dependent of the medium in 
which they are studied. We decided to use computational tools to study the TLR4 
TD-TD protein interactions and to propose a model for the TD-TD dimerization. 
We performed a 250ns MD simulation of the TD and the HR structured as a long 
α-helix, as reported in the NMR study, in a POPC membrane. In this simulation 
the entire peptide enters the membrane and adopts a very tilted disposition 
(around 45o). The polar side chain of Lys653, found between the TD and the HR, 
interacts with the head group of the lipids inducing a soft kink in the helix. Lys666 
is found outside the membrane exposed to the lipid head groups and the solvent 
(Figure 2). 
 
Figure 2: MD simulations of TLR4 TD and HR (uninterrupted α-helix) domain. At t=0ns 
of the MD simulation (A), the protein is perpendicular to the membrane plan. At t=250ns 
(B), the protein adopt a titled position in relation with the membrane plan. 
In addition, we performed the same simulation but starting with an extended 
unstructured HR (Figure 3A). Along the simulation the HR residues explore the 
surrounding of the membrane and largely interact with the lipid head groups 
without penetrating the membrane. The TD adopts a slightly titled orientation in 
the POPC membrane (Figure 3B). Once the HR starts to interact extensively with 
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the membrane it stabilizes for the rest of the MD simulation (Figure 3C), not 
experiencing major changes during the final 50ns. To gain further insights into the 
folding properties of the HR, we performed a MD simulation in water starting 
from an extended conformation of the HR sequence. Along the simulation, the 
peptide has a great tendency to adopt an α-helix (Figure 2: D, E and F). In fact, this 
secondary structure corresponds to the one elucidated by NMR (cf. Figure 1 of the 
original paper)13a and is associated to the insertion in the membrane. 
The reported NMR results by Mineev indicate that there is a short portion (around 
Lys653) inside the full linker sequence TM+HR that would not correspond to a 
structured alpha-helix. The authors propose a full helix inserted in the membrane 
as a possible model for the insertion. We wondered about the secondary structure 
of the linker in water medium, and if it would adopt a preferred conformation. 
Our MD simulation shows that there is a tendency to this peptide to also adopt an 
α-helix structure (Figure 3). These results could also suggest the compatibility with 
the HR region being outside the membrane while maintaining an α-helix 
conformation. This could point to a relevant role of the HR in the IC-IC 
dimerization. The dynamics and conformational behavior of the HR peptide could 
be determinant of the proper IC-IC recognition. Another possibility could be that 
depending on the composition of the membrane, the HR adopts different 
conformations. That could explain the necessity of TLR4 receptor to be in a lipid 
raft to become active. 
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Figure 3: (A, B, and C) MD simulations of TLR4 TD (α-helix, in orange) and HR 
(extended coil, in yellow) domain. (A) The TD was built as an α-helix and HR, built in an 
extended conformation, was attached to it. (B) At the end of the simulation the HR is folded 
against the membrane. (C) Superimposition of one frame per nanosecond from the last 50 
ns of MD simulation. Lys631, Lys653 and Lys666 are represented as sticks; the TD and the 
HR are represented as orange and yellow cartoon, respectively. The membrane is in thin 
lines and the solvent was hidden. (D, E and F) Folding study of the HR by MD simulation 
in water. The 3D structure is shown along the simulation: 0ns (D), 500 ns (E), and 1000 
ns (F). 
7.5 TLR4 TD-TD dimerization 
We used the DAFT approach14 within the Martini Coarse Grained (CG) force field 
to explore TD-TD interaction in POPC membranes. Among the 550 simulations 
that were run, 487 were successfully performed for 1024 ns. We ranked them based 
on Lennard-Jones energy of interaction between the two TD (as calculated by the 
gromacs gmx energy command). We selected the top 5% of the successful 
simulations for closer analysis. 13 out of 24 feature very similar protein-protein 
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interactions (Figure 4). The model with the highest score, which belongs to largest 
cluster, was back-mapped to all-atom following the standard backmapping 
protocol described described by Wassenaar et al.15 and submitted to a 10 ns all-
atom MD simulation with AMBER in a DOPC membrane. No major interaction 
changes were observed. 
 
Figure 4: Superimposition, based on one monomer, of the 13 selected dimerized TD-TD 
poses. Backbone of the pose with the best L-J interactions score is shown in solid red sticks. 
Backbone (grey) and side chains (yellow) of the other poses are superimposed to the best 
pose and shown in semi-transparent sticks. 
7.6 TLR4 TD HR-TD HR dimerization 
We performed additional sets of DAFT experiments (4 sets of 120 simulations) to 
investigate the dimerization behavior of the TD and the HR together, exploring 
unstructured and α-helical conformations of the HR in both Ld and Lo membrane 
types. 
As it was shown in the MD simulations of the monomer of the TD and the HR 
structured as a continuous α-helix (Figure 2) in order for the dimer of the TD and 
the HR (from Lys631 to Lys666), structured as an uninterrupted α-helix, to be fully 
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inserted in the membrane, it has to adopt a very tilted angle in comparison to the 
membrane plan. 
In the Ld membrane model, in order to be fully inserted into the membrane, the 
helix must be tilted, either as a tilted dimer, representing 31% of the poses, leading 
to a nonsymmetrical dimer which might be compatible with dimerized ED-ED and 
ID-ID, either as two separated TD domains, representing 32% of the poses, 
incompatible with a dimerized ED (Figure 5). The symmetrical TD-TD dimer is 
observed in a low percentage (15%) and requires the HR region to be outside the 
membrane, where it is likely to adopt a non-helical conformation according to our 
MD simulations (Figure 3). This behavior points toward an inactive architecture of 
the TLR4/MD-2/TLR4*/MD-2* complex in the Ld membrane. In the case of the Lo 
membrane model, the symmetrical TD-TD dimer is observed in a high percentage 
of the MD simulation (46%) with the HR region outside the membrane. The tilted 
TD-TD dimer is also observed (33%). The HR region not being organized as an α-
helix outside the membrane would provide flexibility to accommodate the IDs. The 
presence of an unstructured HR would thus allow the dimerization of the IDs and 
would point to an active architecture of the TLR4/MD-2/TLR4*/MD-2* complex in 
the Ld membrane. 
 
    
N
O
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ER
 
 (A) (B) (C) (D) 
 
Ld 32% 15% 31% 10% 12% 
Lo 12% 46% 33% 3% 0% 
Figure 5: Different models of dimerization of the TLR4 (TD-HR)2 domain. Resulting 
dimers at the end of the simulations in which TD and HR were parametrized as α-helix. 
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In the two other sets of simulations (in Lo and Ld phases) only the HR was 
imposed to be structure as a α-helix no secondary structure was assigned to the 
other residues. The results do not point to a preferantial binding mode as it can be 
seen in Annex Figure 6. 
Among the 120 dimerization simulations setted up in the Lo phases, 105 were 
successfuly carried out for 2.5 µs and 104 featured a dimer in the last frame. 
Among the dimer the L-J energy of interaction ranges from -1374.0 to -326.9 kcal 
mol-1. In the Ld phases, 114 achieved 0.512 µs and 91 featured a dimer in the last 
frame of simulation. Among the dimer the L-J energy of interaction ranges from -
1324.3 to -304.2 kcal mol-1. 
Unlike in the simulations of the TD alone, a great variety of TD-TD dimer is 
observed and based on the geometry and the energy of interaction, none seemed to 
be favored. The TD-TD dimerization, when HR is added to the structure, seems to 
be mainly driven by HR-HR interactions itself. The introduction of the HR seems 
to create a dimerization “noise”. No major dimerization differences are noted 
between the simulation and the Lo phase and the one in the Ld phase (Annex 
Figure 6). 
7.7 TLR4 intracellular domain 
The homology modelling algorithm retained 6 templates to base the building 
process on: the TIR domain of human TLR1, TLR2 (P681h mutant), TLR2 (C713s 
mutant), TLR6 and TLR10, which it then retrieved from the PDB under the 
accession codes 1FYV, 1FYX, 1O77, 4OM7 and 2J67, respectively. The program 
produced 17 models based on these templates, which were then used to build a 
final hybrid model that was considered best based on its Z-score. The model is a 
dimer as most of the templates also feature a dimer. We compared our model with 
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all the TLR4 ID models reported to date, one from Gond et al.,16  three from Guven-
Maiorov et al.17 and another from Miguel et al.,18 and found that our model present 
great similarities with the latter one (Figure 6). 
 
Figure 6: Intracellular TIR domain of TLR4. A) 3D representation of the homology model 
with details on its structural composition. B) FASTA sequence divided by its secondary 
structure elements. 
A monomer was extracted from the HM and submitted to 100 ns of MD 
simulations. The TIR domain proved to be stable along the simulation (Annex 
Figure 7, left panel, red line). The TIR domain is highly conserved among TIR-
domain-containing proteins and is thus likely to have been accurately modelled. 
The entire ID domain is less stable (Figure S8, left panel, blue line), due to the high 
motion of the C- and N- terminal linkers that are highly flexible as shown in Figure 
S8, right panel.  
The TLR4 ID dimer model was submitted to 200 ns of MD simulations in water. 
We characterized the motion of both TIR domains independently and noted higher 
motion of one of the dimer (Annex Figure 8). The higher motions correspond to the 
CD loop, shown in Figure 6 (cf. RMSF plot in Annex Figure 8, right panel). 
Regarding protein-protein interactions, in the model (starting point of the MD 
simulation) both the BB loop and the Cys747 are interacting with their counterparts 
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(Figure 7). During the simulation, the BB loops interactions are discontinued and 
one of the monomer rotates 90º in relation to the other, leaving both BB loops 
exposed to the solvent in a symmetric manner. 
 
Figure 7: TLR4 ID from 0ns (left) to 200ns (right) of MD simulation in water. The dimer 
is in cartoon representation, Cys747 from both monomer are represented as spheres, chain 
A is in blue, chain B in grey, the BB loops in yellow, and the N-terminal linkers in red.  
In our model we assessed the binding sites of the downstream adaptors based on 
the findings of Guven-Maiorov et al. (2015).17 The protein-protein interaction model 
after 200 ns of MD simulation in somewhat similar to a model reported by the 
same authors (dubbed FF in the original paper) but the overall mode of interaction 
greatly differs as one monomer is rotated 180 degrees compared to our model. 
However the interactions with downstream adaptors, as described in the paper, 
can still take place. The MAL binding site is widely exposed and accessible as the 
TRAM binding site as presented in the paper.18 Concerning protein-protein 
interactions and complexation with downstream adaptors, both models seem to be 
possible. To shed more light into these possibilities, we performed the docking of 
the MAL protein (PDB ID 3ub2) to our model of ID-ID dimer by using ZDOCK. 
We obtained ten docked solutions, one of them being placed at the face that is 
predicted to interact with the membrane according to our MD simulations. The 
other nine docked solutions are coincident in predicting protein-protein 
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interactions at the opposed face, the one that would be exposed to the cellular 
interior. 
 
Figure 8: Protein-protein docking of TLR4 TIR domain (ID-ID dimer) and MAL protein. 
TLR4 ID is shown in grey and blue cartoon and the best 10 docked poses of MAL 8 in 
salmon. 
All poses are binding to the ID-ID dimer at the dimerization interface of the two 
monomers, as reported by Núñez-Miguel et al.18 Nevertheless, this observation 
differs from the signalosome model reported by Guven-Maiorov et al.,17 in which 
the MAL protein seems to interact with one of the monomers of the IC-IC only. 
Our docking results also revealed that two possible binding interfaces are possible, 
although one of them is clearly favored, since 9 out of 10 poses are binding in that 
region (only pose 8 binds on the opposed face). This is in agreement with our 
TD/ID model because only one face is available for adaptor binding since one of 
the IC interface would be interacting with the membrane (data not shown). Most of 
the binding poses predicted by ZDOCK are in agreement as well with Bovijn et al.19 
findings about possible binding interfaces with MAL protein of ID domain.  They 
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identified three possible binding surfaces, two of them corresponding to MAL/ID 
dimerization. One of these interfaces is located at the dimerization interface of TIR 
domain. In 6 out of 10 poses, we can appreciate interactions of MAL with this 
binding interface and in 3 of them the interaction takes place with Arg184, Ala185 
or Tyr187 of Mal, residues reported as possible binding interface of MAL. All these 
considerations strengths the consistency of our ID-ID model and makes it a 
plausible model of the ID-ID dimerization. 
Additionally, we performed MD simulation of the best ranked docking pose of 
MAL with the IC dimer. We observed that the complex remained stable during the 
whole simulation. MAL protein did not change its binding pose with respect to the 
intracellular domain of TLR4. Moreover, at binding interface there is a strong web 
of polar interactions that are maintained during the whole simulation (Figure 9). 
These residues appear also in the work previously mentioned.19 
We also studied another way of dimerization based on an asymmetric model 
following the architecture of MAL protein crystal structure published by Ve et al. 
(PDB ID 5UZB).20 The crystal structure published in this work revealed that MAL 
protein assembles by a head-to-tail arrangement, forming filaments. Given the 
high structure and sequence homology between MAL and IC TLR4, we though 
that the intracellular domain of TLR4 could also dimerize in a symmetric way. 
With this aim, we performed a protein-protein docking using ZDOCK of two IC 
domain monomers, extracted from our model of the dimer. We introduced 
restrictions to the docking based on the mutagenesis experiments reported by 
Bovijn et al.19 We obtained, thus, several poses that are in agreement with this type 
of arrangement. In this case, the B-B loop are not in contact with each other, but 
they interact with the following domains of the next monomer, in a head-to-tail 
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way of dimerization (Figure 10, A). In fact, the superimposition of 5UZB MAL 
crystal structure with our asymmetric model shows how similar the arrangement 
between these two proteins is. (Figure 10, B). 
 
Figure 9: MD simulation of best ranked docked pose of MAL-IC protein-protein docking. 
IC TLR4 dimer domain is shown in grey and blue cartoons. MAL protein is shown in grey 
cartoons.  
In order to propose a model for the binding of MAL to our asymmetric model or 
IC domain, we performed another protein-protein. In this case, MAL dimer 5ZUB 
crystal structure was docked on the asymmetric model of the IC TLR4 dimer 
domain. The docking was guided following not only mutagenesis studies on the IC 
domain, but also on MAL protein.21 Similar to the symmetric model, in this case 
MAL is also interacting with IC domain at the dimerization interface (Figure 10, C). 
This type of arrangement is in agreement with previously reported structures and 
experimental results.20  
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Figure 10: A) Docked pose of protein-protein docking of two monomers of the IC TLR4 
domain. B) Superimpostion of docked pose with 5ZUB MAL crystal structure (green). C) 
Docked pose of protein-protein docking of MAL dimer (green) 5UZB crystal structure on 
the asymmetric IC domain. B-B loop are shown in yellow; Cys747 is highlighted in spheres. 
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Thus, we propose here two possible models for dimerization for the IC domain of 
TLR4: asymmetric and asymmetric ways. Both are in agreement with mutagenesis 
studies on the IC domain that identify residues and regions that are crucial for the 
dimerization of the IC domain and the activation of TLR4. Furthermore, both 
models are also plausible for the binding of MAL protein. This indicates that both 
dimers could exist inside the cell, mediating the signalization of TLR4 depending 
on its formation. In fact, this is in agreement with experimental data pointing in 
that direction.22 
7.8 Conclusions 
Computational studies of the different independent domains composing the TLR4 
were undertaken aiming at uncovering details of the precise mechanism of 
activation of the receptor. We have performed several MD simulations of the 3FXI 
crystal structure, of both dimer and monomer. In the case of the monomer 
simulation, E. Coli LPS maintains its original conformation, with 5 FA inserted in 
the MD-2 pocket and 1 FA chain protruding from MD-2. However, TLR4 changes 
its position with respect to MD-2 protein. That behavior is not observed in the 
dimer simulation, where both TLR4 maintain its position along the simulation, 
indicating that the dimer TLR4/MD-2/TLR4*/MD-2* is more stable than the 
monomer TLR4/MD-2. The activated form of TLR4 is dimeric, which is consistent 
to the results exposed here.  
Secondly, we provided here several models for the transmembrane domain. First 
of all, an MD simulation of the TM with a full α-helix structure inserted in a POPC 
membrane showed an inclination of the protein. On the contrary, this inclination is 
not happening when the HR is not folded as α-helix. These results indicate the 
plasticity of HR, that could be determinant in the dimerization of the IC domain.  
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Coarse grain simulations of the TM dimer inserted in different membrane models 
indicated that, in a Ld membrane, the TM tend to partially dimerize. In the case of 
the simulations in a Lo membrane (mimicking a lipid raft moiety), the 
dimerization of the TM domain is complete. These results, together with the 
previous ones, point to a high plasticity of the TM domain, that can adopt different 
conformations and can change is mode of dimerization depending on the 
environment.  
Finally, in the case of the IC domain, we performed a homology modelling of the 
dimer IC domain based on several TLR4 IC domains. Although the simulation of 
one the monomers indicated the good stability of the protein, a 90º rotation can be 
observed in the MD simulation of the dimer. This rotation exposes the BB loop to 
the solvent in a symmetric way. Moreover, we constructed another IC dimer 
performing a protein-protein docking of two IC monomers. In this case, an 
asymmetric way of dimerization is observed. In the asymmetric model, the BB 
loops are not in contact with each other, and the IC domain dimerizes is a head-to-
tail fashion. This type of arrangement is in agreement with MAL dimer crystal 
structure (PDB ID 5UZB), which shares high homology with TLR4 IC domain. In 
any case, in both models, MAL protein could interact. The protein-protein docking 
and MD simulations performed with the TLR4 IC dimer plus MAL protein showed 
that MAL can form stable complexes with both of our models and interacts with 
residues that have been reported to be crucial to its binding. Thus, both ways of 
dimerization can occur simultaneously and, together with the plasticity of the TM 
domain, this indicates that the dimerization (and thus the activation) is an intricate 
combination of ligand binding, membrane composition and protein structure itself.  
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7.9 Materials and methods 
Setting up the all-atom (AA) membranes. The lipid bilayers were built using the 
online CHARMM-GUI membrane builder.24 Composition of the different system is 
given in SI. Systems were converted to Lipid14 compatible PDB format using the 
charmmlipid2amber.sh script.25  
Full TLR4/MD-2 model construction. The 3D structures of TLR4 and MD-2 were 
retrieved from the protein data bank under the accession code 3FXI. The TD was 
built as an α-helix based on its sequence (Uniprot ID O00206). The 3D structure of 
the ID was predicted and built through homology modelling as explained in 
details in the homology modelling section. 
Homology modelling. The 3D structure of TLR4 ID was predicted and built within 
the homology modelling feature of the YASARA program. TLR4 AA sequence 
spanning from residue 653 to residue 839 was giving as input to the program. 
Modeling speed was set to slow, which yield best results, and other parameters 
were kept default. 
Molecular dynamics simulations. AA MD simulations were performed with either 
Amber14 or Amber16. The force fields ff14SB,26 Lipid14,25 and a combination of 
GAFF27 and GLYCAM0628 were used to described the proteins, the membrane and 
E. coli LPS, respectively. AA simulations of systems containing membranes went 
through the same simulation protocol. Steepest descent gradient algorithm was 
iterated for 5000 steps followed by 5000 iterations of conjugate gradient algorithm 
under no constraint. The system was then heated from 0 to 100 K for 2500 steps in 
the NVT ensemble while the proteins and the lipids were held by a 10 kcal.mol-1 A-
1 harmonic potential. Subsequently, the system was heated from 100K to 303K for 
50000 steps. In membrane system the dimension of the box can change 
considerably during the first nanoseconds of simulation, thus, to allow the 
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program to recalculate them frequently, the first 10 steps of the production run 
were performed for a maximum of 500ps. The temperature was controlled by a 
Langevin thermostat. The warming up phase and the production run were 
performed under an anisotropic NPT ensemble to account for different physical 
properties along the dimensions tangential to the membrane than the one normal 
to it. The analysis was performed using the cpptraj module of AmberTools15.29  
Electron density. If not stated otherwise, the electron-density was calculated over 
the last nanosecond of simulation. 
Coarse-grained MD simulations. Box size was set to 4.5 Å in the directions of the plan 
of the membrane and to 5 Å in the direction normal to the membrane. Input 
structure was generated with Pymol based on the sequences given below. 
Simulations were run for 1024, 1000, 512, 3000 and 2500 ns for simulation of the TD 
in respectively POPC, DOPC (helix), DOPC (helix and coil), DPPC/CHOL (helix) 
and DPPC (helix and coil). The sequence used for the simulations of TM TLR4 in 
POPC is as follows: KTIIGVSVLSVLVVSVVAVLVYK and the secondary structure 
was set to helical. The sequence used for the four other daft simulations is the 
following: TCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGE, 
and the secondary structure was set as follows: 7C20H19C and 3C38H5C for the 
helix and coil model and the helix model, respectively. The coarse-grained 
simulations were performed under the martini22 force field, the systems were 
solvated with regular martini water beads and the salt concentration was set to 
0.15. 
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7.10 Annex  
 
Annex Figure 1: In both plots the minimum fit was performed on the αC of MD-2 in 
complex with a given TLR4, giving information of how the different components of the 
simulations deviate from their initial position in relation to MD-2. On the left: RMSD of 
both TLR4 in the simulation of the dimeric model (in blue and red) and TLR4 in the 
simulation of the monomer (in green). On the right: RMSD of each of the LPS. 
 
Annex Figure 2: On the left: RMSD of both MD-2 in the simulation of the dimeric model 
(in blue and red) and MD-2 in the simulation of the monomer (in green). On the right: 
angle between two vectors defined in Figure S1, providing conformational information 
about the critical residue Phe126 along the simulation. 
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Annex Figure 3: (A) Representation of the vector from the α-carbon (CA) of Pro78 to the 
α-carbon of Thr105, and the vector from amide α-carbon atom (C11) and the ester α-
carbon atom (C21) of FP7, used to follow the orientation of the ligands along the MD 
simulations (cf. S4). FP7 is used as an example; the same applies for the other ligands. MD-
2 is represented in grey an FP7 is depicted in CPK coloring at the exception of the carbon 
atoms that are in green. (B) Representation of two vectors, within MD-2, starting both 
from the α-carbon (CA) of residue Phe126 to, respectively, the phenyl C-4 atom (CZ) of the 
same residue and the α-carbon (CA) of residue Ser21. Agonist MD-2 from PDB ID 2E59 
and antagonist MD-2 from PDB ID 3FXI are represented in semi-transparent blue and 
pink cartoons, respectively. 
 
Annex Figure 4: Left: area per lipids. Right: total electron density profiles of the five 
membrane types (water excluded). 
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Annex Figure 5: On the left: area (in Å2) occupied by the membrane models Ld, Lo and 
POPC over time (ns). On the right: total electron density profiles of the five membrane 
types (water excluded). 
 
Annex Figure 6: Superimposition, based on one monomer, of all the poses from the CG 
simulations that presented a dimer in the final step of simulation. Backbone of residues 
between Lys631 and Lys653, which are the residues spanning through the membrane, are 
represented in orange sticks. Backbone of other residues are in yellow sticks. 
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Annex Figure 7: MD simulation of monomeric TLR4 ID in water. Left: RMSD. RMS 
fluctuation per residues. 
 
Annex Figure 8: MD simulation of dimeric TLR4 ID in water. Left: RMSD. RMS 
fluctuation per residues. 
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Annex Table 1: Different type of lipids and sterols used in this study. 
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Membrane 
Model 
Lipid Type 
Upper 
Leaflet 
Number 
Lower 
Leaflet 
Number 
CHOL-POPC 
CHOL 370 370 
POPC 370 370 
POPE-POPC 
POPE 315 315 
POPC 315 315 
POPC POPC 586 586 
DPPC-POPC 
DPPC 305 305 
POPC 305 305 
DPPC-POPE 
DPPC 329 329 
POPE 329 329 
ASYMMETRIC 
MODEL 
CHOL 
DPPC 
DPPE 
POPE 
POPC 
DOPE 
DOPC 
263 250 
Annex Table 2: Composition of the different models of membranes. 
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Lipid 14 Residues 
 Description LIPID14 Residue Name 
Acyl Chain 
Lauroyl (12:0) LA 
Myristoyl (14:0) MY 
Palmitoyl (16:0) PA 
Stearoyl (18:0) ST 
Head Group 
Oleoyl (18:1 n-9) OL 
Phosphatidylcholine PC 
Annex Table 3: Lipid14 residues name. 
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Conclusions 
This Thesis has been focused in two main receptors related to immunity: lectins 
and Toll-like receptor 4. On one hand, we have contributed to the advance in 
lectins modulation by the design of modulators of galectins 1, 3 and 7, and DC-
SIGN with improved affinity and selectivity. On the other hand, we have deepen 
the understanding of the molecular recognition events involving TLR4/MD-2 and 
some modulators at atomic level, together with the construction of the full model 
of TLR4/MD-2 heterodimer, and we have identified novel modulators with 
antagonist activity. This work has been carried out by means of computational 
methodologies, such as MD and CG simulations, ligand-protein and protein-
protein docking, and virtual screening. We have combined the computational 
work with experimental biological assays, and fruitful collaborations with expert 
groups in organic synthesis, NMR and ITC. Overall, we have helped to provide 
new insights for the understanding of the molecular recognition events underlying 
the biological functions of some lectins and TLR4. 
We have developed a fragment-based computational protocol for the rational 
design of galectin modulators. We have focused in galectins 1, 3, and 7 and 
performed a virtual screening in the adjacent pocket to the CRD yielding the 
design of 500 lactose-based possible ligands. These compounds were docked in all 
the galectins, and the best candidates were selected to be synthesized. Binding and 
affinity studies by NMR and ITC confirmed the predictions, and allowed us to 
describe lactose derivatives as galectin ligands with improved affinity and 
selectivity towards galectins 1, 3, and 7. These selective ligands may contribute to 
the understanding of the highly relevant biological functions of galectins and their 
role in several pathological processes, such as cancer and immune diseases. 
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By applying a similar computational protocol as that for the design of galectin 
ligands, we approached DC-SIGN: the mannose binding site and the vicinal 
pockets. The results showed that, while the mannose binding site and the calcium 
coordinating residues present a stable conformation, the surroundings regions are 
more dynamic. We observed that Val351, which interacts with the second residue 
of a dimannoside, can adopt two conformations that may affect the ligand 
recognition. On the other hand, Phe313 also suffers conformation changes and 
opens up the so-called “ammonium pocket”. This pocket was identified by means 
of VS, since most of the screened fragments bear an ammonium that was binding 
in that site. This pocket is adjacent to the mannose binding site and, happily, the 
oxygen of carbon 2 of the mannose residue points towards it. This finding allowed 
us to design mannoside-based ligands based on these fragments and taking into 
account the synthetic availability. Docking and MD simulation of these ligands to 
DC-SIGN predicted increased affinity compared to reported mannoside 
derivatives. 
Moving along the Thesis, we have studied the binding mode of several TLR4 
modulators. Agonist peptides RS01 and RS09 were proposed to bind to the MD-2 
pocket. RS09, due to the presence of more hydrophobic residues in its structure, 
was predicted to be buried inside the MD-2 pocket, while RS01 was predicted to 
bind at the rim. MD simulations showed that only RS01 was able to maintain the 
agonist conformation of Phe126 loop of MD-2, in agreement with the reported 
experimental activity that shows that RS01 is a better agonist than RS09. 
The binding mode of the TLR4 antagonist peptide has also been elucidated. This 
peptide, a mimetic of TLR4-binding motif of MD-2, was predicted to bind to TLR4 
mimicking the MD-2 binding mode. In fact, its TLR4-bound conformation was 
kept in a similar way to that for MD-2. Modifications of the structure of these 
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peptides could lead to the design of peptide mimetics with useful applications as 
TLR4 modulators. 
The endogenous lipid cardiolipin was also studied. We demonstrated that CL can 
actually bind to TLR4/MD-2, and our molecular modelling studies revealed that 
the FA chains of CL are inserted in the MD-2 hydrophobic pocket while the 
phosphate polar head is located at the rim of MD-2, interacting with residues from 
both TLR4 and MD-2. Moreover, we have shown that a heterodimer of TLR4/MD-2 
with a molecule of CL in one monomer and a molecule of E. coli LPS in the other 
monomer can be formed, and that fact could explain the synergistic effect observed 
in vitro. 
Finally, the tetracylated and pentacylated mixture of Bacteroides vulgatus LPS was 
an interesting case of study. Our molecular modelling studies indicate that both 
LPSBv-tetra and LPSBv-penta can bind to the MD-2/TLR4 system in a similar pose to 
that for E. coli LPS. The observed agonist behavior of LPSBv-penta and the observed 
antagonist behavior of LPSBv-tetra could explain the weak agonist behavior of 
LPSBv 
We have also undertaken a VS protocol on TLR4/MD-2 to identify potential 
binders to this receptor. After structure-based and ligand-based VS protocols, and 
the redocking of the best compounds, we selected 50 ligands to carry out in vitro 
studies on HEK BLUE TLR4 cells. This assays identified 7 compounds with 
antagonist activity on TLR4 and the experiments with J744 macrophage cell line 
confirmed the activity of 2 of them, without presenting cytotoxicity. Thus, these 
two molecules came up as new scaffolds with a non-LPS structure with antagonist 
activity on TLR4 
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Finally, we studied the dimerization of the different TLR4 domains: extracellular, 
intracellular, and transmembrane domains. We provided several computational 
models for the dimerization of the TM domain and our results indicate that the 
membrane composition affects the dimerization and, thus, possibly, the activation 
of TLR4. We also provided two possible models for the dimerization of the 
intracellular domain: symmetric and asymmetric dimers. Both conformations 
could occur simultaneously in the cell, and our predictions indicate that MAL 
adaptor protein is able to bind to both models. These results all together contribute 
to the understanding the dynamism of TLR4 and to highlight the important role of 
the membrane composition for the ligand recognition and protein assembly, as key 
players in the TLR4 activation. 
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